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Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy 
characterized by subpopulations of leukemia-initiating or leukemia stem cells (LSC) that 
give rise to clonally related non-stem leukemic blasts. The LSC model proposes that 
since LSC and their blast progeny are clonally related, their functional properties must be 
due to epigenetic differences. In addition, the cell of origin of LSC among normal 
hematopoietic stem and progenitor cells (HSPCs) has yet to be clearly demonstrated. In 
order to investigate the role of epigenetics in LSC function and hematopoietic 
development, we profiled DNA methylation and gene expression of CD34+CD38-, 
CD34+CD38+ and CD34- cells from 15 AML patients, along with 6 well-defined HSPC 
populations from 5 normal bone marrows using Illumina Infinium 
HumanMethylation450 BeadChip and Affymetrix Human Genome U133 Plus 2.0 Array. 
To define LSC and blast functionally, we performed engraftment assays on the three 
subpopulations from 15 AML patients and defined 20 LSCs and 24 blast samples. We 
identified the key functional LSC epigenetic signature able to distinguish LSC from 
blasts that consisted of 84 differential methylations regions (DMRs) in 70 genes that 
correlated with differential gene expression. HOXA cluster genes were enriched within 
the LSC epigenetic signature. We found that most of these DMRs involve epigenetic 
alteration independent of underlying mutations, although several are downstream targets 
of genetic mutation in epigenome modifying enzymes and upstream regulators. The LSC 
epigenetic signature could predict overall survival for AML patients independent of 
known risk factors such as age and cytogenetics. We characterized epigenetic changes 
during normal human hematopoietic development and identified key novel regulators for 
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hematopoietic differentiation such as HMHB1 and MIR539. We found that global 
hypomethylation is a critical mechanism of lineage commitment in human hematopoiesis. 
Our DNA methylation analysis in human hematopoiesis revealed variable epigenetic 
regulation compared to murine hematopoiesis. Furthermore, we found that LSC 
populations formed two distinct clusters resembling either lymphoid-primed multipotent 
progenitors (L-MPPs) or granulocyte/macrophage progenitors (GMPs). These results 
provide the first evidence for epigenetic variation between LSC and their blast progeny in 
AML, and its prognostic power. We also provided comprehensive methylome map of 
human hematopoiesis and identified epigenetically distinct subgroups of AML LSCs that 
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Epigenetics is the study of information that is heritable after cell division other than the 
primary DNA sequence. Epigenetics is involved in many cellular processes such as 
embryonic development, differentiation, and an interaction with environmental stimuli. 
Mechanisms of epigenetics include DNA methylation, histone modification, chromatin 
factors, chromatin structure, and noncoding RNAs. Dysregulation of the epigenetic 
modifications is known to be involved in many diseases such as cancer. 
 
Definition (historical and modern) 
Conrad Waddington first coined the term ‘epigenetics’ in 1942 as a mechanism of 
how genotype brought about phenotype during development (Waddington, 2012). He 
proposed the ‘Epigenetic landscape’ as a model for cellular development that a ball is 
rolling down a hill to the lowest points (Goldberg et al., 2007). The ‘Epigenetic landscape’ 
is a metaphor of how a cell (a ball) decides its fate (the lowest points) (Goldberg et al., 
2007). The role of epigenetics is evident in multicellular organisms, where the vast 
majority of cells have the same genomic sequence, yet exhibit distinct cellular 
phenotypes.  All cells in the human body originate from the same source, pluripotent 
stem cells in the inner cell mass (ICM) of a blastocyst. The pluripotent stem cell 
differentiates into different types of cells such as neurons, hepatocytes, or tubular 
epithelial cells, which constitute brain, liver, and kidney, respectively. As all these cells 
come from the pluripotent stem cells in the ICM, they have the same genomic sequence, 
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yet display distinct phenotypes and functionality (Figure 1.1). In order to investigate the 
role of epigenetics in different levels of biological processes systematically, NIH 
Roadmap Epigenomics Project was launched in 2008 (Bernstein et al., 2010). The NIH 
Roadmap Epigenomics Project defines epigenetics as both heritable and other stable and 
long-term changes in gene expression regulation of a cell. Collective efforts to provide a 
public resource of epigenomic information have generated comprehensive epigenomic 
maps of DNA methylation, histone modifications, DNA binding protein, chromatin 
accessibility, and noncoding RNAs in diverse cell types and tissues (Bernstein et al., 
2010; Roadmap Epigenomics et al., 2015).  Among the epigenetic modifications, DNA 
methylation will be the focus of this thesis.  
 
DNA methylation 
In mammals, DNA methylation is generally referred to as a covalent modification 
in which a methyl group is attached to the fifth position of cytosine in CpG dinucleotides. 
Note that non-CG methylation in CHG and CHH (H=A, C or T) contexts has been 
reported in stem cell, neuron, and other differentiated tissues, yet its functional role is still 
an active research area (Lister et al., 2013; Lister et al., 2009; Ramsahoye et al., 2000; 
Schultz et al., 2015). DNA methylation is established and maintained by three DNA 
methyltransferases: DNMT1, DNMT3A and DNMT3B (Li et al., 1992; Okano et al., 
1999). These enzymes use S-adenosyl methionine (SAM) as a methyl group donor. 
DNMT1 is responsible for methylation of hemimethylated DNA after DNA replication, 
while DNMT3A and DNMT3B are able to methylate both hemi and unmethylated DNA, 
4	  
so serve as de novo methyl transferases (Leonhardt et al., 1992; Okano et al., 1999). The 
human genome contains about 28 million CpGs and 60-80% of those are generally 
methylated (Smith and Meissner, 2013). A small portion (~10%) of CpGs, not 
methylated clusters together, and thus establishes a genomic region called CpG islands, 
which are predominantly located in the promoter of coding genes (Bird, 1986; Deaton 
and Bird, 2011). Maintaining the unmethylated status of CpG islands requires 
transcription factor binding, deposition of histone variant H2A.Z, and trimethylation of 
histone H3 at lysine4 (H3K4me3) that inhibit the binding of DNA methyltransferases 
(Brandeis et al., 1994; Conerly et al., 2010; Macleod et al., 1994; Otani et al., 2009). The 
repression of CpG island-promoters genes is largely mediated by histone modification, 
particularly trimethylation of histone H3 at lysine27 (H3K27me3), and polycomb 
proteins (Bartke et al., 2010; Brinkman et al., 2012; Jones, 2012). However, DNA 
methylation at CpG island promoters does occur to suppress CpG island containing genes 
that are targets of specific biological processes such as X-chromosome inactivation and 
genomic imprinting (Jones, 2012).  
Recently, the CpG-island centric view has been challenged, as methods to 
measure DNA methylation have been improved with the development of array and 
sequencing technology. There has been an accumulation of evidence that other genomic 
regions also have important roles in development and disease progression. A large 
portion (~80%) of methylation differences among different tissues in human and mouse 
has been reported to not occur in CpG islands, but ‘CpG island shores’, located up to 2kb 
distant from CpG islands (Irizarry et al., 2009). Besides the differential methylation 
involved in normal tissue development, most differentially methylated regions (DMRs) 
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that distinguish human colon cancer from normal colon tissues, human induced 
pluripotent stem (iPS) cells from fibroblast, and murine hematopoietic stem and 
progenitor cells (HSPCs) are located in CpG island shores (Doi et al., 2009; Hansen et al., 
2011; Irizarry et al., 2009; Ji et al., 2010). Interestingly, the tissue-specific, cancer-
specific and reprogramming-specific DMRs (tDMR, cDMR, and rDMR, respectively) 
showed statistically significant overlap with each other, indicating that there may be a 
core set of genomic regions targeted for epigenetic regulation during normal development 
and disease progression. In addition, DNA methylation at CpG island shores showed 
strong inverse correlation with gene expression, while DNA methylation at CpG islands 
did not show a statistically significant correlation with gene expression in these data sets, 
suggesting functional importance of CpG island shores in diverse biological contexts 
(Doi et al., 2009; Irizarry et al., 2009; Ji et al., 2010).  
In cancer epigenetics, it has long been known that hypermethylation in CpG 
islands is a core mechanism of cancer progression, yet various types of alterations have 
been observed in other genomic regions. For example, in colon cancer, hypermethylation 
is a major type of change in CpG island shores (Irizarry et al., 2009). A large-scale 
change in half the genomic regions called hypomethylated ‘block’ has been identified in 
solid tumors with increased variation in expression of genes inside the blocks (Hansen et 
al., 2011; Timp et al., 2014; Timp and Feinberg, 2013). Stochastic variation of DNA 
methylation in cDMRs distinguished solid tumors from its normal counter parts, and 
different stages of tumors (Hansen et al., 2011; Timp et al., 2014). Thus, epigenetic 
dysregulation of increased epigenetic plasticity with genetic mutation would be a critical 
mechanism of cancer progression (Feinberg et al., 2006; Timp and Feinberg, 2013).    
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Recently, this hypomethylated large domain has also been observed in ageing phenotype. 
Sun-exposed epidermal samples in older people (Age>65) showed the hypomethylated 
blocks that overlapped with blocks in colon cancer and squamous cell carcinoma 
(Vandiver et al., 2015). The hypomethylated blocks largely overlap with higher order 
genomic regions such as large organized chromatin lysine-modifications (LOCKs) or 
nuclear lamin-associated domains (LADs), suggesting the altered large scale DNA 
methylation is associated with dysregulation of the large scale genomic regions in disease 
progression.  
 Besides CpG islands and shores, gene body methylation has received a lot of 
attention, yet its functional importance remains to be determined. DNA methylation in 
gene bodies has traditionally been thought to silence repetitive DNA sequences, such as 
retroviruses and LINE elements (Yoder et al., 1997). Recent evidence suggests that gene 
body methylation positively correlates with gene expression in normal tissues and cancer 
samples (Kulis et al., 2012; Varley et al., 2013; Yang et al., 2014).   Potential 
mechanisms of gene body methylation in the regulation of gene expression include 
effects on transcription elongation or splicing regulation (Jones, 2012; Laurent et al., 
2010). However, the functional role of gene body methylation in transcription regulation 
is not evident yet, compared to other genomic regions.  
 
DNA demethylation 
DNA methylation is a stable covalent modification on genomic sequences, while 
it is also reversible. Both passive and active loss of DNA methylation can occur through 
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diverse biological processes. Passive DNA demethylation occurs during consecutive 
DNA replication in the absence of functional DNMT1 activity (Kohli and Zhang, 2013). 
Recent advances in identification of enzymes involved in methyl group removal from 
cytosine have facilitated our understanding of active DNA demethylation process. Ten-
eleven translocation (TET) family enzymes, TET1, TET2, and TET3 are able to oxidize 
methyl cytosine and generate intermediate products including 5-hydroxymethylcytosine 
(5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2010; Ito et al., 
2011; Kriaucionis and Heintz, 2009; Tahiliani et al., 2009).  These oxidized 5mC 
intermediates undergo further removal processes: passive removal by sequential DNA 
replication, direct removal, or DNA repair pathway-associated removal (Kohli and Zhang, 
2013). Among these, the base excision repair (BER) pathway has been actively 
investigated. Thymine DNA glycosylase (TDG), an enzyme involved in BER is known to 
have an ability to remove thymine from G-T mismatches from normal DNA context 
(Cortazar et al., 2007). Recently, it has been reported that TDG is required for epigenetic 
stability in embryonic development in mice (Cortellino et al., 2011). Since TDG has an 
ability to remove thymine from G-T mispair, it has been hypothesized that 5mC or 
oxidized 5mCs may be converted to thymine or uracil by deaminase first. Several studies 
have suggested that AID/APOBEC enzymes,  known cytosine deaminases, play a role in 
deamination of the 5mC in reprogramming or embryonic development (Bhutani et al., 
2010; Kumar et al., 2013; Popp et al., 2010). Yet, a controversy over the role of the 
deaminases in DNA demethylation still exists, due to their limited enzyme activities on 
modified cytosines (Kohli and Zhang, 2013). In addition to the deaminase-mediated BER, 
other studies have shown that TDG can directly remove 5fC and 5caC (He et al., 2011; 
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Maiti and Drohat, 2011). DNA demethylation is implicated in multiple biological 
processes including pre-implantation methylation dynamics, primordial germ cell (PGS) 
reprograming, maintenance of stem cell pluripotency and cancer development (Kohli and 
Zhang, 2013). 
 
Methods to measure DNA methylation  
Array-based (CHARM and Illumina Infinium HumanMethylation450 BeadChip) 
In 2008, the comprehensive high-throughput arrays for relative methylation 
(CHARM) method was developed to provide the first platform to interrogate DNA 
methylation in a genome-wide and non-CpG island biased manner (Irizarry et al., 2008). 
CHARM utilizes a methylation dependent restriction enzyme, McrBC, that cleaves DNA 
containing methylated cytosines. Sheared genomic DNA is divided into two fractions; 
one for undigested control and the other for McrBC digestion. The undigested control and 
McrBC digested samples undergo size selection. The size selected DNA is amplified and 
hybridized to a tiling array that excluded isolated CpGs. The log-ratio of the signal 
intensities from the array of the untreated and McrBC treated samples (M-value) is 
measured. Since methylation status of neighboring CpGs is likely to correlate with each 
other, the measured M-value is averaged within a given genomic region of interest. This 
process is called ‘Genome-weighted smoothing’ that improves the accuracy and 
specificity of measuring methylation at CpG sites (Irizarry et al., 2008). Many studies 
have applied CHARM to identify genome-wide differential methylation in different 
model systems: tissue development, cellular reprogramming, hematopoiesis, cancer, and 
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behavior of social insects (Doi et al., 2009; Herb et al., 2012; Irizarry et al., 2009; Ji et al., 
2010; Kim et al., 2010; Kim et al., 2011).  
 Illumina has endeavored to develop commercially available arrays to measure 
genome-wide DNA methylation, and produced Infinium HumanMethylation27 BeadChip 
(27K) and 450 BeadChip (450K). As implied in its name, 27K covers about 27000 CpG 
sites, mostly enriched in CpG islands, while 450K covers about 480000 CpG sites 
encompassing diverse genomic regions selected from previous studies for tDMR, cDMR, 
rDMR, non-CpG methylated sites, and miRNA promoter regions other than CpG islands. 
In this section, we will focus on 450K, the method used in this thesis. The 450K array 
utilizes bisulfite conversion and genotyping of the C/T polymorphism method to detect 
methylation at a CpG site quantitatively. Methylated cytosine remains as cytosine, but 
unmethylated cytosine is converted to uracil after bisulfite conversion (Clark et al., 1994; 
Frommer et al., 1992). Note that this method does not distinguish 5mC from 5hmC, 
because 5hmC remains as cytosine after bisulfite conversion (Huang et al., 2010). For  
the 450K array, DNA sample is treated with bisulfite, then amplified by PCR. The 
bisulfite treated and amplified DNA is hybridized on the 450K array that returns the 
measurement of methylation level at CpG sites on a probe on the array (Dedeurwaerder et 
al., 2011).  
Sequencing-based (Bisulfite pyrosequencing and whole-genome bisulfite sequencing 
(WGBS)) 
 Two different levels of sequencing technology are widely used to measure DNA 
methylation: bisulfite pyrosequencing for a small genomic regions and WGBS for 
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genome-wide level. Bisulfite pyrosequencing is based on bisulfite conversion. As 
explained above, methylated cytosine is not affected by bisulfite treatment, while 
unmethylated cytosine is converted to uracil, and eventually thymidine after PCR 
amplification. Step-wise incorporation of deoxynucleotide triphosphates (dNTPs) during 
sequence extension releases pyrophosphates, which are converted to ATP by 
sulphurylase. Then, luciferase converts luciferin to oxyluciferin using ATP and produces 
light, which will be detected by pyrosequencing machine. The intensity of the released 
light is proportional to the amount of the nucleotides incorporated at a single base site. 
The C to T ratio can be quantitatively measured by the amount of dCTP or dTTP 
incorporation at a cytosine of a CpG site which can be inferred from the intensity of light 
released (Bassil et al., 2013). Bisulfite pyrosequencing has been used to detect 
quantitative methylation and individual CpG sites or to validate results from array-based 
methods (Doi et al., 2009; Herb et al., 2012; Ji et al., 2010; Kim et al., 2010). 
 Next-generation sequencing technology has allowed the development of WGBS, 
enabling researchers to investigate quantitative DNA methylation level at CpG sites 
genome-wide.  WGBS uses bisulfite conversion as in bisulfite pyrosequencing, but the 
bisulfite converted DNA undergoes next-generation sequencing instead of region specific 
amplification. The high throughput sequencing data returns read numbers of cytosine 
versus thymidine, therefore yielding a quantitative measure of DNA methylation at all 
CpG sites in the genome (Laird, 2010; Lister et al., 2009). Several statistical methods and 
software packages have been developed to analyze the WGBS data: BSmooth, Bismark, 
and so on. Among these packages, BSmooth offers relatively accurate measurement of 
DNA methylation at individual CpG sites from low coverage WGBS data by using 
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smoothing algorithm (Hansen et al., 2012). WGBS enables researchers to discover not 
only DMRs, but also non-CG methylation in stem cells and large genomic DNA 
methylation changes in cancer and sun exposed skin in elderly people (Hansen et al., 
2011; Lister et al., 2009; Vandiver et al., 2015). 
 
2. Hematopoiesis  
Overview 
 Hematopoiesis is one of the best studied, but complicated developmental systems. 
It consists of a hierarchical process initiated by hematopoietic stem cells (HSCs) that 
differentiate into other hematopoietic progenitor cells and eventually produce all the 
mature differentiated blood lineages (Chao et al., 2008; Doulatov et al., 2012).  
Experimental investigation of the hematopoietic system in the mouse was pioneered by 
Till and McCulloch who identified a small subset of cells from the mouse bone marrow 
which could self-renew and form myeloerythroid colonies (Becker et al., 1963; Till and 
Mc, 1961). These studies facilitated other investigators to develop assays such as the in 
vitro clonal assay combined with fluorescence-activated cell sorting (FACS), to identify 
and characterize hematopoietic stem and progenitor populations in mouse and human 
(Chao et al., 2008; Doulatov et al., 2012).  The classical model of hematopoiesis 
demonstrates that fully differentiated blood cells constitute two major lineages: myeloid 
and lymphoid. Myeloid lineage cells include granulocytes, monocytes, erythrocytes, and 
megakaryocytes that give rise to platelets. Lymphoid lineage cells include T, B, and 




 Identification of stem and progenitor cells (HSPCs) has promoted our 
understanding of human hematopoiesis. Multiple different cell surface markers were 
identified and used for isolation of HSPCs. For example, CD34 is a well known marker 
for the HSPCs that posses regenerative potential (Civin et al., 1984; DiGiusto et al., 1994; 
Krause et al., 1996). Among these CD34+ HSPCs, additional markers such as CD90, 
CD38, CD45RA, CD123, and CD10 enable researchers to isolate different components of 
the hierarchy. Several studies have demonstrated that HSC resides in Lin-CD34+CD38-
CD90+ population (Chao et al., 2008). Further investigation to identify downstream 
progenitors of HSC has established that multipotent progenitor (MPP) cells are contained 
in Lin-CD34+CD38-CD90-CD45RA- (Majeti et al., 2007). After HSC gives rise to 
MPPs, MPPs further differentiate into progenitors for myeloid or lymphoid lineages. In 
myeloid lineage differentiation, the common myeloid progenitors (CMPs) develop into 
either GMPs or megakaryocyte/erythrocyte progenitors (MEPs). Interleukin-3 receptor 
alpha chain (CD123) and CD45RA distinguish CMP, GMP and MEP: CMPs reside in 
Lin-CD34+CD38+CD123+CD45RA-, GMPs in Lin-CD34+CD38+CD123+CD45RA+, 
and MEPs in Lin-CD34+CD38+CD123-CD45RA- (Chao et al., 2008). Lymphoid lineage 
differentiation is more complicated, since L-MPP is able to generate lymphoid lineage 
cells, as well as monocytes, macrophages and dendritic cells by differentiating into GMP. 
This L-MPP population is contained in Lin-CD34+CD38-CD90-CD45RA+ (Doulatov et 
al., 2010; Goardon et al., 2011).  This thesis will demonstrate DNA methylation 
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differences among human HSPCs and compare epigenetic plasticity between human and 
mouse hematopoietic development.  
 
DNA methylation in normal hematopoiesis 
Two studies have investigated genome-wide DNA methylation in mouse 
hematopoietic development using array or sequencing based methods (Bock et al., 2012; 
Ji et al., 2010). Ji et al. performed CHARM examining 4.6 million CpG sites throughout 
the genome for MPPs, common lymphoid progenitors (CLPs), CMPs, GMPs, and 
thymocyte progenitors (DN1, DN2, DN3). Global methylation changes were involved in 
fate decision at the myeloid or lymphoid commitment stage: decreased methylation for 
myeloid and gain of methylation for lymphoid commitment. This first comprehensive 
methylome map of hematopoietic progenitor cells in murine hematopoiesis identified 
potential novel regulators such as Arl4c and Jdp2, as well as previously known 
transcription factor for hematopoietic differentiation, Meis1. This study demonstrated 
DNA methylation is a core mechanism for hematopoietic development, and epigenetic 
plasticity regulates lineage commitment (Ji et al., 2010). In another study, Bock et al.  
investigated genome-wide DNA methylation of HSCs, MPP1s, MPP2s, CMPs, CLPs, 
GMPs, MEPs, CD4-T cells, CD8-T cells, B cells, erythrocytes, granulocytes, monocytes 
using reduced representation bisulfite sequencing (RRBS). They observed similar pattern 
of epigenetic plasticity in cell fate decision: hypermethylation in CLPs and 
hypomethylation in CMPs. DNA methylation has played a crucial role for silencing of 
genes involved in myeloid differentiation in lymphoid lineage cells and vice versa. For 
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example, promoters of key transcription factor (TF) for myeloid differentiation such as 
Tal1, or binding sites of significant myeloid TFs such as Gata1 were highly methylated in 
CLPs compared to CMPs. This study has demonstrated that the information from the 
combination of DNA methylation and gene expression data accurately inferred cellular 
identity of different blood cells, underscoring the value of DNA methylation in 
hematopoietic development (Bock et al., 2012).   
 For human hematopoiesis, a recent study provided genome-wide DNA 
methylation profile for HSPCs. This study used a nano HpaII-tiny-fragment-enrichment-
by-ligation-mediated-PCR (nanoHELP) assay to investigate DNA methylation of long-
term HSCs (LT-HSCs), short-term HSCs (ST-HSCs), CMPs, and MEPs. Loss of 
methylation has been observed when ST-HSC differentiated into CMPs, and methylation 
changes has been correlated with gene expression at this transition, while other 
commitments such as CMP to MEP transition did not show statistically significant 
correlation between DNA methylation and gene expression. These HSC commitment-
associated methylation patterns were able to predict overall patient survival in three 
independent AML patient cohorts, indicating the importance of epigenetic regulation for 
normal hematopoietic development (Bartholdy et al., 2014). This thesis will compare our 
results of comprehensive methylome map of human hematopoiesis to the mouse studies 
and the human study. 
 
3. AML and LSC 
AML 
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AML is a genetically heterogeneous cancer of myeloid lineage blood cells, and 
characterized by an accumulation of immature myeloid lineage blood cells in bone 
marrow. Since AML is caused by diverse pathogenic mechanisms, it is very important to 
identify subgroups based on the different features of the disease such as morphology and 
genetic alterations (Lowenberg et al., 1999). The French-American-British (FAB) 
classification is the most common method to differentiate the heterogeneous disease 
based on the morphology of leukemic blasts, indicating the degree of differentiation 
(Table 1.1) (Bennett et al., 1976, 1985). Specific cytogenetic abnormalities such as 
translocations and chromosome rearrangements correlate with particular FAB subtypes 
(Table 1.1). These cytogenetic lesions have been used in prognosis to predict clinical 
outcomes and relapse rate (Table 1.2) (Byrd et al., 2002; Grimwade et al., 1998; Slovak 
et al., 2000). In addition to cytogenetic abnormalities, other genetic mutations play an 
important role in leukemogenesis, as about a half of AML cases do not harbor a 
cytogenetic lesion (Dohner, 2007; Lowenberg et al., 1999). The Cancer Genome Atlas 
(TCGA) has provided a public resource of genomic map of over 200 AML patients by 
performing either whole-genome sequencing or whole-exome sequencing. This 
comprehensive sequencing for a large cohort of AML patients revealed the mutational 
landscape of AML. Interestingly, AML genomes have relatively fewer genetic mutations 
compared to other solid tumors, 13 mutations on average, with only 5 in genes 
recurrently mutated in AML. Genetic alterations were classified to nine different 
categories based on their biological functions of genes harboring the alterations: TF 
fusions (18% of cases), NPM1 mutation (27%), tumor suppressors (16%), DNA 
methylation enzymes (44%), activated signaling genes (59%), myeloid TFs (22%), 
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chromatin modifiers (30%), cohesion-complex genes (13%) and spliceosome-complex 
genes (14%). TF-fusion includes PML-RARA, MYH11-CBFB, RUNX1-RUNX1T1, and 
PICALM-MLLT10; TP53, WT1, and PHF6 for tumor suppressors; DNMT3A, DNMT3B, 
DNMT1, TET1, TET2, IDH1, and IDH2 for DNA methylation enzymes; FLT3, KIT, 
KRAS/NRAS, PTPs, and other Tyr or Ser-Thr kinases; RUNX1, CEBPA, and other 
myeloid TFs for myeloid TFs; MLL-X fusions, MLL-PTD, NUP98-NSD1, ASXL1, 
EZH2, KDM6A, and other modifiers for chromatin modifying enzymes.  This study has 
suggested common mutations such as DNMT3A, NPM1, CEBPA, IDH1/2 and RUNX1, 
which were mutually exclusive to TF-fusion might be involved in the initiation of AML 
(Cancer Genome Atlas Research, 2013).   
 
LSC model  
 LSC model postulates that AML is organized as a hierarchy like normal 
hematopoiesis, in which LSCs give rise to leukemic blast cells like HSCs give rise to 
normal progenitors and differentiated cells. In the 1990s, Dick’s group identified that a 
small subset of CD34+CD38- cells were uniquely able to transplant AML into immune 
deficient mice (Bonnet and Dick, 1997; Lapidot et al., 1994). These observations lead to 
the hypothesis that LSCs possess increased self-renewal capacity, which enables LSCs to 
maintain and propagate the disease by generating bulk cancer cells (Kreso and Dick, 
2014). Later, improved xenotransplantation models have revealed that LSC activity can 
be identified in other subpopulations as well such as CD34+CD38+ or CD34- (Eppert et 
al., 2011; Goardon et al., 2011; Martelli et al., 2010; Sarry et al., 2011; Taussig et al., 
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2008; Taussig et al., 2010).  Recently, surface makers other than CD34 and CD38 were 
identified to enrich for LSCs among heterogeneous cells.  C-type lectin-like molecule-1 
(CLL-1) was expressed in one third of CD34+CD38- compartment of 29 AML patients 
(van Rhenen et al., 2007). CD96 was highly expressed in CD34+CD38- compartment of 
about two thirds of AML patients (Hosen et al., 2007).  T-cell Ig mucin-3 (TIM3), was 
elevated in LSC fraction compared to normal HSCs (Jan et al., 2011; Kikushige et al., 
2010). CD47 was highly expressed in LSC, and expression of it protected LSCs from 
being phagocytosed by macrophages (Majeti et al., 2009b). CD25 and CD32 were also 
identified as novel marker for LSCs (Saito et al., 2010). Even though, many studies have 
reported a variety of surface markers for LSC, heterogeneous expression of these markers 
in patients suggests a complex immunophenotype that cannot be applied universally in 
AML.  
 Recently, several studies have investigated genome-wide gene expression profiles 
of LSCs compared to HSCs or leukemia progenitor cells (LPCs) (de Jonge et al., 2011; 
Eppert et al., 2011; Gentles et al., 2010; Majeti et al., 2009a).  Majeti et al. performed the 
first genome-wide gene expression analysis of LSCs compared with HSCs. They 
identified 3005 differentially expressed genes, enriched in pathways such as Wnt 
signaling, MAP kinase signaling, adherence junction, ribosome, and T cell receptor 
signaling (Majeti et al., 2009a). Gentles et al. identified 52 genes which distinguished 
CD34+CD38- LSCs from CD34+CD38+ LPCs through genome-wide gene expression 
analysis. This study showed 52 genes which were associated with overall, event-free, and 
relapse-free survival and with therapeutic response (Gentles et al., 2010). De Jonge et al. 
compared CD34+ fractions with the CD34- subfraction of AML patients and CD34+ 
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normal progenitor compartment, and found that the top 50 CD34+ specific genes were 
able to predict overall survival of AML patients (de Jonge et al., 2011). These studies 
used the cell surface markers CD34 and CD38 to define LSC compartment, following the 
traditional LSC model. Eppert et al. have defined LSCs functionally using a xenograft 
assay. They sorted AML cells into 4 different fractions based on CD34 and CD38 
expression first, then performed a xenograft assay on these fractions from 16 AML 
patients. They compared the gene expression profile of the functionally validated LSC to 
non-LSC or HSCs. The analysis demonstrated that LSC and HSC share a core 
transcriptional program, indicating the commonality between the two populations would 
be derived from ‘stemness’ property. The genes related to the stemness were associated 
with clinical outcome (Eppert et al., 2011).  
 
Cell of origin 
 A number of both mouse and human studies have investigated the cell of origin in 
AML. Mouse studies have typically utilized retroviral oncogene transduction or knock-in 
models to explore this question and have generally led to the conclusion that committed 
progenitors, in particular CMP and/or GMP, serve as the cell of origin for most AML 
models. In one study of MN1-induced AML, retroviral transduction of single CMP, but 
not GMP or HSC, resulted in the development of AML, indicating tight restriction of 
transformation by this oncogene (Heuser et al., 2011). In a second study using a mouse 
model of MLL-AF9 AML, the cell of origin influenced biological properties such as gene 
expression, epigenetics, and drug responses (Krivtsov et al., 2013). Both of these studies 
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highlight the significance of this question for leukemogenesis and potential therapies. In 
contrast to mouse models, inferring the cell of origin in human leukemia is only possible 
based on features of the disease. Studies investigating the cell of origin of human AML 
using surface immunophenotype and gene expression originally suggested AML LSC 
arise from HSC (Kreso and Dick, 2014). However, a more recent study that compared 
genome-wide gene expression and surface markers of LSCs to those of normal HSPCs 
suggests that LSCs arise from more committed progenitors, including L-MPP and GMP 
(Goardon et al., 2011). In blast-crisis chronic myeloid leukemia (CML), GMPs with 
activation of beta-catenin from patients showed increased self-renewal and leukemogenic 
potential (Jamieson et al., 2004). Notably, three studies have recently reported that 
leukemogenic mutations existed in HSC, called ‘pre-leukemic HSC’ that underwent 
further clonal evolution to give rise to AML LSC. These studies have demonstrated a 
hierarchy among genetic mutations during clonal evolution of the pre-leukemic HSCs. 
For example, mutations in epigenome modifying enzymes such as DNMT3A, IDH1/2 
have occurred earlier than mutations of genes involved in activated signaling such as 
FLT3 and NPM1 (Corces-Zimmerman et al., 2014; Jan et al., 2012; Shlush et al., 2014). 
These two studies suggest that the pre-leukemic HSCs which harbor the early occurring 
genetic mutations is a cell of origin in AML, which may lead to disease relapse after 
remission.  
 
4. DNA methylation in AML  
Somatic mutations in epigenome modifying enzymes in AML 
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 Dysregulation of the epigenome is a common feature in AML, as indicated by the 
recent discoveries that a number of epigenome modifying genes are mutated in AML. 
These genes include several involved in the regulation of DNA methylation such as 
IDH1/2, DNMT3A, and TET2, and modulation of chromatin modifications such as 
ASXL1, EZH2, and others (Abdel-Wahab et al., 2012; Cancer Genome Atlas Research, 
2013; Ley et al., 2010; Yan et al., 2011). Beyond somatic mutations in these epigenome 
modifying factors, characterization of DNA methylation in bulk AML cells has revealed 
great heterogeneity among patient cases. Figueroa et al. examined ~350 AML patient 
samples using HpaII tiny fragment enrichment by ligation-mediated PCR (HELP) 
interrogating ~14000 unique gene loci. This study identified 16 distinct clusters among 
the patients based on DNA methylation profile, which some of the clusters were 
associated with particular genetic aberrations such as mutations in CEBPA, NPM1, 
AML1-ETO, CBFb-MYH11, and PML-RARA (Figueroa et al., 2010b). This study  
showed the first epigenetically distinct subtypes in AML, associated with genetic 
alterations. However, this study was done before genetic mutations in epigenetic 
modifiers were identified.  The mutations in epigenome modifying enzymes induce 
aberrant methylation in the AML cells. In particular, AML with IDH1 or IDH2 mutations 
was associated with globally increased DNA methylation (Cancer Genome Atlas 
Research, 2013; Figueroa et al., 2010a). MLL fusion or mutations in NPM1, DNMT3A, 
or FLT3 were associated with decreased DNA methylation. It is interesting to observe 
that about a half of AML patients (44%) harbored a genetic mutation in DNA 
methylation enzymes, suggesting a critical role of this process in leukemogenesis (Cancer 
Genome Atlas Research, 2013). Recent studies have investigated how genetic mutations 
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in DNA methylation enzymes play an important role in leukemic transformation. Challen 
et al. has shown loss of function of DNMT3A disturbed HSC differentiation over serial 
transplantation, while the LT-HSC compartment expanded (Challen et al., 2012). 
DNMT3A mutations have been associated with overexpression of HSC specific genes, 
such as HOXA and HOXB genes in AML patients (Yan et al., 2011). As mentioned 
previously, TET enzymes are known to be involved in DNA demethylation by producing 
5hmC intermediates. It has been reported that bone marrow samples from patients with 
myeloid malignancies with TET2 mutations showed decreased 5hmC with 
hypomethylation compared to normal controls, and the interruption of TET2 function in 
mouse model has displayed myeloid-skewed differentiation of HSCs. (Ko et al., 2010; 
Moran-Crusio et al., 2011; Quivoron et al., 2011). TET2 mutation has been implicated in 
clonal hematopoiesis in elderly individuals (Busque et al., 2012; Genovese et al., 2014; 
Jaiswal et al., 2014; Xie et al., 2014). Several studies identified recurrent mutations in 
IDH1 and IDH2 in AML patients and their function in leukemogenesis (Figueroa et al., 
2010a; Marcucci et al., 2010; Mardis et al., 2009; Ward et al., 2010).  IDH1/IDH2 
mutations displayed a neomorphic enzymatic activity generating 2-hydroxyglutarate (2-
HG) from α-ketoglutarate (Dang et al., 2009; Ward et al., 2010). 2-HG, oncometabolite, 
has been shown to inhibit TET enzyme activity, and induce promoter hypermethylation 
(Figueroa et al., 2010a; Shih et al., 2012). All the studies have demonstrated the 
significant role of the DNA methylation enzymes in regulation of epigenome in 
hematopoietic differentiation and disease development.  
Genetic mutations in chromatin modifying enzymes play a significant role in 
leukemogenesis. For example, loss of function mutations of ASXL1 causes a genome-
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wide loss of H3K27me3 and collaborates with oncogenes to promote leukemogenesis 
(Abdel-Wahab et al., 2012). The role of EZH2 mutation in myeloid malignancies is 
complicated, as both loss of function and gain of function mutations in EZH2, a histone 
lysine methyltransferase and a member of a PRC2 complex have been implicated in 
leukemogenesis (Ernst et al., 2010; Lund et al., 2014) 
Clinical implication of epigenetics in AML patients 
 Mutations in DNMT3A, IDH1, IDH2, and TET2 have been linked to clinical 
prognosis such as risk stratification and therapeutic responses in AML patients (Shih et 
al., 2012). DNMT3A mutation has been associated with adverse overall survival in 
intermediate-risk group patients (Ley et al., 2010; Patel et al., 2012). TET2 mutation has 
shown adverse overall survival in AML patients with intermediate-risk, while IDH1 or 
IDH2 mutation, which frequently co-occurred with NPM1 mutations, has shown 
favorable clinical outcome (Patel et al., 2012).  
 In addition to the association of genetic mutation in DNA methylation enzymes 
with clinical outcome, DNA methylation itself has been indicated as a prognostic marker. 
Figueroa et al. showed an association of distinct methylation clusters of AML patients to 
overall survival and demonstrated that 15 genes with aberrant DNA methylation could 
predict overall survival of AML patients (Figueroa et al., 2010b). Furthermore, 
quantitative DNA methylation has successfully predicted clinical outcome in AML 
patients (Bullinger et al., 2010). Deneberg et al. has reported that hypermethylation at 
polycomb group (PcG) target genes was associated with favorable clinical outcome in 
cytogenetically normal AML (CN-AML) (Deneberg et al., 2011).  
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 Besides the prognostic power of DNA methylation, the alteration of DNA 
methylome of myeloid malignancies has been a target of therapy, as it is reversible. 
Azacitidine and decitabine, DNMT inhibitors, are widely used to improve clinical 
outcome in AML (Estey, 2013). Recent studies have reported that drugs regulating 
chromatin modification could be an effective therapy for AML patients. For example, 
suppression of bromodomain-containing 4 (BRD4), which recognizes acetylated lysine 
on histone, by the small molecule inhibitor, JQ1, demonstrated anti-leukemic effects 
(Valent and Zuber, 2014; Zuber et al., 2011).  Small molecule inhibitors of DOT1L, a 
telomeric silencing 1-like histone 3 lysine 79 (H3K79) methyltransferase, have shown 
therapeutic effects against MLL-fusion AML (Daigle et al., 2013; Daigle et al., 2011). 



































Table 1.1. French-American-British (FAB) classification. 
 
Type Name                 Cytogenetics 
M0 Undifferentiated acute myeloblastic leukemia  
M1 Acute myeloblastic leukemia with minimal maturation  
M2 Acute myeloblastic leukemia with maturation t(8;21)(q22;q22), t(6;9) 
M3 Acute promyelocytic leukemia (APL) t(15;17) 
M4 Acute myelomonocytic leukemia inv(16)(p13q22), del(16q) 
M4eo Acute myelomonocytic leukemia with eosinophilia inv(16), t(16;16) 
M5 Acute monocytic leukemia del (11q), t(9;11), t(11;19) 
M6 Acute erythroid leuekmia  



















Table 1.2. Cytogenetics and prognosis. 
 
Risk groups Cytogenetics 5-year survival Relapse rate 
Good t(8;21), t(15;17), inv(16) 70% 33% 
Intermediate Normal, +8, +21, +22, del(7q), Abnormal 11q23 48% 50% 










 Epigenetic signature of leukemia stem cell 
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This work is an ongoing project of the Feinberg Lab and Johns Hopkins. All publication 
rights are reserved for these institutions and the presentation of this work here does not 
preclude future publication elsewhere. 
 
Summary 
AML is a hematopoietic malignancy, composed of a hierarchy that LSCs give rise 
into Blast cells. Since LSC is clonally related to Blasts, we hypothesized that particular 
epigenetic features would endow the distinct capacity of LSC, which can initiate and 
propagate the disease. Here, we first demonstrated epigenetic differences between LSCs 
and Blasts by performing genome-wide methylation analysis. We identified 84 DMRs in 
70 genes, so called LSC epigenetic signature, which have shown differential methylation 
and expression. We found that HOXA cluster genes were enriched in LSC epigenetic 
signature, suggesting a critical role of these genes to confer the unique ability of LSC. 
The LSC epigenetic signature was partially dependent on genetic mutation in upstream 
regulators and epigenome modifying enzymes, yet about a half of it was independent of 
genetic mutation. The LSC epigenetic signature showed prognostic power in both DNA 
methylation and gene expression data sets, independent of previously known clinical 
factors such as age. These results provide the first evidence for epigenetic variation 
between LSC and their blast progeny in AML, and moreover, demonstrate that DMRs 




AML LSC and Blasts Exhibit Epigenetic Differences That Define an LSC Epigenetic 
Signature 
To formally investigate epigenetic differences between LSC and blast progeny, 
we sought to identify DMRs between functionally-defined AML LSC-enriched 
populations and their downstream non-engrafting blasts from a cohort of 15 primary 
patient samples. We obtained samples from 15 AML patients (Tables 2.1 and 2.2) and 
isolated subpopulations based on the expression of CD34 and CD38 including: Lin-
CD34+CD38-, Lin-CD34+CD38+, and Lin-CD34- (Figure 2.1). We then performed 
comprehensive genome-scale DNA methylation analysis using the Illumina Infinium 
HumanMethylation450 bead chip array. While AML LSC were originally described to be 
exclusively contained in the CD34+CD38- subpopulation, recent reports have indicated 
that leukemia-initiating cells can also be detected in multiple compartments including 
both the CD34+CD38+ and CD34- subpopulations, although usually at lower frequencies 
(Eppert et al., 2011; Goardon et al., 2011; Sarry et al., 2011).  
In order to identify LSC and blast populations, we conducted xenotransplantation 
assays on all three CD34/CD38 subpopulations from each of the 15 AML cases (Table 
2.3). Similar to other reports, leukemic engraftment was observed from at least one 
subpopulation in 10 out of 15 AML patients. As expected, LSC activity dramatically 
decreased following the immunophenotypic hierarchy with 64.3% of CD34+CD38-, 
46.7% of CD34+CD38+, and 26.7% of CD34- subpopulations engrafting in vivo (Table 
2.3). To identify epigenetic markers of functional LSC, we performed DMR analysis 
between the 20 LSC-containing (engrafting) and 24 blast-containing (non-engrafting) 
fractions (hereafter termed “LSC” and “Blast”). The analysis identified 3030 DMRs, of 
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which 91.4% were hypomethylated in LSC (Table 2.4, see Appendix1 and Table 2.5). 
These DMRs were further classified according to their global genomic location 
including: islands (regions with a GC content greater than 50% and an observed/expected 
CpG ratio of more than 0.6), shores (regions within 2kb of an island), shelves (regions 2 
to 4kb away from an island), and open sea (isolated CpG sites in the genome without a 
specific designation). These DMRs were nearly evenly distributed in CpG islands 
(27.8%) and open seas (29%), (Table 2.5). In addition, the DMRs strongly correlated 
with gene expression at CpG islands and open seas, whereas most hypomethylated DMRs 
in the engrafting populations were associated with transcriptional up-regulation of 
associated genes (Figure 2.2).  
We next sought to integrate DNA methylation with gene expression analysis to 
identify an LSC epigenetic signature by extracting genes which passed a DMR p value 
<0.01 cutoff and exhibited >0.5 log2 fold gene expression change between the LSC and 
Blast populations, with an inverse relationship between gene expression and DNA 
methylation within 2kb of the transcriptional start site (TSS). We excluded gene body 
DMRs, as there was no statistically significant positive correlation in AML or normal 
hematopoiesis comparisons (Figure 2.3). We applied a minimum absolute value log2 0.5 
fold gene expression cutoff, similarly to our previous LSC gene expression signature 
using the same microarray platform (Gentles et al., 2010). With these parameters, we 
identified 84 regions of 70 unique genes exhibiting differential methylation and gene 
expression in LSC compared to Blasts (Table 2.6).   
We compared our LSC epigenetic signature to the LSC gene expression 
signatures from previous studies (Eppert et al., 2011; Gentles et al., 2010).  Only six out 
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of 70 genes were found in these earlier studies, suggesting most of the genes identified 
here comprise a novel signature for LSC defined first by DMR analysis and refined by 
gene expression differences. One gene in this signature, REC8, which encodes a kleisin 
family protein that is associated with the cohesin complex, was hypomethylated and 
transcriptionally up-regulated in LSC (Figure 2.4a and Table 2.6). Notably, mutations of 
components of the cohesin complex have been identified in AML and other tumor types 
(Losada, 2014; Thol et al., 2014). We speculate that hypomethylation and increased 
expression of REC8 in LSC might be related to cohesin complex activity in LSC. We also 
identified HOXA5, HOXA6, HOXA7, HOXA9, and HOXA10 in the LSC epigenetic 
signature (Figure 2.4b-d and Table 2.6). These HOXA cluster genes were hypomethylated 
and highly expressed in LSC (Table 2.6). Notably, HOXA9 showed hypomethylation and 
increased expression in LSC (Figure 2.4b and Table 2.6), and aberrant expression of 
HOXA9 is known to be involved in increased proliferation of HSPCs and leukemogenesis, 
suggesting a critical role in LSC activity (Chung et al., 2006; Lehnertz et al., 2014; 
Takeda et al., 2006; Thorsteinsdottir et al., 2002).  
Because the MLL subtype is itself associated with changes in expression of 
members of the HOXA gene cluster (Drabkin et al., 2002; Milne et al., 2002), we 
performed a second DMR analysis excluding the 5 LSC populations from the 2 MLL 
patients in our cohort. We observed substantial overlap between the sets of DMRs 
without MLL cases and with all samples. For the key LSC epigenetic signature, 81 of 84 
DMRs, including the HOXA genes, were present after removal of the MLL cases (Table 
2.7). Considering all DMRs with p < 0.01 (not just the LSC signature), there was 77% 
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overlap (Table 2.7). Thus, the presence of the MLL subtype was not a confounding 
variable in defining the LSC epigenetic signature. 
The LSC Epigenetic Signature is Partially Dependent on Underlying Somatic 
Mutations 
In order to identify important pathways and upstream regulators of LSC activity, 
we utilized Ingenuity Pathway Analysis (IPA). The most significantly enriched pathway 
was fatty acid α oxidation (Table 2.8), and inhibitors of this pathway have been 
previously shown to induce apoptosis of leukemia cells (Samudio et al., 2010). Ingenuity 
upstream regulator analysis identified NPM1, ASXL1, and KAT6A as the most significant 
upstream regulators of the LSC epigenetic signature genes, primarily through regulation 
of HOXA genes including HOXA5, HOXA6, HOXA7, HOXA9, and HOXA10 (Table 2.9). 
Significantly, all three of these upstream regulators have been found to be mutated in 
AML and likely serve as driver genes (Cancer Genome Atlas Research, 2013). In 
particular, mutations in ASXL1 and NPM1 have been shown to cooperate with HOX 
genes to initiate leukemia by enhancing self-renewal and proliferation of hematopoietic 
progenitors (Abdel-Wahab et al., 2012; Vassiliou et al., 2011). Consistent with this, we 
observed that NPM1 mutation was associated with decreased methylation and increased 
expression of HOXA5, HOXA6, HOXA7, HOXA9, and HOXA10 compared to NPM1 
wild-type samples in the TCGA cohort (Figure 2.5).  
We then sought to investigate the LSC epigenetic signature for its association 
with AML mutations in the TCGA cohort (Figure 2.6). The TCGA cohort consists of 200 
AML patient samples with associated DNA methylation, gene expression, and full 
genotyping from genome/exome sequencing (Cancer Genome Atlas Research, 2013). 
33	  
First, we identified the epigenetic signatures associated with individual AML mutations 
by performing DMR analysis between wild-type and mutant patient samples (Figure 2.6). 
The mutations tested included epigenome modifying enzymes such as DNMT3A, IDH1/2, 
and TET1/2, and upstream regulators of our LSC epigenetic signature, NPM1 and ASXL1 
(Figure 2.6). KAT6A was not included as there was no patient who had this mutation 
among the patients investigated on methylation arrays. Next, we examined the overlap 
between the mutation-associated DMRs and our LSC epigenetic signature (Figure 2.6). 
Each LSC epigenetic signature gene was classified into three categories: (1) upstream 
regulator-associated if differentially methylated in association with any mutation in 
upstream regulators; (2) epigenome modifying enzyme-associated if differentially 
methylated in association with any mutation in epigenetic enzymes; or (3) mutation-
independent if it was not differentially methylated in association with either upstream 
regulator or epigenome modifying enzyme (Figure 2.6 and Table 2.10). Of the 84 LSC 
DMRs, 28 (33.3%) and 27 (32.1%) were associated with upstream regulator or 
epigenome modifying enzyme mutations, respectively (Figure 2.6 and Table 2.10). 
However, 40 DMRs (47.6%) including HOXA7 and HOXA9 were mutation-independent 
targets (Figure 2.6 and Table 2.10). It should be noted that some of the LSC differentially 
methylated genes, including HOXA7 and HOXA9, have multiple DMRs regulated by 
different mechanisms. For example, HOXA7 has 4 DMRs in the LSC epigenetic 
signature; one associated with mutation in NPM1, two associated with mutation in 
DNMT3A, TET1, and NPM1, and one mutation-independent (Table 2.10). Therefore, we 
annotated each DMR in those genes differently with DMR numbering such as 
HOXA9/DMR1 (Figure 2.6 and Table 2.10). A small subset (11 signatures) of upstream 
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regulator and epigenetic enzyme associated LSC epigenetic signatures overlapped, 
including REC8, HOXA6, and HOXA7 (Figure 2.6 and Table 2.10). This analysis showed 
that all the HOXA genes are epigenetically regulated by at least one upstream regulator, 
and HOXA6, HOXA7/DMR2, and HOXA7/DMR3 are common targets of both upstream 
regulators and epigenetic enzymes (Figure 2.6 and Table 2.10), and all of these changes 
involved DNA hypomethylation. In addition, hypomethylation of HOXA7/DMR1 
occurred independently of mutations (Figure 2.6 and Table 2.10). Together, these results 
suggest that overexpression of HOXA genes mediated by DNA hypomethylation is a core 
mechanism for LSC activity.  
The LSC Epigenetic Signature is Associated with Overall Survival in Human AML 
We hypothesized that if the LSC epigenetic signature reflected key drivers of the 
functional differences between LSC and Blasts, then this signature should be associated 
with clinical outcomes in human AML. First, we tested the association between the LSC 
epigenetic signature and overall survival in the DNA methylation data from the TCGA 
AML cohort (Cancer Genome Atlas Research, 2013). To assign each TCGA patient to an 
LSC-like or Blast-like category, we calculated scores of each TCGA sample based on the 
probability of being closer to either LSC or Blasts. A comparable number of samples 
were assigned to each category by this method (99 for Blast-like and 93 for LSC-like). In 
univariate survival analysis, the LSC-like group showed worse outcome compared to the 
Blast-like group (hazard ratio (HR) =2.3, (95% confidence interval (CI) =1.6-3.4); 
p=1.07 x10-5) (Figure 2.7a). The LSC-like vs Blast-like stratification remained associated 
with overall survival in multivariate analysis together with other known prognostic 
factors such as age (considered as a continuous variable), cytogenetic risk (assessed as 
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high vs low risk and intermediate vs low risk), NPM1, and FLT3 mutations (HR=1.9, 
(95% CI= 1.2-2.9); p=0.003; Table 2.11).   
Next, we tested the association between expression of LSC epigenetic signature 
genes and clinical outcome using four different cohorts including TCGA (Cancer 
Genome Atlas Research, 2013), a cohort of normal karyotype patients (Dufour et al., 
2010; Metzeler et al., 2008), and two cohorts of mixed karyotype patients (Valk et al., 
2004; Wilson et al., 2006; Wouters et al., 2009).  These cohorts consist of a total of 776 
AML patients treated on different clinical protocols that also exhibited distinct biological 
characteristics(Gentles et al., 2010). We observed a strong correlation between the 
relative expression of LSC epigenetic signature genes and overall survival in the TCGA 
cohort (correlation=0.49; p=4 x10-13; Figure 2.8). The more highly expressed a gene was 
in LSC compared to Blasts, the more robust its association with worse overall survival. In 
all four cohorts, the overall expression level of the signature genes was significantly 
associated with overall survival, with higher expression associated with worse clinical 
(Table 2.12). This association remained significant in multivariate Cox regression 
including age (continuous), cytogenetic risk, NPM1, and FLT3 mutations (HR=1.7, (95% 
CI, 1.0-2.7); p= 0.03; Table 2.11). Similar results were observed for the three other 
cohorts in univariate and multivariate analyses (Figures 2.7c-e, Tables 2.12 and 2.13).  
Finally, we tested if mutations in epigenetic enzymes such as DNMT3A, IDH1/2, 
TET2, and ASXL1 affected the prognostic impact of the LSC epigenetic signature in the 
TCGA cohort. As described previously, mutation in DNMT3A, but none of the other 
genes, was associated with patient overall survival (Table 2.14). Multivariate survival 
analysis including DNMT3A mutation showed that our LSC epigenetic signature 
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remained independently associated with clinical outcome in both the DNA methylation 
and gene expression data from TCGA, even when incorporating cytogenetic risk group 
(Table 2.15), as well as within the intermediate cytogenetic risk group alone (Table 2.16). 
Overall, these results demonstrate that the LSC epigenetic signature defined by DNA 
methylation and gene expression is associated with overall survival in human AML.  
 
Discussion 
The cancer stem cell (CSC) model was originally proposed based on observations 
from human AML in which only subpopulations of leukemia-initiating or LSC possessed 
engraftment potential (Bonnet and Dick, 1997; Lapidot et al., 1994). According to this 
model, the LSC give rise to downstream Blasts that lack critical stem cell properties. As 
LSC and their non-engrafting Blast progeny are clonally related, a major implication of 
this leukemia stem cell model is that their functional properties must be due to epigenetic 
differences. Here, we provide such evidence by characterizing global DNA methylation 
features of LSC defined by xenotransplantation of AML subpopulations, compared to 
non-engrafting Blast cells, demonstrating that AML LSC exhibit global hypomethylation 
compared to non-LSC Blast cells. Integrating DNA methylation and gene expression 
analysis, we identified 84 regions of 70 genes as the LSC epigenetic signature. 64 of 
these 70 genes were not reported in previous gene expression studies for LSC (the 
exceptions being CD34, SH3BP5, RBPMS, LTB, MS4A3, and VNN1) (Eppert et al., 2011; 
Gentles et al., 2010). Most of the LSC epigenetic signature was mutation-independent, 
not associated with mutations in upstream regulators or epigenome-modifying enzymes 
suggesting that leukemogenesis may converge on these primary epigenetic signatures We 
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also identified some mutation-associated epigenetically dysregulated genes, including 
REC8 and HOXA7. Together, these epigenetic signatures represent potential therapeutic 
targets regardless of the different types of the underlying mutations present in individual 
AML cases. Furthermore, the LSC epigenetic signature was prognostic of patient overall 
survival independently of known survival predictors such as age and cytogenetic 
abnormalities, emphasizing its functional importance.  
Apart from its prognostic effect, the LSC epigenetic signature represents a 
molecular target that may improve patient survival and prevent relapse. Recently, 
epigenetic therapy with hypomethylating agents azacytidine and decitabine has been 
approved for the treatment of AML. Randomized trials demonstrated improved overall 
survival compared to chemotherapy, but also indicated limited effect on relapse rate in 
high-risk AML (Estey, 2013). Our results indicate that LSC are relatively 
hypomethylated compared to Blasts, suggesting that they may be less effectively targeted 
by hypomethylating agents, possibly accounting for their limited efficacy in relapse-free 
survival. It would be of great interest to see how the LSC epigenetic signature is affected 
by these drugs. 
More specifically, this LSC epigenetic signature was markedly enriched for 
members of the HOXA cluster, suggesting this cluster is a key driver of LSC function. 
The HOXA cluster has been implicated as a key regulator of hematopoiesis and myeloid 
malignancy (Alharbi et al., 2013). In particular, HOXA9 is known to be involved in 
increased proliferation of HSPC and leukemogenesis (Thorsteinsdottir et al., 2002), even 
occurring as a fusion oncogene in rare cases (Nakamura et al., 1996). Moreover, 
increased expression of HOXA9 has been found to be an adverse prognostic factor in 
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AML (Golub et al., 1999). Other HOXA family members including posterior (HOXA7, 
HOXA9, and HOXA10) and anterior (HOXA6) members have been implicated in 
leukemogenesis, as overexpression of these genes in normal mouse HSPC leads to 
increased self-renewal, transformation, and development of myeloid malignancies (Bach 
et al., 2010).  The functional LSC epigenetic signature provided here demonstrates that 
the HOXA family is a key driver of AML LSC that may function in imparting aberrant 
self-renewal.  
 
Materials and Methods 
Human Samples 
Human acute myeloid leukemia (AML) samples were collected from patient peripheral 
blood (PB) or bone marrow (BM) at Stanford hospital, according to an IRB-approved 
protocol (22264), and informed consent was obtained from all subjects.  PBMC or 
BMMC were separated with Ficoll-Paque Plus (Amersham Biosciences, Piscataway, NJ, 
Catalog number: 17-1440-03), and cryopreserved in 1 x freezing medium (90%FBS + 
10%DMSO).  All the AML experiments were conducted with cryopreserved PBMC or 
BMMC samples that were thawed and washed in IMDM medium containing 10% FBS. 
Flow Cytometry Analysis and Cell Sorting 
A battery of antibodies (Abs) was used for staining, analysis and sorting of progenitor 
cells from	   AML patient PBMCs/BMMCs, as well as lineage analysis human 
chimerism/engraftment	  (Table 2.17).  Cells were either analyzed or sorted using a FACS 
Aria II cytometer (BD Biosciences, Franklin Lakes, NJ).  Analysis of flow cytometry raw 
data was done with FlowJo Software (Treestar, Ashland, OR). 
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Xenotransplantation Assay 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG) were obtained from The Jackson 
Laboratory (Bar Harbor, ME) and bred in a specific pathogen-free environment per 
Stanford Administrative Panel on Laboratory Animal Care Guidelines (Protocol 22264).  
Six to eight week-old adult mice were exposed to 200 rads of gamma irradiation at least 
two hours (up to 24 hours) prior to transplantation.  Up to 500 thousand fresh-sorted 
AML cell subpopulation were resuspended in 30 µl of Hank’s Balanced Salt Solution 
(HBSS) (Gibco Life Technologies, Grand Island, NY) containing 2% FBS, and injected 
intravenously via the tail vein using a 29-gauge needle. For each cell subpopulation, at 
least three technical replicates were performed by transplantation of three aliquot of cells 
into three mice. Around 150 mice in total were used. Neither randomization nor blinding 
was used for this study. 
After eight weeks, mice were euthanized with CO2 according to IRB approved protocol 
(22264).  BM were isolated using scissors and needle flashing, then underwent hypotonic 
red cell lysis using ACK (Ammonium-Chloride-Potassium) lysing buffer (Life 
Technologies, Grand Island, NY, Catalog# A10492). BMMCs were stained with Ab 
combinations (Table 2.17) on ice for 30 minutes, and dead cells were excluded by 
propidium iodide (PI) staining.  Human myeloid engraftment (hCD45+CD33+) and 
lymphoid engraftment (hCD45+CD19+) were analyzed on flow as described before. 
Illumina Infinium Human Methylation 450 Bead Array Assay  
Genomic DNA from each sample was purified using the MasterPure DNA purification 
kit (Epicentre) according to the manufacturer’s protocol. The genomic DNA (250-500ng) 
was treated with sodium bisulfate using the Zymo EZ DNA Methylation Kit (ZYMO 
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Research) as recommended by the manufacturer, with the alternative incubation 
conditions for the Illumina Infinium Methylation Assay. Converted DNA was eluted in 
11ul of elution buffer. DNA methylation level was measured using Illumina Infinium HD 
Methylation Assay (Illumina) according to the manufacturer’s specifications. 
Methylation array data are deposited at the Gene Expression Omnibus (GEO) with 
accession number GSE63409. 
Illumina Infinium Human Methylation 450 Bead Array Analysis 
Raw intensity files were obtained using minfi package (Aryee et al., 2014) to calculate 
methylation ratios (Beta values). The data was normalized using Illumina preprocessing 
method implemented in minfi. Several quality control measures were applied to remove 
arrays with low quality. Control probes were examined on the 450k array to assess 
several measures including bisulfite conversion, extension, hybridization, specificity and 
others. Next, median methylated and unmethylated signals were calculated for each 
arrays; no array was identified for signal values lower than 10.5. For multidimensional 
scaling analysis, probes containing an annotated SNP (dbSNP137) at the single-base 
extension or CpG sites were removed (17398 probes removed). Minfi 1.8.9 was used. 
Bump hunting method previously described was applied to identify DMRs in 450k array 
(Aryee et al., 2014; Jaffe et al., 2012). Beta value of 0.1 (10% of methylation difference) 
was used as cutoff when finding DMRs. Statistical significance was assigned by 
permutations testing and the P-value cutoff used for downstream analysis was <0.01 that 
corresponded to Benjamini-Hochberg adjusted p-value <0.1 (data not shown) unless 
different cutoff was designated in result part. Bumphunter 1.2.0 was used. Same method 
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was applied to identify DMRs for the second DMR analysis of LSC vs Blast that we 
removed 5 LSC cases from 2 MLL patients (SU042 and SU046). 
Affymetrix Microarray Expression Analysis  
Total RNA was extracted from each FACS-sorted cell population using RNeasy® Plus 
Mini (QIAGEN, Valencia, CA, Catalog#: 74134) according to the manufacture’s 
protocol.  All RNA samples were quantified with 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA), subjected to reverse transcription, two consecutive 
rounds of linear amplification, and production and fragmentation of biotinylated cRNA.  
15µg of cRNA from each sample was hybridized to HG U133 Plus 2.0 microarrays.  
Hybridization and scanning were performed according to the manufacture’s instruction 
(Affymetrix).  This step was performed at the PAN center of Stanford University. Data 
were normalized by GC robust multi-array average method and analyzed on 
R/Bioconductor. SU042 CD34+38+ was removed from further analysis due to low 
quality. SU001 was excluded, as the samples from this patient were not included on 
expression array (GEO GSE63270). 
Sanger Sequencing to Detect AML Mutations 
Genomic DNA was extracted from patient BMMC or PBMC using QIAmp DNA Mini 
Kit (QIAGEN, Valencia, CA, Catalog#: 51304) according to the manufacture’s 
instruction.  PCR primers were designed to cover exon 3-11 of TET2, exon 4 of IDH1/2, 
and exon 7-23 of DNMT3A (Table 2.18).  The PCR reaction premix consists of 1x of 
OneTaq 2x Master Mix (NEB, Ipswich, MA, Catalog#: M0482L), 0.2µM forward and 
reverse primers respectively, and 10ng (up to 100ng) genomic DNA as template. The 
reaction was under the condition of 95ºC initial denaturation for 30 seconds, 45 cycles of 
42	  
extension containing 94ºC for 30 seconds, 56ºC for 1 minute (or as necessary) and 72ºC 
for 1 minute, and a final extension at 72ºC 5 minutes.  The PCR products were 
concentrated with PCR purification kit (QIAGEN, Valencia, CA, Catalog#: 28106), then 
submitted to Sequentech (Mountain View, CA) for sequencing of both forward and 
reverse directions using 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA) 
according to the manufacturer’s instruction.  The sequencing data was analyzed using 
Sequencher 5.1 (Gene Codes Corporation, Ann Arbor, MI), and single-nucleotide 
polymorphism (SNP) was excluded by checking NCBI website before getting the final 
mutation results. 
Survival Analysis 
Survival analysis was performed to assess the association of LSC DNA methylation and 
gene expression signatures with clinical outcome (overall survival) in 4 different cohorts. 
For DNA methylation data set (TCGA), patients were separated into two groups; LSC-
like and Blast-like based on the methylation profile of each individual. Survival was 
compared between the two groups using the coxph function in R (survival package 2.37), 
with significance assessed by log-rank test. For gene expression, the genes in the LSC 
epigenetic signature were identified in expression datasets for which survival outcomes 
were available. The first principal component of their expression levels was computed, 
and patients were stratified as “high” or “low” relative to its median value. Survival 
differences between the groups were assessed by log-rank test. In multivariate analyses, 
age was incorporated as a continuous variable, mutations were coded as present/absent 
(1/0), and assessment of cytogenetic risk was treated as individual groups and done for 
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intermediate vs low-risk and High vs low risk (Figure 2.9). Analysis was also performed 
within intermediate risk groups. 
Statistical Analysis 
To assign cell identity of LSC/Blast to TCGA samples, mean methylation value of each 
LSC epigenetic signature (84 DMRs) for LSC/Blast (methylation profile) was retrieved 
and standard deviation of the mean value for each signature was calculated. Then scores 
(probability density values as log value) for each TCGA sample regarding LSC and Blast 
profile was calculated using dnorm function with the mean and standard deviation 
calculated in previous step. Maximum value of scores between the ones regarding LSC 
and Blast methylation profile was chosen, and then cell identity assigned.  
Bioinformatics Analysis 
QIAGEN’s Ingenuity IPA (Ingenuity® Systems, www.ingenuity.com) was performed for 












  Supplementary Figure 1. Pre-sort and post-sort FACS analysis of subpopulations 
from human AML.  Top panel: FACS-sorting scheme of three immunophenotypically 
defined subpopulations from human AML samples. Other panels: Two rounds of post-
sort analysis to check the purity of sorting. 
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Figure 2.1. Pre-sort and post-sort FACS analysis of subpopulations from human 
AML.  Top panel: FACS-sorting scheme of three immunophenotypically defined 
subpopulations from human AML samples. Other panels: Two rounds of post-sort 
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Supplementary Figure 2. Gene expression inversely correlates with DMRs at CpG 
island and open sea. Engrafting (LSC) and non-engrafting (Blast) subpopulations from 
primary AML cases were profiled for DNA methylation and gene expression to identify 
differentially methylated regions (DMRs) and differentially expressed genes between 
these two groups DMRs that are located within kb of gene transcriptional start sites 
(TSSs - black dots) were classified into  groups according to their distance relative to a 
CpG island: island shore shelf and open sea DMRs located further than kb away 
from TSSs are denoted as black pluses Log ratios of differential expression were 
plotted against differential methylation (all values are Blast compared to LSC) Wilcoxon 
rank-sum tests were performed to test the null hypothesis that the expression differences 
for the hypo- or hypermethylated DMRs within kb of gene TSSs (black dots) showed 
stronger inverse correlation than the expression differences of the random DMRs that 
are located further than kb of TSSs (black pluses) Random DMRs were shown in the 
middles of DNA methylation axis regardless of their methylation differences 
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Figure 2.2. Gene expression inversely correlates with DMRs at CpG island and open 
sea. Engrafting (LSC) and non-engrafting (blast) subpopulations from primary AML 
cases were profiled for DNA methylation and gene expression to identify differentially 
methylated regions (DMRs) and differentially expressed genes between these two groups. 
DMRs that are located within 2kb of gene transcriptional start sites (TSSs - black dots) 
were classified into 4 groups according to their distance relative to a CpG island: island, 
shore, shelf, and open sea. DMRs located further than 2kb away from TSSs are denoted 
as black pluses. Log2 ratios of differential expression were plotted against differential 
methylation (all values are blast compared to LSC). Wilcoxon rank-sum tests were 
performed to test the null hypothesis that the expression differences for the hypo- or 
hypermethylated DMRs within 2kb of gene TSSs (black dots) showed stronger inverse 
correlation than the expression differences of the random DMRs that are located further 
than 2kb of TSSs (black pluses). Random DMRs were shown in the middles of DNA 
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Figure 2.3. Gene body methylation doesn’t show statistically significant positive 
correlation with gene expression. DMRs that are located in gene body (TSS to 
transcription end site (TES)) were classified into three groups according to their distance 
relative to a CpG island: island, shore, shelf/open sea. Random DMRs that don’t locate in 
gene body are denoted as black pluses. Log2 ratios of differential expression were plotted 
against differential methylation. Wilcoxon rank-sum tests were performed to test the null 
hypothesis that the expression differences for the hypo- or hypermethylated DMRs 
located in gene body (black dots) showed stronger positive correlation than the 
expression differences of the random DMRs that do not locate in gene body (black 
pluses). (a) LSC vs Blast. All values for DNA methylation and gene expression are from 
LSC-Blast. (b) Normal hematopoiesis. HSC vs GMP and HSC vs MEP are shown. All 
values for DNA methylation and gene expression are from group2 – group1 for group1 vs 
group2 comparisons. 
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Figure 2.4. AML LSC and Blasts exhibit epigenetic differences that define an LSC 
epigenetic signature. Plots of differentially methylated regions (DMRs) indicating 
genomic loci for REC8 (a), HOXA9 (b), HOXA7 (c) and HOXA10 (d), four LSC 
epigenetic signature genes that are hypomethylated and upregulated in LSC. Top: level of 
CpG methylation (beta) of each sample for the region; Middle: CpG density (curve), CpG 
sites (black tick marks), CpG islands (red lines); Bottom: gene annotation.	  
	  



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 4. NPM1 mutation is associated with decreased 
methylation and increased expression of HOXA genes. (a) Box plots show 
methylation level for NPM1 mutants and wild-type samples for DMRs for HOXA5, 
HOXA6, HOXA7, HOXA9, and HOXA10 in the TCGA dataset. t-test assuming unequal 
variance was performed to look at statistical significance of the association between 
NPM1 mutation and methylation. DNA methylation of all the HOXA genes was 
significantly associated with NPM1 mutation. (b) Box plots show gene expression (Log2 
value) for NPM1 mutants and wild-type samples for HOXA5, HOXA6, HOXA7, HOXA9, 
and HOXA10 in the TCGA dataset. t-test assuming unequal variance showed NPM1 
mutation highly correlated with increased expression of all the HOXA genes tested. 
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Figure 2.5. NPM1 mutation is associated with decreased methylation and increased 
expression of HOXA genes. (a) Box plots show methylation level for NPM1 mutants and 
wild-type samples for DMRs for HOXA5, HOXA6, HOXA7, HOXA9, and HOXA10 in the 
TCGA dataset. t-test assuming unequal variance was performed to look at statistical 
significance of the association between NPM1 mutation and methylation. DNA 
methylation of all the HOXA genes was significantly associated with NPM1 mutation. (b) 
Box plots show gene expression (Log2 value) for NPM1 mutants and wild-type samples 
for HOXA5, HOXA6, HOXA7, HOXA9, and HOXA10 in the TCGA dataset. t-test 
assuming unequal variance showed NPM1 mutation highly correlated with increased 












Figure 2.6. The LSC epigenetic signature is partially dependent on underlying 
somatic mutations. Shown is a schematic flow chart of mutation association analysis. 
We compared our LSC epigenetic signature to the mutation specific DMRs obtained from 
TCGA data set. The LSC epigenetic signature was classified into three different groups, 
and each DMR is shown in this diagram. Note that several genes such as HOXA9 have 
multiple DMRs and different DMRs in one gene are annotated with DMR number such 
as HOXA9/DMR1.  
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Figure 2.7. The LSC epigenetic signature is associated with overall survival in 
human AML. (a) TCGA samples were classified as LSC-like or Blast-like based on 
DNA methylation alone by generating methylation profiles of the LSC and Blast 
populations, and then calculating scores of each sample based on the probability of being 
closer to either LSC or Blast. Kaplan-Meier survival analysis was then applied to these 
groups as indicated. Statistical significance was determined by the Log-rank test (n=192; 
93 LSC-like and 99 Blast-like patients). (b-e) Expression of the LSC epigenetic signature 
genes was combined to create an LSC score, which was then calculated in AML samples 
from four independent cohorts including TCGA (n=182; 91 high and 91 low score 
patients) (b) Metzeler et al (n=163; 81 high and 82 low score patients) (c), Wouters et al 
(n=262; 131 high and 131 low score patients) (d), and Wilson et al (n=169, 84 high and 
85 low score patients) (e). In each cohort, patients were classified into high and low 
groups based on the median value. Kaplan-Meier survival analysis was then applied to 









Figure 2.8. The gene expression of the LSC epigenetic signature highly correlates 
with clinical outcome in the TCGA dataset. Each dot represents an LSC epigenetic 
signature gene. Survival z-score was plotted against log2 ratio of differential expression 



























Supplementary Figure 5. The gen expression of the LSC epigenetic signature 
highly correlates with clinical outcome in the TCGA dataset EaFh dot represents an 
LSC epigenetiF signature gene Survival z-sFore was plotted against log ratio of 
differential expression of the LSC epigenetiF signature genes in TCGA 
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Figure 2.9. R script for multivariate survival analysis. (a) Multivariate survival 
analysis for DNA methylation data in TCGA. The line or a variable that show how we 
treated cytogenetic groups is colored in red. (b) Multivariate survival analysis for gene 
expression data in TCGA. The line or a variable that show how we treated cytogenetic 
groups is colored in red. 
a
b












## GEP analysis and survival
dmrexp = read.delim("TCGA_AML_newDMR_p001_fc05.eigengenes.pcl", stringsAsFactors=FALSE)
amlinfo2 = merge(amlinfo,dmrexp, by="Array")
medexp = median(amlinfo2$DMR_p0.01_fc0.5, na.rm=TRUE)
amlinfo2$medexp = 1







Supplementary Figure 10. R script for multivariate survival analysis. (a) 
Multivariate survival analysis for DNA methylation data in TCGA. The line or a variable 
that show how we treated cytogenetic groups is colored in red. (b) M ltivariate survival 
analysis for gene expression data in TCGA. The line or a variable that show how we 
treated cytogenetic groups is colored in red.  
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Table 2.1. Clinical features of AML patients in this study  
	  
Sample 





SU001 59 F 1° R Normal 99 AML-not otherwise specified M2 
SU006 51 F 1° D Failed to grow 94 AML-not otherwise specified M1 
SU008 64 M 1° D Normal 3 AML-not otherwise specified M1 
SU014 59 M 1° D Normal 18 AML-not otherwise specified ND 
SU029 65 F 1° D inv(9)(p11q13) 8 
AML with multilineage dysplasia 
without antecedent MDS M2 
SU032 47 M 1° D Normal 68 AML-not otherwise specified M5 
SU035 46 M 1° D Failed to grow 98 AML-not otherwise specified M5 
SU036 71 F 1° D t(8;21) 47 AML with t(8;21)(q22;q22) ND 
SU042 61 F 1° D t(10;11) 8 AML with 11q23 (MLL) M5b 
SU046 53 F 1° D t(6;11) 94 AML with 11q23 (MLL) M5 
SU056 56 M 1° D Complex cytogenetics 99 
AML with multilineage dysplasia 
without antecedent MDS M0 
SU266 65 M 1° D inv(3) 96 AML with inv(3)(q21q26) ND 
SU267 58 M 1° D Normal 66 AML with multilineage dysplasia without antecedent MDS ND 
SU302 59 M 1° D Normal 14 AML-not otherwise specified ND 
SU306 33 F 1° D No analyzable metaphases <1 AML-not otherwise specified M5a 





Table 2.2. Genetic mutations identified 
Patient 






TKD NPM1 KIT CEBPA 
SU001 wt wt wt wt wt nd wt nd nd 
SU006 wt wt wt wt wt nd wt nd nd 
SU008 wt wt wt wt mut wt wt nd nd 
SU014 wt R132H wt wt mut nd mut nd nd 
SU029 1149FS wt wt R882H mut nd mut nd nd 
SU032 Y1649C wt wt wt wt nd wt nd nd 
SU035 wt wt wt wt wt nd wt nd nd 
SU036 wt wt wt wt nd nd wt mut nd 
SU042 wt wt wt S837* wt nd wt nd nd 
SU046 wt wt wt wt wt wt wt nd Nd 
SU056 wt wt wt wt wt wt wt nd wt 
SU266 E1010D wt wt wt wt wt wt nd wt 
SU267 wt R132C wt R882H wt wt wt nd wt 
SU302 wt wt wt R882H wt wt mut wt mut 
SU306 wt wt R140Q ΔV149 wt mut mut wt wt 
Abbreviations: FS, frameshift mutation; wt, wild type; mut, mutant; nd, no data; * stop; Δ, deletion. 
Note: Sanger sequencing was performed on TET2 exon 3-11, IDH1, IDH2 exon 4, and DNMT3A exon 3-11.  More details are provided in Table 2.18.  




Table 2.3. Engraftment of AML subpopulations 
Patient ID “CD34-” “CD34+CD38+” “CD34+CD38-” 
SU001 No No No 
SU006 No No Yes 
SU008 No No No 
SU014 No No No 
SU029 Yes Yes Yes 
SU032 No No No 
SU035 Yes No Yes 
SU036 No No No 
SU042 Yes Yes Yes 
SU046 Yes Yes ND 
SU056 No Yes Yes 
SU266 No Yes Yes 
SU267 No Yes Yes 
SU302 No Yes Yes 
SU306 No No Yes 















Table 2.4. DMRs of LSC vs Blast (See Appendix1)
64	  






   * P value cutoff of 0.01 was used to calculate the number of DMRs (see Methods) 
	  
Comparisons 
(Group1 versus Group2) 
Numbers of DMRs* Locations of DMRs relative to CpG islands (%) 
Group1>Group2 Group1<Group2 Islands Shores Shelves Open seas 
Blast vs LSC 2769 261 27.8 37.8 5.4 29 
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Table 2.6. LSC epigenetic signature  
chr start end diffMethyl island diffexp Gene DMR_TSS_dist 
chr17 56356470 56356963 0.200454417 Island -2.771069849 MPO 1304 
chr7 27209463 27209582 -0.190449837 Island 2.262250718 HOXA9 -194 
chr7 27205200 27205262 -0.205288088 Island 1.750125912 HOXA9 -51 
chr7 27203430 27203546 -0.200286397 Island 1.750125912 HOXA9 1603 
chr7 27206073 27206907 -0.1623543 Island 1.750125912 HOXA9 -924 
chr7 27204052 27204981 -0.150359078 Island 1.750125912 HOXA9 168 
chr7 30029717 30029808 -0.232917635 Island 1.682967495 SCRN1 -402 
chr1 208083913 208084071 -0.175662022 Island 1.581896622 CD34 612 
chr8 87526705 87527257 -0.175070398 Island 1.492929541 CPNE3 -8 
chr7 27213984 27214383 -0.149812433 Island 1.460273965 HOXA10 0 
chr12 12502846 12502846 -0.262873441 Island 1.309407455 MANSC1 329 
chr5 141488047 141488121 -0.196034559 Island 1.163061111 NDFIP1 314 
chr10 124638756 124639630 -0.206994825 Island 1.098988409 FAM24B 0 
chr5 74162602 74162809 -0.198910627 Island 0.984734984 FAM169A 0 
chr11 30605787 30606026 -0.194575258 Island 0.976935267 MPPED2 -226 
chr5 40681444 40681444 -0.278087288 Island 0.968009601 PTGER4 -1406 
chr7 27195918 27196286 -0.172243476 Island 0.940816384 HOXA7 10 
chr7 27198025 27198896 -0.165502698 Island 0.940816384 HOXA7 -1729 
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chr16 122031 122031 -0.238501186 Island 0.9115447 RHBDF1 562 
chr4 75230391 75230615 -0.236192175 Island 0.91073247 EREG 244 
chr12 39299364 39299726 -0.170515768 Island 0.881992857 CPNE8 0 
chr17 27045043 27045302 -0.210388337 Island 0.87035073 RAB34 -97 
chr11 65325158 65325249 -0.218616458 Island 0.852913568 LTBP3 139 
chr17 27044169 27044685 -0.191399132 Island 0.851673857 RAB34 0 
chr11 124747075 124747263 -0.258430121 Island 0.825061807 ROBO3 -338 
chr1 110254692 110255096 -0.204217813 Island 0.820222184 GSTM5 0 
chr10 74034644 74034667 -0.241705206 Island 0.765158417 DDIT4 -963 
chr14 24640947 24641852 -0.346838032 Island 0.704630646 REC8 0 
chr17 5000803 5001047 -0.180094485 Island 0.639449923 ZFP3 -1867 
chr13 88326244 88326244 -0.254835678 Island 0.622086898 SLITRK5 -1375 
chr7 27188020 27188465 -0.198478999 Island 0.611495803 HOXA6 -652 
chr1 46859671 46860511 -0.204828969 Island 0.603323126 FAAH 0 
chr10 128593922 128594144 -0.21139227 Island 0.532062199 DOCK1 0 
chr12 124247223 124247223 -0.291619587 Island 0.531144201 ATP6V0A2 -1636 
chr22 38610376 38610795 -0.197239852 Island 0.519140873 MAFF -516 
chr12 104697193 104697631 -0.159774024 Island 0.511530854 EID3 893 
chrX 92928508 92928610 -0.215885822 Island 0.509900024 NAP1L3 0 
chr17 56357994 56358318 0.235604062 Shore -2.771069849 MPO 0 
chr2 47597118 47597331 0.170825315 Shore -1.989838284 EPCAM -652 
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chr12 112204756 112205368 -0.177217632 Shore 1.798343931 ALDH2 -6 
chr12 112203801 112204506 -0.167361987 Shore 1.798343931 ALDH2 244 
chr7 27205504 27205514 -0.189312475 Shore 1.750125912 HOXA9 -355 
chr3 15372726 15372965 -0.191871292 Shore 1.691364717 SH3BP5 923 
chr7 30028281 30028307 -0.439758955 Shore 1.682967495 SCRN1 1008 
chr7 30027454 30027454 -0.299227828 Shore 1.682967495 SCRN1 1861 
chr7 27184077 27184159 -0.156088057 Shore 1.652615374 HOXA5 -794 
chr22 38201496 38201848 -0.328478194 Shore 1.54987965 H1F0 -242 
chr8 30243930 30243930 -0.252405503 Shore 1.369854497 RBPMS -1888 
chr7 100465051 100465833 -0.20478317 Shore 1.281381937 TRIP6 -78 
chr7 27193351 27194013 -0.193087116 Shore 1.195082055 HOXA7 219 
chr7 25018503 25018595 -0.16970931 Shore 0.966906711 OSBPL3 1066 
chr7 27196759 27197239 -0.177214748 Shore 0.940816384 HOXA7 -463 
chr1 220922046 220922217 -0.186478516 Shore 0.904301462 MOSC2 -436 
chr1 67772896 67773044 -0.179679693 Shore 0.859823651 IL12RB2 2 
chr3 49170496 49170794 0.161770178 Shore -0.78786347 LAMB2 0 
chrY 21728575 21728575 0.23566283 Shore -0.772593829 CYorf15A 692 
chr1 186650441 186650479 -0.254143241 Shore 0.757276969 PTGS2 -885 
chr5 76249502 76250527 -0.21663642 Shore 0.713935248 CRHBP -634 
chr6 31549563 31550090 -0.20860554 Shore 0.705812972 LTB 112 
chr4 90757139 90757378 -0.206564689 Shore 0.683467526 SNCA -293 
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chr9 5831674 5831999 -0.28057155 Shore 0.672688294 ERMP1 -697 
chrX 110039536 110039604 -0.240784813 Shore 0.667757542 CHRDL1 -543 
chr4 156681475 156681475 -0.306895344 Shore 0.655209216 GUCY1B3 -1234 
chr1 60280088 60280106 -0.186569105 Shore 0.648435017 HOOK1 488 
chr18 47016218 47016218 -0.284177026 Shore 0.616623366 LOC729046 /// RPL17 -932 
chr7 24614206 24614348 -0.286787283 Shore 0.557276298 MPP6 -1183 
chr1 61549542 61549982 -0.239027386 Shore 0.555128781 NFIA -1563 
chr12 93966060 93967711 -0.165376292 Shore 0.52397313 SOCS2 0 
chr2 216877276 216877750 -0.197016908 Shore 0.50372197 MREG 565 
chr21 37442759 37442777 -0.191372117 Shore 0.503048275 CBR1 -423 
chr3 136539328 136539328 -0.246575275 Shore 0.501386314 TMEM22 -1351 
chr10 45474317 45474372 -0.183899524 shelf 0.931044445 C10orf10 -60 
chr1 156211409 156211434 -0.185683842 shelf 0.589711142 BGLAP 570 
chr11 59823993 59824116 0.161461095 Open sea -2.706906127 MS4A3 14 
chr6 133035379 133035379 -0.242403002 Open sea 1.849875377 VNN1 -191 
chr6 31556255 31556255 -0.244242862 Open sea 1.1249658 LST1 -1279 
chr13 48987165 48987165 0.238629161 Open sea -1.003641807 LPAR6 -562 
chr14 106354912 106354912 -0.234479961 Open sea 0.985697199 FAM30A 1067 
chr1 26644515 26645313 -0.164618365 Open sea 0.874440839 CD52 -31 
chr4 159442782 159442782 -0.447897492 Open sea 0.781456346 RXFP1 117 
chr10 98031125 98031337 -0.152269885 Open sea 0.696536347 BLNK 0 
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chr7 47611829 47611926 -0.220983979 Open sea 0.619420183 TNS3 -918 
chrX 154563852 154563968 -0.175452155 Open sea 0.518822469 CLIC2 0 
chr7 18535072 18535786 -0.206752311 Open sea 0.507854096 HDAC9 0 
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Table 2.7. Second DMR analysis to examine confounding effect of MLL cases 
 LSC epigenetic signature DMRs (p value<0.01) 
All Samples 84 3030 
No MLL cases 49 1398 





























Table 2.8. Ingenuity pathway analysis 
Ingenuity Canonical Pathways  -log(p-value) Molecules 
Fatty Acid α-oxidation 2.8E00 ALDH2,PTGS2 
Melatonin Degradation III 1.81E00 MPO 
Anandamide Degradation 1.81E00 FAAH 
NRF2-mediated Oxidative Stress Response 1.73E00 GSTM5,MAFF,CBR1 
VDR/RXR Activation 1.59E00 BGLAP,HOXA10 
Eicosanoid Signaling 1.57E00 PTGS2,PTGER4 
Phenylethylamine Degradation I 1.47E00 ALDH2 
HGF Signaling 1.35E00 DOCK1,PTGS2 
Prostanoid Biosynthesis 1.34E00 PTGS2 
Parkinson's Signaling 1.31E00 SNCA 
Corticotropin Releasing Hormone Signaling 1.25E00 PTGS2,GUCY1B3 
Granzyme A Signaling 1.22E00 H1F0 
Glutathione Redox Reactions I 1.12E00 CLIC2 
Relaxin Signaling 1.12E00 RXFP1,GUCY1B3 
Aryl Hydrocarbon Receptor Signaling 1.12E00 GSTM5,NFIA 
Histamine Degradation 1.09E00 ALDH2 
eNOS Signaling 1.08E00 LPAR6,GUCY1B3 
Tryptophan Degradation X (Mammalian, via Tryptamine) 1.08E00 ALDH2 
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Oxidative Ethanol Degradation III 1.08E00 ALDH2 
Putrescine Degradation III 1.06E00 ALDH2 
Ethanol Degradation IV 1.06E00 ALDH2 
Triacylglycerol Degradation 1.03E00 FAAH 
Phenylalanine Degradation IV (Mammalian, via Side Chain) 1.02E00 ALDH2 
Gap Junction Signaling 1.01E00 BGLAP,GUCY1B3 
IL-9 Signaling 9.95E-01 SOCS2 
MIF-mediated Glucocorticoid Regulation 9.83E-01 PTGS2 
Role of JAK2 in Hormone-like Cytokine Signaling 9.83E-01 SOCS2 
Dopamine Degradation 9.5E-01 ALDH2 
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 9.39E-01 MPO,HOXA10 
Inhibition of Angiogenesis by TSP1 9.39E-01 GUCY1B3 
Glutathione-mediated Detoxification 9.39E-01 GSTM5 
IL-8 Signaling 9.35E-01 MPO,PTGS2 
Endothelin-1 Signaling 9.35E-01 PTGS2,GUCY1B3 
Sertoli Cell-Sertoli Cell Junction Signaling 9.35E-01 MPP6,GUCY1B3 
ILK Signaling 9.32E-01 DOCK1,PTGS2 
Ethanol Degradation II 8.99E-01 ALDH2 
MIF Regulation of Innate Immunity 8.9E-01 PTGS2 
FcγRIIB Signaling in B Lymphocytes 8.81E-01 BLNK 
Primary Immunodeficiency Signaling 8.23E-01 BLNK 
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Noradrenaline and Adrenaline Degradation 8.23E-01 ALDH2 
Lymphotoxin β Receptor Signaling 7.93E-01 LTB 
Role of IL-17A in Arthritis 7.93E-01 PTGS2 
Nur77 Signaling in T Lymphocytes 7.79E-01 HDAC9 
Huntington's Disease Signaling 7.74E-01 HDAC9,SNCA 
Colorectal Cancer Metastasis Signaling 7.6E-01 PTGS2,PTGER4 
Phototransduction Pathway 7.59E-01 GUCY1B3 
Role of JAK1 and JAK3 in γc Cytokine Signaling 7.46E-01 BLNK 
Phospholipase C Signaling 7.43E-01 BLNK,HDAC9 
Cell Cycle: G1/S Checkpoint Regulation 7.4E-01 HDAC9 
CD40 Signaling 7.34E-01 PTGS2 
Antiproliferative Role of Somatostatin Receptor 2 7.22E-01 GUCY1B3 
Macropinocytosis Signaling 7.16E-01 RAB34 
Role of MAPK Signaling in the Pathogenesis of Influenza 7E-01 PTGS2 
IL-17 Signaling 6.94E-01 PTGS2 
T Helper Cell Differentiation 6.94E-01 IL12RB2 
JAK/Stat Signaling 6.94E-01 SOCS2 
Glucocorticoid Receptor Signaling 6.92E-01 BGLAP,PTGS2 
Growth Hormone Signaling 6.89E-01 SOCS2 
Small Cell Lung Cancer Signaling 6.84E-01 PTGS2 
STAT3 Pathway 6.84E-01 SOCS2 
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TREM1 Signaling 6.73E-01 MPO 
Prolactin Signaling 6.73E-01 SOCS2 
Cyclins and Cell Cycle Regulation 6.63E-01 HDAC9 
Serotonin Degradation 6.63E-01 ALDH2 
Superpathway of Melatonin Degradation 6.58E-01 MPO 
ErbB Signaling 6.26E-01 EREG 
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 6.17E-01 LTB 
Crosstalk between Dendritic Cells and Natural Killer Cells 6.09E-01 LTB 
FAK Signaling 6.09E-01 DOCK1 
Neuregulin Signaling 5.97E-01 EREG 
Chronic Myeloid Leukemia Signaling 5.97E-01 HDAC9 
PPAR Signaling 5.93E-01 PTGS2 
p53 Signaling 5.77E-01 HDAC9 
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 5.73E-01 DOCK1 
Telomerase Signaling 5.73E-01 HDAC9 
IGF-1 Signaling 5.73E-01 SOCS2 
Paxillin Signaling 5.62E-01 DOCK1 
Cholecystokinin/Gastrin-mediated Signaling 5.48E-01 PTGS2 
Pancreatic Adenocarcinoma Signaling 5.41E-01 PTGS2 
Type I Diabetes Mellitus Signaling 5.31E-01 SOCS2 
Nitric Oxide Signaling in the Cardiovascular System 5.28E-01 GUCY1B3 
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Gαs Signaling 5.25E-01 PTGER4 
Hereditary Breast Cancer Signaling 5.12E-01 HDAC9 
Gα12/13 Signaling 5.09E-01 LPAR6 
14-3-3-mediated Signaling 5.06E-01 SNCA 
RhoA Signaling 4.91E-01 LPAR6 
LXR/RXR Activation 4.8E-01 PTGS2 
PI3K/AKT Signaling 4.8E-01 PTGS2 
Ovarian Cancer Signaling 4.67E-01 PTGS2 
PI3K Signaling in B Lymphocytes 4.67E-01 BLNK 
Sperm Motility 4.61E-01 GUCY1B3 
Type II Diabetes Mellitus Signaling 4.54E-01 SOCS2 
Protein Kinase A Signaling 4.53E-01 PTGS2,H1F0 
IL-12 Signaling and Production in Macrophages 4.51E-01 IL12RB2 
Cellular Effects of Sildenafil (Viagra) 4.44E-01 GUCY1B3 
Synaptic Long Term Depression 4.23E-01 GUCY1B3 
CXCR4 Signaling 4.03E-01 DOCK1 
Axonal Guidance Signaling 3.99E-01 DOCK1,ROBO3 
Acute Phase Response Signaling 3.81E-01 SOCS2 
Dopamine-DARPP32 Feedback in cAMP Signaling 3.73E-01 GUCY1B3 
Role of NFAT in Regulation of the Immune Response 3.7E-01 BLNK 
Dendritic Cell Maturation 3.66E-01 LTB 
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B Cell Receptor Signaling 3.62E-01 BLNK 
Role of NFAT in Cardiac Hypertrophy 3.54E-01 HDAC9 
Calcium Signaling 3.54E-01 HDAC9 
Mitochondrial Dysfunction 3.5E-01 SNCA 
Agranulocyte Adhesion and Diapedesis 3.47E-01 CD34 
ERK/MAPK Signaling 3.45E-01 DOCK1 
mTOR Signaling 3.4E-01 DDIT4 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 3.29E-01 LTB 
Integrin Signaling 3.27E-01 DOCK1 
Actin Cytoskeleton Signaling 3E-01 DOCK1 
cAMP-mediated signaling 2.97E-01 PTGER4 
LPS/IL-1 Mediated Inhibition of RXR Function 2.96E-01 GSTM5 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 2.94E-01 BGLAP 
G-Protein Coupled Receptor Signaling 2.48E-01 PTGER4 
Xenobiotic Metabolism Signaling 2.38E-01 GSTM5 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 





Table 2.9. Ingenuity upstream regulator analysis 
Upstream Regulator p-value of overlap Target molecules in dataset 
ASXL1 8.18E-12 HOXA10,HOXA5,HOXA6,HOXA7,HOXA9 
KAT6A 4.16E-07 HOXA5,HOXA7,HOXA9 





KMT2A 6.98E-06 HOXA10,HOXA5,HOXA7,HOXA9 
raloxifene 8.44E-06 BGLAP,BLNK,DDIT4,LAMB2,MPPED2,PTGS2 
nimesulide 1.38E-05 EREG,MPO,PTGS2 
1-methyl-4-
phenylpyridinium 1.66E-05 DDIT4,MPO,SNCA 
mir-223 2.19E-05 CD34,CRHBP,GSTM5,MREG,NFIA 




diethylstilbestrol 2.93E-05 BGLAP,EREG,HOXA10,HOXA9,SOCS2,VNN1 
EZH2 3.78E-05 HOXA10,HOXA6,HOXA7,HOXA9,LTB,PTGS2 
PHF1 5.19E-05 HOXA10,HOXA6,HOXA9 
RNF20 7.67E-05 HOXA10,HOXA9 
MEN1 1.18E-04 BGLAP,HOXA7,HOXA9 
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paricalcitol 1.28E-04 BGLAP,PTGER4,PTGS2 
bexarotene 1.53E-04 C10orf10,DDIT4,MAFF,PTGS2 
PSIP1 1.60E-04 HOXA7,HOXA9 
arsenite 2.08E-04 EREG,MAFF,MPO,PTGS2 
HBP1 2.14E-04 H1F0,PTGS2 
LIF 2.18E-04 BGLAP,CD34,EREG,PTGS2,SOCS2 
IL12 (complex) 2.39E-04 FAAH,IL12RB2,LTB,PTGS2,SOCS2 
staurosporine 2.58E-04 BGLAP,CPNE3,MPO,PTGS2 
AHR 2.64E-04 ALDH2,CBR1,GSTM5,HDAC9,LTBP3,PTGS2 
trans-
hydroxytamoxifen 3.27E-04 BLNK,DDIT4,LAMB2,MPPED2 
meloxicam 3.42E-04 MPO,PTGS2 
3-methylcholanthrene 3.52E-04 BGLAP,GSTM5,PTGS2 
beta-naphthoflavone 3.73E-04 CBR1,GSTM5,SOCS2 
tretinoin 3.85E-04 BGLAP,CBR1,CD34,CD52,EPCAM,HOXA5,HOXA9,MPO,MPP6,MS4A3,PTGS2,REC8 
miR-196a-5p (and 
other miRNAs w/seed 
AGGUAGU) 3.89E-04 FAM169A,HDAC9,HOOK1,HOXA5,HOXA7,HOXA9 
RNF2 3.96E-04 HOXA5,HOXA7,REC8 








PLA2G4A 5.00E-04 GSTM5,PTGS2 
miR-221-3p (and 
other miRNAs w/seed 
GCUACAU) 5.37E-04 CLIC2,CPNE8,DDIT4,HOXA7,NDFIP1,OSBPL3,SLITRK5 
RNA polymerase II 5.75E-04 BGLAP,BLNK,HOXA7,HOXA9,PTGS2 
mir-196 5.89E-04 HOXA7,HOXA9 
EREG 5.89E-04 EREG,PTGS2 
infliximab 6.08E-04 DDIT4,IL12RB2,PTGS2 
E. coli B5 
lipopolysaccharide 6.79E-04 ALDH2,IL12RB2,MPO,PTGS2,SOCS2 
NFATC2 6.79E-04 IL12RB2,PTGS2,SH3BP5,SOCS2 
RELB 7.03E-04 LTB,MPO,PTGS2 
doxycycline 7.37E-04 HOXA10,MPO,PTGS2 
ESR1 7.85E-04 DDIT4,EREG,GUCY1B3,LTB,PTGS2,SOCS2 
BDKRB2 7.91E-04 PTGS2,SNCA 
dexmedetomidine 7.91E-04 DDIT4,PTGS2 
CBFB 1.00E-03 MPO,PTGER4,SOCS2 
TNF 1.02E-03 ALDH2,BGLAP,C10orf10,EREG,HDAC9,HOXA9,LTB,MAFF,MPO,PTGS2,RBPMS,SOCS2 
miR-1243 (miRNAs 
w/seed ACUGGAU) 1.13E-03 BLNK,NAP1L3,SNCA 
CSF3 1.14E-03 CD34,HOXA7,LTB,MPO 
NPC2 1.15E-03 PTGER4,PTGS2 
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ceruletide 1.15E-03 MPO,PTGS2 
forskolin 1.15E-03 BGLAP,CRHBP,DDIT4,EREG,GSTM5,HOXA5,PTGS2 
dexamethasone 1.22E-03 BGLAP,C10orf10,CBR1,CRHBP,DDIT4,EREG,GSTM5,HOXA7,LAMB2,LTB,PTGS2,SOCS2 
fumonisin B1 1.28E-03 LTB,PTGS2 
genistein 1.30E-03 EREG,GUCY1B3,HOXA10,OSBPL3,PTGS2 
EHF 1.37E-03 BLNK,EREG,VNN1 
HOXA9 1.41E-03 CD34,CLIC2,HOXA9,NFIA 
DOT1L 1.42E-03 HOXA10,HOXA9 
CSF2 1.46E-03 LTB,MPO,PTGER4,PTGS2,REC8,SOCS2 
stearic acid 1.56E-03 PTGS2,SNCA 
Histone h3 1.62E-03 BGLAP,HOXA10,HOXA5,HOXA7,HOXA9 
prostaglandin A1 1.72E-03 LPAR6,PTGS2 
BMP15 1.72E-03 EREG,PTGS2 
beta-
glycerophosphoric 
acid 1.72E-03 BGLAP,PTGS2 
CFTR 1.81E-03 BLNK,FAAH,PTGS2 
SND1 1.88E-03 EREG,PTGS2 
wortmannin 1.92E-03 BGLAP,PTGER4,PTGS2,SOCS2 
COL18A1 2.00E-03 CD34,DDIT4,PTGS2 
JAK 2.04E-03 PTGER4,SOCS2 
TRIB3 2.04E-03 BGLAP,DDIT4 
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SP3 2.15E-03 BGLAP,EREG,IL12RB2,PTGS2 
IFNG 2.20E-03 BLNK,C10orf10,FAAH,HDAC9,IL12RB2,LAMB2,LST1,LTB,PTGS2,SOCS2 
CD28 2.25E-03 GUCY1B3,IL12RB2,PTGER4,PTGS2,SOCS2 
cigarette smoke 2.27E-03 GSTM5,MAFF,PTGS2,SOCS2 
FOLR1 2.34E-03 EPCAM,LAMB2,MPP6 
AREG 2.40E-03 EREG,PTGS2 
RUNX1 2.48E-03 BGLAP,CD34,MPO 
Sos 2.49E-03 DOCK1,HOOK1,LTBP3,PTGS2 
FOS 2.63E-03 BGLAP,DOCK1,EREG,HOOK1,LTBP3,PTGS2 
dextran sulfate 2.76E-03 GSTM5,MPO,PTGS2,REC8 
3-methyladenine 2.78E-03 PTGS2,SNCA 
grape seed extract 2.78E-03 MPO,PTGS2 
butylated 
hydroxyanisol 2.78E-03 CBR1,GSTM5 
thromboxane A2 2.80E-03 PTGS2 
Gαq 2.80E-03 PTGS2 
Jnkk 2.80E-03 PTGS2 
olesoxime 2.80E-03 MPO 
Pad2 2.80E-03 PTGS2 
LPAR5 2.80E-03 PTGS2 
PAP1 2.80E-03 PTGS2 
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FLT4 2.80E-03 BGLAP 
Tpl2 kinase inhibitor 2.80E-03 PTGS2 
Mucin 2.80E-03 PTGS2 
PF-4523655 2.80E-03 DDIT4 
cucurbitacin E 2.80E-03 PTGS2 
dixanthogen 2.80E-03 GSTM5 
EDN2 2.80E-03 PTGS2 
CLN3 2.80E-03 HOOK1 
SIGLEC7 2.80E-03 PTGS2 
SIGLEC9 2.80E-03 PTGS2 
WDR61 2.80E-03 HOXA9 
ACSL4 2.80E-03 PTGS2 
TFF1 2.80E-03 PTGS2 
TLE6 2.80E-03 BGLAP 
Pla2g2a 2.80E-03 PTGS2 
LY311727 2.80E-03 PTGS2 
BN 50730 2.80E-03 PTGS2 
1-(1-glycero)dodeca-
1,3,5,7,9-pentaene 2.80E-03 PTGS2 
CGP77675 2.80E-03 PTGS2 
Ro 31-7549 2.80E-03 PTGS2 
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arachidic acid 2.80E-03 SNCA 
n-6 docosapentaenoic 
acid 2.80E-03 PTGS2 
long-chain alcohol 2.80E-03 PTGS2 
IL10 2.91E-03 C10orf10,FAAH,HDAC9,IL12RB2,PTGS2 
HDAC4 2.95E-03 CHRDL1,HDAC9,PTGS2 
PRKG1 2.98E-03 GUCY1B3,MPO 
COMMD3-BMI1 2.98E-03 HOXA7,HOXA9 
HOXA7 2.98E-03 CD34,HOXA7 
NR3C2 3.03E-03 DDIT4,NFIA,PTGS2 
TSC22D3 3.19E-03 BGLAP,PTGS2 
miR-3976 (miRNAs 
w/seed AUAGAGA) 3.19E-03 CPNE3,HDAC9 
miR-3186-5p 
(miRNAs w/seed 
AGGCGUC) 3.19E-03 CLIC2,FAM169A 
UPF2 3.19E-03 MPPED2,PTGS2 
taurine 3.19E-03 MPO,PTGS2 
tetrachlorodibenzodio
xin 3.21E-03 BLNK,CBR1,HDAC9,PTGS2,SOCS2 
STAT6 3.22E-03 ALDH2,LTB,PTGS2,SOCS2 
IFNA2 3.32E-03 IL12RB2,LPAR6,REC8,SOCS2 
ERK 3.38E-03 BGLAP,EREG,MAFF,PTGS2 
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benzo(a)pyrene 3.38E-03 EREG,MAFF,MPO,PTGS2 
Immunoglobulin 3.49E-03 LST1,MAFF,MPO,PTGS2 
Histone h4 3.65E-03 BGLAP,HOXA9,PTGS2 
melatonin 3.74E-03 BGLAP,MPO,PTGS2 
FGF1 3.93E-03 GSTM5,LTB,PTGS2 
miR-139-5p 
(miRNAs w/seed 
CUACAGU) 4.04E-03 DDIT4,HOXA9,NDFIP1,NFIA,SOCS2 
PTGS1 4.08E-03 PTGER4,PTGS2 
HBEGF 4.08E-03 EREG,PTGS2 
diclofenac 4.08E-03 MPO,PTGS2 
fulvestrant 4.14E-03 BGLAP,DDIT4,GUCY1B3,PTGS2 
indomethacin 4.47E-03 CD34,MPO,PTGER4,PTGS2 
Hsp27 4.57E-03 BGLAP,PTGS2 
IFNE 4.57E-03 PTGER4,PTGS2 
TGFB1 4.58E-03 ALDH2,BGLAP,CD34,DDIT4,EREG,LTBP3,MPP6,PTGER4,PTGS2,RBPMS,ROBO3 
ATF4 4.65E-03 BGLAP,DDIT4,PTGS2 
NFE2L2 4.82E-03 BGLAP,CBR1,GSTM5,MAFF,PTGS2 
miR-1277-3p (and 
other miRNAs w/seed 
ACGUAGA) 4.82E-03 CPNE3,NDFIP1 
IKZF1 4.87E-03 BLNK,DOCK1,SH3BP5 
IKBKB 4.88E-03 EREG,LTB,PTGS2,SOCS2 
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ZBTB16 5.08E-03 BGLAP,CD34 
AGTR1 5.08E-03 GSTM5,PTGS2 
TXNIP 5.08E-03 DDIT4,PTGS2 
H89 5.10E-03 BGLAP,EREG,PTGS2 
IL27 5.21E-03 C10orf10,IL12RB2,PTGS2 
miR-155-5p 
(miRNAs w/seed 
UAAUGCU) 5.31E-03 HOOK1,LPAR6,NDFIP1,NFIA,RAB34,ZFP3 
STK11 5.33E-03 EREG,LTB,PTGS2 
Growth hormone 5.45E-03 BGLAP,GSTM5,SOCS2 
arbutin 5.59E-03 PTGS2 
1-alpha,24(R),25-
trihydroxyvitamin D3 5.59E-03 BGLAP 
prostaglandin E3 5.59E-03 PTGS2 
24R,25-
dihydroxyvitamin D3 5.59E-03 BGLAP 
des-Arg(10)-kallidin 5.59E-03 PTGS2 
sPla2 5.59E-03 PTGS2 
cyanidin 3-O-
glucoside 5.59E-03 PTGS2 
ASB2 5.59E-03 HOXA9 
VRK2 5.59E-03 PTGS2 
NOX5 5.59E-03 PTGS2 
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TMEM8B 5.59E-03 PTGS2 
soy isoflavones 5.59E-03 PTGS2 
3,4-
dihydroxyphenyletha
nol 5.59E-03 PTGS2 
PTPRG 5.59E-03 CD34 
PLA2G2F 5.59E-03 PTGS2 
IDE 5.59E-03 SNCA 
OSTF1 5.59E-03 BGLAP 
ECSIT 5.59E-03 PTGS2 
CBR1 5.59E-03 PTGS2 
ARHGDIB 5.59E-03 PTGS2 
SH3GLB2 5.59E-03 PTGS2 
SC68376 5.59E-03 PTGS2 
pyridoxal 5.59E-03 PTGS2 
zileuton 5.59E-03 PTGS2 
bifenthrin 5.59E-03 PTGS2 
thiamin 
pyrophosphate 5.59E-03 MPO 
benzylamine 5.59E-03 PTGS2 
bumetanide 5.59E-03 PTGS2 
incyclinide 5.59E-03 PTGS2 
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methylprednisolone 
acetate 5.59E-03 PTGS2 
vanillic acid 5.59E-03 PTGS2 
indolo(3,2-
b)carbazole 5.59E-03 SOCS2 
tetrahydropalmatine 5.59E-03 PTGS2 
epoxyeicosatrienoic 
acid 5.59E-03 PTGS2 
poly(ADP-ribose) 5.59E-03 PTGS2 
laminaran 5.59E-03 PTGS2 
lipooligosaccharide 5.59E-03 PTGS2 
1beta,25-
dihydroxyvitamin D3 5.59E-03 BGLAP 
BAPTA-AM 5.61E-03 PTGS2,SOCS2 
ICAM1 5.89E-03 IL12RB2,MPO 
miR-3680-5p 
(miRNAs w/seed 
ACUCACU) 5.89E-03 HOOK1,RBPMS 
miR-4716-5p 
(miRNAs w/seed 
CCAUGUU) 5.89E-03 NFIA,OSBPL3 
nonylphenol 5.89E-03 EREG,PTGS2 
IL18 6.32E-03 IL12RB2,MPO,PTGS2 
ARHGAP21 6.46E-03 PTGS2,SH3BP5 
N-acetylsphingosine 6.46E-03 GSTM5,PTGS2 
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AGT 6.68E-03 EREG,GSTM5,HOXA9,PTGS2,SNCA 
luteolin 6.76E-03 MPO,PTGS2 
WT1 6.99E-03 EREG,SH3BP5,SLC35G2 
PPRC1 7.06E-03 DDIT4,PTGS2 
APOA1 7.06E-03 MPO,PTGS2 
VitaminD3-VDR-
RXR 7.37E-03 BGLAP,HOXA10 
EGFR 7.49E-03 EREG,HOXA7,PTGER4,PTGS2 
baicalin 7.68E-03 BGLAP,CBR1 
DUSP1 7.68E-03 IL12RB2,PTGS2 
mifepristone 7.97E-03 DDIT4,EPCAM,HOXA10,PTGS2 
EPO 8.07E-03 CD52,MPO,PTGS2,SOCS2 
prostaglandin E2 8.27E-03 EREG,PTGER4,PTGS2,SOCS2 
NOG 8.33E-03 BGLAP,PTGS2 
DKK1 8.33E-03 BGLAP,EPCAM 
sulprostone 8.37E-03 PTGS2 
chloride 8.37E-03 PTGS2 
W146 8.37E-03 PTGS2 
imperatorin 8.37E-03 PTGS2 
Eif2 8.37E-03 PTGS2 
pycnogenols 8.37E-03 PTGS2 
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pinoresinol 8.37E-03 PTGS2 
HN 8.37E-03 SH3BP5 
RGD1560225 8.37E-03 PTGS2 
SPEN 8.37E-03 BGLAP 
CTSK 8.37E-03 PTGS2 
ERC1 8.37E-03 PTGS2 
AA-861 8.37E-03 PTGS2 
amifostine 8.37E-03 PTGS2 
trimetazidine 8.37E-03 MPO 
tenidap 8.37E-03 PTGS2 
acacetin 8.37E-03 PTGS2 
flavone 8.37E-03 PTGS2 
12-
hydroxyeicosatetraen
oic acid 8.37E-03 PTGS2 
epiallopregnanolone 8.37E-03 PTGS2 
IRF1 8.61E-03 IL12RB2,LTB,PTGS2 
ZBTB20 8.66E-03 GSTM5,SOCS2 
miR-517a-3p (and 
other miRNAs w/seed 
UCGUGCA) 8.66E-03 HOXA5,NFIA 
miR-124-3p (and 
other miRNAs w/seed 
AAGGCAC) 8.98E-03 ATP6V0A2,CPNE3,ERMP1,HOXA5,NAP1L3,NDFIP1,NFIA,OSBPL3,RAB34,RHBDF1,SLITRK5 
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Gm-csf 9.00E-03 PTGS2,SOCS2 
PDGFB 9.00E-03 BGLAP,PTGS2 
FGF10 9.00E-03 PTGS2,VNN1 
glutathione 9.00E-03 MPO,PTGS2 
miR-1321 (and other 
miRNAs w/seed 
AGGGAGG) 9.20E-03 CD34,CHRDL1,HOXA10,OSBPL3 
bucladesine 9.30E-03 BGLAP,FAAH,PTGER4,PTGS2 
carbonyl cyanide m-
chlorophenyl 
hydrazone 9.34E-03 DDIT4,PTGS2 
2-deoxyglucose 9.69E-03 DDIT4,PTGS2 
SRF 9.74E-03 GSTM5,MPPED2,MS4A3,PTGS2 
zymosan 1.00E-02 C10orf10,PTGS2 
BNIP3L 1.04E-02 BLNK,LTB 
hemin 1.08E-02 GUCY1B3,PTGS2 
miR-4793-5p 
(miRNAs w/seed 
CAUCCUG) 1.11E-02 ALDH2,NDFIP1 
HDAC3 1.11E-02 CD34,PTGS2 
Nfatc 1.11E-02 PTGS2 
8-chloro-cAMP 1.11E-02 PTGS2 
2-(3-
hydroxypropoxy)calci
triol 1.11E-02 BGLAP 
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NF-kappaB decoy 1.11E-02 PTGS2 
trans-cinnamaldehyde 1.11E-02 PTGS2 
tylophorine 1.11E-02 PTGS2 
nebivolol 1.11E-02 PTGS2 
RSPO3 1.11E-02 PTGS2 
LEO1 1.11E-02 HOXA9 
SGPL1 1.11E-02 PTGS2 
ARID2 1.11E-02 BGLAP 
LIN9 1.11E-02 BGLAP 
TMEM119 1.11E-02 BGLAP 
betulin 1.11E-02 PTGS2 
PPP1R1B 1.11E-02 SNCA 
ENPP1 1.11E-02 BGLAP 
MUC2 1.11E-02 PTGS2 
HSD11B2 1.11E-02 BGLAP 
PHF19 1.11E-02 HOXA5 
NUCB2 1.11E-02 PTGS2 
TDO2 1.11E-02 PTGS2 
TIA1 1.11E-02 PTGS2 
UBE2D1 1.11E-02 PTGS2 
AJUBA 1.11E-02 DOCK1 
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SKLB023 1.11E-02 PTGS2 
farnesyl transferase 1.11E-02 MPO 
SULT1E1 1.11E-02 PTGS2 
ANXA6 1.11E-02 BGLAP 
HDAC8 1.11E-02 HOXA5 
furosemide 1.11E-02 PTGS2 
1-butanol 1.11E-02 PTGS2 
lestaurtinib 1.11E-02 MPO 
lansoprazole 1.11E-02 PTGS2 
7,8-dihydro-7,8-
dihydroxybenzo(a)py
rene 9,10-oxide 1.11E-02 PTGS2 
ethyl linoleate 1.11E-02 PTGS2 
cadmium sulfate 1.11E-02 PTGS2 
polyphosphate 1.11E-02 BGLAP 
vanadium pentoxide 1.11E-02 PTGS2 
aclarubicin 1.11E-02 PTGS2 
ecdysterone 1.11E-02 BGLAP 
FOXL2 1.15E-02 MAFF,PTGS2 
NFATC3 1.15E-02 DDIT4,PTGS2 
miR-3944-5p 
(miRNAs w/seed 
GUGCAGC) 1.17E-02 CD34,NFIA,SH3BP5 
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miR-3974 (miRNAs 
w/seed AAGGUCA) 1.19E-02 ERMP1,MS4A3 
seocalcitol 1.19E-02 BGLAP,PTGS2 
Salmonella enterica 
serotype abortus equi 
lipopolysaccharide 1.21E-02 EREG,MAFF,PTGS2 
PPARD 1.21E-02 ALDH2,PTGER4,PTGS2 
8-bromo-cAMP 1.23E-02 ALDH2,BGLAP,PTGS2 
PTHLH 1.23E-02 BGLAP,PTGS2 
PDGF BB 1.24E-02 EREG,GUCY1B3,LAMB2,PTGS2 
SP1 1.25E-02 BGLAP,EREG,IL12RB2,LTB,PTGS2 
INHBA 1.27E-02 CPNE8,EREG,MPPED2 
miR-3649 (miRNAs 
w/seed GGGACCU) 1.29E-02 CPNE3,HOXA10,MAFF 
bortezomib 1.29E-02 BGLAP,PTGS2,SNCA 
MAPK1 1.31E-02 BGLAP,OSBPL3,PTGS2,SOCS2 
IRF2 1.31E-02 IL12RB2,PTGS2 
miR-3115 (miRNAs 
w/seed UAUGGGU) 1.31E-02 HDAC9,PTGER4 
miR-3928-3p 
(miRNAs w/seed 
GAGGAAC) 1.31E-02 GSTM5,OSBPL3 
CD14 1.31E-02 MPO,PTGS2 
INSR 1.33E-02 ALDH2,CBR1,EREG,SOCS2 
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STAT5A 1.35E-02 IL12RB2,LTB,SOCS2 
15-deoxy-delta-12,14 
-PGJ 2 1.37E-02 BGLAP,MPO,PTGS2 
MAP3K14 1.39E-02 LTB,PTGS2 
ILX-23-7553 1.39E-02 BGLAP 
pyrophosphate 1.39E-02 BGLAP 
nitrate 1.39E-02 MPO 
dibutyryl cGMP 1.39E-02 PTGS2 
dienogest 1.39E-02 PTGS2 
Cpla2 1.39E-02 PTGS2 
TET1 1.39E-02 HOXA9 
elocalcitol 1.39E-02 BGLAP 
GPR68 1.39E-02 PTGS2 
carvacrol 1.39E-02 PTGS2 
PARG 1.39E-02 PTGS2 
Atf 1.39E-02 PTGS2 
PLCE1 1.39E-02 PTGS2 
CDH4 1.39E-02 PTGS2 
PAPOLA 1.39E-02 PTGS2 
DSPP 1.39E-02 BGLAP 
FIGF 1.39E-02 BGLAP 
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PLAA 1.39E-02 PTGS2 
2-cyclohexen-1-one 1.39E-02 PTGS2 
pyridoxal phosphate-
6-azophenyl-2',4'-
disulfonic acid 1.39E-02 PTGS2 
mevalonolactone 1.39E-02 PTGS2 
3-aminotriazole 1.39E-02 MPO 
butylated 
hydroxytoluene 1.39E-02 PTGS2 
NADPH 1.39E-02 PTGS2 
5-hydroxytryptophan 1.39E-02 PTGS2 
N-acetylglucosamine 1.39E-02 PTGS2 
ginsenoside Rg1 1.39E-02 PTGS2 
miR-144-3p 
(miRNAs w/seed 
ACAGUAU) 1.40E-02 CLIC2,HOXA10,HOXA7,NDFIP1,NFIA,PTGS2,SOCS2 
progesterone 1.42E-02 FAAH,HOXA10,MPO,PTGER4,PTGS2 
POR 1.43E-02 EREG,GSTM5,VNN1 
IL17A 1.43E-02 EREG,MPO,PTGS2 
miR-2355-3p 
(miRNAs w/seed 
UUGUCCU) 1.43E-02 ATP6V0A2,ERMP1 
TBP 1.43E-02 HOXA9,PTGS2 
ATP-gamma-S 1.52E-02 EREG,PTGS2 
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RARB 1.52E-02 HOXA5,PTGS2 
CDX2 1.52E-02 HOXA5,HOXA9 
SPIB 1.52E-02 BLNK,EPCAM 
cobalt chloride 1.52E-02 DDIT4,PTGS2 
L-triiodothyronine 1.52E-02 BGLAP,CBR1,PTGS2,RAB34 
estradiol benzoate 1.56E-02 PTGER4,PTGS2 
1-methyl-4-phenyl-
1,2,3,6-
tetrahydropyridine 1.56E-02 MPO,PTGS2 
IL4 1.58E-02 ALDH2,FAAH,IL12RB2,LTB,PTGS2,SOCS2 
DOCK8 1.60E-02 PTGS2,SH3BP5 
SPDEF 1.60E-02 CD34,LAMB2 
MAP2K3 1.60E-02 PTGS2,RAB34 
miR-448-3p (and 
other miRNAs w/seed 
UGCAUAU) 1.61E-02 DDIT4,MPPED2,NFIA,SLITRK5,SOCS2,ZFP3 
miR-223-3p 
(miRNAs w/seed 
GUCAGUU) 1.64E-02 DDIT4,NFIA,SLC35G2,SNCA 
EDN1 1.65E-02 EREG,PTGER4,PTGS2 
miR-1839-5p (and 
other miRNAs w/seed 
AGGUAGA) 1.65E-02 HDAC9,HOXA7 
nitrite 1.67E-02 MPO 
teichoic acid 1.67E-02 PTGS2 
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LRRC26 1.67E-02 LTB 
CACNA1C 1.67E-02 PTGS2 
EN2 1.67E-02 SNCA 
PDGFD 1.67E-02 PTGS2 
PTGDR 1.67E-02 PTGS2 
SSPN 1.67E-02 PTGS2 
DES 1.67E-02 HOXA10 
OGN 1.67E-02 BGLAP 
TAB2 1.67E-02 PTGS2 
PROK1 1.67E-02 PTGS2 
PIM3 1.67E-02 IL12RB2 
WAC 1.67E-02 BGLAP 
glaucocalyxin A 1.67E-02 PTGS2 
RNF17 1.67E-02 MPO 
SNW1 1.67E-02 BGLAP 
XPA 1.67E-02 PTGS2 
PITPNA 1.67E-02 PTGS2 
Pde4d 1.67E-02 PTGS2 
ambroxol 1.67E-02 MPO 
EGTA acetoxymethyl 
ester 1.67E-02 PTGS2 
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olmesartan 
medoxomil 1.67E-02 PTGS2 
GW 5074 1.67E-02 PTGS2 
4-nitroquinoline-1-
oxide 1.67E-02 PTGS2 
ferric nitrilotriacetate 1.67E-02 PTGS2 
RWJ 67657 1.67E-02 PTGS2 
dibenzoylmethane 1.67E-02 PTGS2 
ibandronic acid 1.67E-02 BGLAP 
dieldrin 1.67E-02 SNCA 
propyl gallate 1.67E-02 PTGS2 
phosphatidic acid 1.67E-02 PTGS2 
phenylamil 1.67E-02 BGLAP 
canrenoate potassium 1.67E-02 PTGS2 
miR-3615 (miRNAs 
w/seed CUCUCGG) 1.69E-02 CD34,SLITRK5 
SASH1 1.69E-02 PTGS2,SH3BP5 
ERG 1.69E-02 DOCK1,GUCY1B3,SNCA 
SMAD4 1.76E-02 BGLAP,EREG,PTGS2 
isotretinoin 1.83E-02 HOXA5,PTGS2 
SP600125 1.86E-02 BGLAP,DDIT4,PTGS2 
TRAF2 1.88E-02 EPCAM,RHBDF1 
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MET 1.92E-02 PTGS2,SH3BP5 
GW9662 1.92E-02 MPO,PTGS2 
ascorbic acid 1.92E-02 BGLAP,PTGS2 
16,16-
dimethylprostaglandi
n E2 1.94E-02 PTGER4 
(6)-gingerol 1.94E-02 PTGS2 
Rhox4b (includes 
others) 1.94E-02 CD34 
Glucocorticoid-GCR 1.94E-02 BGLAP 
CTR9 1.94E-02 HOXA9 
sphingomyelinase 1.94E-02 PTGS2 
DVL1 1.94E-02 PTGS2 
RAPGEF1 1.94E-02 PTGS2 
ENO1 1.94E-02 PTGS2 
TPSD1 1.94E-02 PTGS2 
LPAR2 1.94E-02 PTGS2 
APOBEC1 1.94E-02 PTGS2 
SF3B2 1.94E-02 HOXA5 
MLLT3 1.94E-02 HOXA9 
IL18RAP 1.94E-02 PTGS2 
PLA2G2A 1.94E-02 PTGS2 
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NEDD4 1.94E-02 SNCA 
4-coumaric acid 1.94E-02 PTGS2 
zimelidine 1.94E-02 C10orf10 
eugenol 1.94E-02 PTGS2 
atropine 1.94E-02 PTGS2 
S-allyl-L-cysteine 1.94E-02 PTGS2 
20alpha-
hydroxycholesterol 1.94E-02 BGLAP 
IL13 1.97E-02 CD52,PTGS2,SNCA,VNN1 
TGFA 1.97E-02 EREG,PTGS2 
miR-3180-3p (and 
other miRNAs w/seed 
GGGGCGG) 1.99E-02 DDIT4,NFIA,SLITRK5,ZFP3 
GATA2 2.02E-02 CD34,MPO 
miR-3691-5p 
(miRNAs w/seed 
GUGGAUG) 2.02E-02 CPNE8,CRHBP 
FGFR1 2.02E-02 BGLAP,PTGS2 
SNCA 2.02E-02 BGLAP,SNCA 
imatinib 2.02E-02 BLNK,SOCS2 
ESR2 2.03E-02 EREG,PTGS2,SOCS2 
CEBPB 2.06E-02 BGLAP,BLNK,PTGER4,PTGS2 
TRAF3 2.07E-02 EPCAM,RHBDF1 
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actinomycin D 2.08E-02 GSTM5,GUCY1B3,PTGS2 
ciglitazone 2.12E-02 MPO,PTGS2 
miR-4318 (miRNAs 
w/seed ACUGUGG) 2.17E-02 EPCAM,MREG 
6-hydroxydopamine 2.17E-02 DDIT4,SNCA 
eicosapentenoic acid 2.17E-02 PTGS2,SNCA 




octadecylcarbonate 2.22E-02 PTGS2 
ganglioside GD1a 2.22E-02 PTGS2 
ganglioside GM1 2.22E-02 PTGS2 
desoxycorticosterone 2.22E-02 PTGS2 
SMTNL1 2.22E-02 PTGS2 
atrazine 2.22E-02 PTGS2 
voltage-gated calcium 
channel 2.22E-02 CD34 
Cyclin A 2.22E-02 CD34 
BCG vaccine 2.22E-02 PTGS2 
TCF/LEF 2.22E-02 PTGS2 
RNF40 2.22E-02 BGLAP 
EN1 2.22E-02 SNCA 
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TFRC 2.22E-02 SNCA 
IL1R2 2.22E-02 MPO 
GRIP1 2.22E-02 PTGS2 
CBX8 2.22E-02 HOXA9 
VEGFC 2.22E-02 PTGS2 
PIM2 2.22E-02 IL12RB2 
DLX5 2.22E-02 BGLAP 
S1PR3 2.22E-02 PTGS2 
PLA2G5 2.22E-02 PTGS2 
WNT3 2.22E-02 PTGS2 
naproxen 2.22E-02 PTGS2 
allyl isothiocyanate 2.22E-02 PTGS2 
NCX-4040 2.22E-02 PTGS2 
capsazepine 2.22E-02 PTGS2 
flufenamic acid 2.22E-02 PTGS2 
lapatinib 2.22E-02 EREG 
carnosol 2.22E-02 PTGS2 
glimepiride 2.22E-02 BGLAP 
acetic acid 2.22E-02 MPO 
palmitoyl-Cys((RS)-
2,3-di(palmitoyloxy)-
propyl)-Ala-Gly-OH 2.22E-02 PTGS2 
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rutin 2.22E-02 PTGS2 
tosyllysine 
chloromethyl ketone 2.22E-02 PTGS2 
mannan 2.22E-02 PTGS2 
22(S)-
hydroxycholesterol 2.22E-02 BGLAP 
lead acetate 2.22E-02 GSTM5 
MYB 2.22E-02 CD34,PTGS2 
TBK1 2.22E-02 PTGS2,SH3BP5 
MKL2 2.27E-02 GSTM5,MS4A3 
miR-3622a-3p (and 
other miRNAs w/seed 
CACCUGA) 2.27E-02 ATP6V0A2,FAM169A 
allopurinol 2.32E-02 MPO,PTGS2 
miR-4438 (miRNAs 
w/seed ACAGGCU) 2.32E-02 HOXA5,SH3BP5 
FBXO32 2.32E-02 HOOK1,PTGS2 
VEGFA 2.33E-02 ALDH2,CD34,PTGS2 
WNT3A 2.33E-02 BGLAP,DDIT4,PTGS2 
okadaic acid 2.37E-02 BGLAP,PTGS2 
TFAP2A 2.42E-02 EREG,PTGER4 
Rxr 2.48E-02 BGLAP,PTGS2 
NRAS 2.48E-02 CD34,PTGS2 
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daidzein 2.48E-02 OSBPL3,PTGS2 
TCF 2.48E-02 EPCAM,PTGS2 
ganglioside 2.49E-02 PTGS2 
tannic acid 2.49E-02 PTGS2 
ganglioside GT1 2.49E-02 PTGS2 
RUNX1T1 2.49E-02 CD34 
dovitinib 2.49E-02 LTB 
FAT1 2.49E-02 PTGS2 
NEK7 2.49E-02 PTGS2 
SLC18A2 2.49E-02 SNCA 
SOX8 2.49E-02 VNN1 
mir-194 2.49E-02 SOCS2 
CD209 2.49E-02 PTGS2 
PRDX1 2.49E-02 PTGS2 
NEK6 2.49E-02 PTGS2 
TAF6 2.49E-02 HOXA9 
BTC 2.49E-02 PTGS2 
HPSE 2.49E-02 PTGS2 
ammonium 
trichloro(dioxoethyle
ne-O,O'-)tellurate 2.49E-02 MPO 
bupivacaine 2.49E-02 MPO 
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domoic acid 2.49E-02 PTGS2 
phenyl-N-tert-
butylnitrone 2.49E-02 PTGS2 
racemic flurbiprofen 2.49E-02 PTGS2 
ketorolac 2.49E-02 PTGS2 
mesalamine 2.49E-02 PTGS2 
rhodioloside 2.49E-02 BGLAP 
nickel chloride 2.49E-02 PTGS2 
hexamethoxyflavone 2.49E-02 PTGS2 
theophylline 2.49E-02 MPO 
tyrphostin AG 127 2.49E-02 PTGS2 
tyrphostin AG 1024 2.49E-02 PTGS2 
saturated fatty acid 2.49E-02 PTGS2 
arachidonyltrifluorom
ethane 2.49E-02 PTGS2 
L-N6-(1-iminoethyl)-
lysine 2.49E-02 PTGS2 
miR-342-5p (and 
other miRNAs w/seed 
GGGGUGC) 2.49E-02 CD34,LST1,NFIA,ZFP3 
PPARG 2.49E-02 BGLAP,MPO,PTGS2,VNN1 
PARP1 2.53E-02 PTGS2,SOCS2 
fatty acid 2.53E-02 PTGS2,VNN1 
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MYD88 2.58E-02 MAFF,PTGS2,SH3BP5 
TAL1 2.58E-02 DOCK1,MPO 
phorbol esters 2.58E-02 HOXA5,PTGS2 
camptothecin 2.59E-02 LAMB2,LST1,MAFF,PTGER4,PTGS2 
PPARA 2.64E-02 ALDH2,PTGS2,SOCS2,VNN1 
SAMSN1 2.69E-02 PTGS2,SH3BP5 
aspirin 2.69E-02 MPO,PTGS2 
EPHB1 2.76E-02 PTGS2 
(+)-catechin 2.76E-02 PTGS2 
Pdgfr 2.76E-02 EREG 
FFAR4 2.76E-02 PTGS2 
SGPP1 2.76E-02 PTGS2 
NQO2 2.76E-02 PTGS2 
FOXN1 2.76E-02 MREG 
mir-130 2.76E-02 HOXA5 
NMNAT1 2.76E-02 SOCS2 
RYBP 2.76E-02 HOXA7 
PTAFR 2.76E-02 PTGS2 
VIM 2.76E-02 BGLAP 
DEFB103A/DEFB10
3B 2.76E-02 PTGS2 
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TAS1R3 2.76E-02 DDIT4 
edaravone 2.76E-02 PTGS2 
methylene blue 2.76E-02 MPO 
clomipramine 2.76E-02 C10orf10 
cinnamaldehyde 2.76E-02 PTGS2 
rosmarinic acid 2.76E-02 PTGS2 
morin 2.76E-02 PTGS2 
midostaurin 2.76E-02 PTGS2 
8-oxo-7-
hydrodeoxyguanosine 2.76E-02 PTGS2 
allopregnanolone 2.76E-02 PTGS2 
formononetin 2.76E-02 BGLAP 
miR-502-5p (and 
other miRNAs w/seed 
UCCUUGC) 2.80E-02 MARC2,MREG 
salmonella minnesota 
R595 
lipopolysaccharides 2.86E-02 MAFF,PTGS2 
bisindolylmaleimide I 2.91E-02 BGLAP,PTGS2 
tamoxifen 2.95E-02 C10orf10,MAFF,PTGS2 
ERBB2 2.95E-02 CD34,EREG,LTBP3,PTGS2,RAB34 
miR-224-5p 
(miRNAs w/seed 
AAGUCAC) 2.96E-02 CPNE8,HOXA5,MAFF,NFIA 
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miR-128-3p (and 
other miRNAs w/seed 
CACAGUG) 2.98E-02 HOXA10,HOXA5,HOXA9,LPAR6,MPPED2,NFIA,RAB34 
TRIM24 3.03E-02 BLNK,SOCS2 
L-histidine 3.04E-02 DDIT4 
estriol 3.04E-02 HOXA10 
DNA-
methyltransferase 3.04E-02 PTGS2 
CARD9 3.04E-02 MPO 
Agtr1b 3.04E-02 PTGS2 
SYK/ZAP 3.04E-02 PTGS2 
PP2A 3.04E-02 PTGS2 
Rac 3.04E-02 PTGS2 
trypsin 3.04E-02 PTGS2 
Adaptor protein 1 3.04E-02 PTGS2 
T 0070907 3.04E-02 PTGS2 
Collagen Alpha1 3.04E-02 PTGS2 
IL13RA2 3.04E-02 VNN1 
PLD1 3.04E-02 PTGS2 
MTA3 3.04E-02 BLNK 
MAPK10 3.04E-02 PTGS2 
ITGA3 3.04E-02 PTGS2 
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MZF1 3.04E-02 CD34 
HNRNPAB 3.04E-02 PTGS2 
sesamin 3.04E-02 PTGS2 
manumycin A 3.04E-02 PTGS2 
amiloride 3.04E-02 PTGS2 
enterolactone 3.04E-02 BGLAP 
phospholipid 3.04E-02 PTGS2 
puerarin 3.04E-02 PTGS2 
tyrphostin AG 1296 3.04E-02 PTGS2 
miR-200b-3p (and 
other miRNAs w/seed 
AAUACUG) 3.05E-02 ATP6V0A2,CHRDL1,CRHBP,DDIT4,HOOK1,HOXA5,NFIA 
fenofibrate 3.07E-02 HOXA7,MPO,PTGS2 
Ca2+ 3.07E-02 BGLAP,FAAH,PTGS2 
GNA15 3.08E-02 GUCY1B3,LAMB2 
GW501516 3.14E-02 PTGER4,VNN1 
hyaluronic acid 3.20E-02 MPO,PTGS2 
CD3 3.20E-02 GUCY1B3,IL12RB2,PTGER4,PTGS2,SOCS2 
hydrogen peroxide 3.22E-02 BGLAP,DDIT4,PTGER4,PTGS2 
NFKBIA 3.22E-02 EREG,GSTM5,HOXA10,PTGS2 
MAPT 3.23E-02 ERMP1,GSTM5,SNCA 
F2 3.23E-02 EREG,HDAC9,PTGS2 
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cephaloridine 3.26E-02 DDIT4,GSTM5 
bisphenol A 3.26E-02 EREG,PTGS2 
miR-3189-5p 
(miRNAs w/seed 
GCCCCAU) 3.27E-02 FAM169A,MPPED2,SLITRK5 
PD173074 3.31E-02 LTB 
NFkB (family) 3.31E-02 PTGS2 
perhexiline 3.31E-02 C10orf10 
chlorcyclizine 3.31E-02 C10orf10 
HRH1 3.31E-02 PTGS2 
STAT1/3/5 dimer 3.31E-02 SOCS2 
harmine 3.31E-02 PTGS2 
astragalin 3.31E-02 PTGS2 
SLAMF1 3.31E-02 IL12RB2 
PLA2G10 3.31E-02 PTGS2 
MIR101 3.31E-02 PTGS2 
mir-214 3.31E-02 PTGS2 
miR-643 (miRNAs 
w/seed CUUGUAU) 3.31E-02 EREG 
KLF10 3.31E-02 BGLAP 
TRPC1 3.31E-02 SNCA 
NPPC 3.31E-02 GUCY1B3 
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10-nitrooleate 3.31E-02 PTGS2 
GNA13 3.31E-02 PTGS2 
PDCD4 3.31E-02 PTGS2 
RHOB 3.31E-02 PTGS2 
ebselen 3.31E-02 PTGS2 
N-(3-
oxododecanoyl)-
homoserine lactone 3.31E-02 PTGS2 
dimethyl fumarate 3.31E-02 PTGS2 
D-sphingosine 3.31E-02 PTGS2 
SKF-38393 3.31E-02 BGLAP 
N,N-
dimethylsphingosine 3.31E-02 PTGS2 
buthionine 
sulfoximine 3.31E-02 PTGS2 
progestin 3.31E-02 HOXA10 
NR1I3 3.32E-02 GSTM5,MAFF 
KAT5 3.32E-02 EREG,HOXA9 
NR3C1 3.38E-02 BGLAP,DDIT4,LTB,PTGS2,SNCA 
INHA 3.38E-02 EREG,PTGS2 
cyclic AMP 3.40E-02 BGLAP,EPCAM,PTGS2 
miR-4687-3p 
(miRNAs w/seed 
GGCUGUU) 3.44E-02 C10orf10,HDAC9 
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JAK2 3.44E-02 MPO,PTGS2 
RB1 3.50E-02 BGLAP,H1F0,ROBO3 
miR-361-5p 
(miRNAs w/seed 
UAUCAGA) 3.54E-02 ATP6V0A2,GUCY1B3,NFIA 
MKL1 3.56E-02 GSTM5,MS4A3 
RARA 3.56E-02 HOXA5,PTGS2 
leukotriene C4 3.58E-02 PTGS2 
SIM2 3.58E-02 ROBO3 
TRPV1 3.58E-02 PTGS2 
LPAR1 3.58E-02 PTGS2 
CSF3R 3.58E-02 MPO 
CD46 3.58E-02 PTGER4 
PTGFR 3.58E-02 PTGS2 
PTGER1 3.58E-02 PTGS2 
PLD2 3.58E-02 PTGS2 
SP7 3.58E-02 BGLAP 
FABP1 3.58E-02 FAAH 
Go6983 3.58E-02 PTGS2 
1,2-
dimethylhydrazine 3.58E-02 PTGS2 
mevastatin 3.58E-02 PTGS2 
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SU5402 3.58E-02 LTB 
icatibant 3.58E-02 PTGS2 
farnesyl 
pyrophosphate 3.58E-02 PTGS2 
gamma-linolenic acid 3.58E-02 PTGS2 
prostaglandin 3.58E-02 PTGS2 
auranofin 3.58E-02 PTGS2 
IL5 3.68E-02 LTB,RBPMS,SOCS2 
CCND1 3.75E-02 CPNE3,EREG,MAFF 
miR-381-3p (and 
other miRNAs w/seed 
AUACAAG) 3.76E-02 ATP6V0A2,HOXA9,NDFIP1,NFIA,OSBPL3,SNCA 
miR-3198 (and other 
miRNAs w/seed 
UGGAGUC) 3.81E-02 IL12RB2,SCRN1 
miR-4421 (and other 
miRNAs w/seed 
CCUGUCU) 3.81E-02 H1F0,MANSC1 
HDAC2 3.81E-02 CD34,PTGS2 
A23187 3.81E-02 DDIT4,PTGS2 
sulforafan 3.81E-02 GSTM5,PTGS2 
prostaglandin A2 3.85E-02 LPAR6 
lonafarnib 3.85E-02 PTGS2 
cyclooxygenase 3.85E-02 PTGS2 
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IKK (complex) 3.85E-02 PTGS2 
dihydroartemisinin 3.85E-02 PTGS2 
KLF9 3.85E-02 HOXA10 
mir-135 3.85E-02 HOXA10 
PDGFRA 3.85E-02 BGLAP 
PRDX2 3.85E-02 PTGS2 
BAG1 3.85E-02 PTGS2 
salmeterol 3.85E-02 DDIT4 
hydrogen sulfide 3.85E-02 PTGS2 
N1,N11-
diethylnorspermine 3.85E-02 PTGS2 
myricetin 3.85E-02 PTGS2 
neuroprotectin D1 3.85E-02 PTGS2 
gambogic acid 3.85E-02 PTGS2 
Cd2+ 3.85E-02 PTGS2 
manganese 3.85E-02 PTGS2 
paraquat 3.93E-02 PTGS2,SNCA 
miR-26a-5p (and 
other miRNAs w/seed 
UCAAGUA) 3.96E-02 ERMP1,HOOK1,HOXA5,HOXA9,MREG,PTGS2 
corticosterone 4.06E-02 DDIT4,PTGS2 
IL21 4.06E-02 IL12RB2,SOCS2 
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miR-3103-5p (and 
other miRNAs w/seed 
GAGGGAG) 4.11E-02 ALDH2,CD34,CHRDL1 
epoprostenol 4.12E-02 PTGS2 
cyclic GMP 4.12E-02 IL12RB2 
TMSB4 4.12E-02 BGLAP 
1'-acetoxychavicol 
acetate 4.12E-02 PTGS2 
IGFBP7 4.12E-02 PTGS2 
MAPK8IP1 4.12E-02 SNCA 
PLCG2 4.12E-02 PTGS2 
CD83 4.12E-02 PTGS2 
S1PR2 4.12E-02 PTGS2 
SP2 4.12E-02 BGLAP 
RPS6KA5 4.12E-02 PTGS2 
ITGAL 4.12E-02 IL12RB2 
RND3 4.12E-02 PTGS2 
CD47 4.12E-02 IL12RB2 
pyridoxine 4.12E-02 PTGS2 
rofecoxib 4.12E-02 PTGS2 
caffeic acid 4.12E-02 PTGS2 
lauric acid 4.12E-02 PTGS2 
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resveratrol 4.27E-02 BGLAP,MPO,PTGS2 
miR-4300 (and other 
miRNAs w/seed 
GGGAGCU) 4.30E-02 GSTM5,HOXA7,MPPED2 
POU2F1 4.32E-02 DDIT4,GSTM5 
lovastatin 4.32E-02 MPP6,PTGS2 
misoprostol 4.38E-02 PTGS2 
RNASEL 4.38E-02 PTGS2 
SALL4 4.38E-02 EPCAM 
CGB (includes 
others) 4.38E-02 PTGS2 
PRKCI 4.38E-02 PTGS2 
HDC 4.38E-02 PTGS2 
SCGB1A1 4.38E-02 PTGS2 
superoxide 4.38E-02 PTGS2 
allyl sulfide 4.38E-02 GSTM5 
D609 4.38E-02 PTGS2 
amlodipine 4.38E-02 PTGS2 
piperine 4.38E-02 PTGS2 
2-
arachidonoylglycerol 4.38E-02 PTGS2 
leptomycin B 4.38E-02 PTGS2 
acadesine 4.38E-02 PTGS2 
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Alpha catenin 4.39E-02 EREG,PTGS2 
BMP7 4.39E-02 BGLAP,CD34 
miR-340-5p 
(miRNAs w/seed 
UAUAAAG) 4.41E-02 CPNE8,GUCY1B3,H1F0,HOXA10,MAFF,MPPED2,NFIA,RBPMS 
IL1RN 4.52E-02 HDAC9,PTGS2 
miR-324-5p 
(miRNAs w/seed 
GCAUCCC) 4.58E-02 HOXA9,MPPED2,ZFP3 
interferon beta-1a 4.59E-02 LTB,SNCA 
5-azacytidine 4.59E-02 MAFF,PTGS2 
miR-130a-3p (and 
other miRNAs w/seed 
AGUGCAA) 4.62E-02 EREG,HOXA5,MPPED2,NAP1L3,NFIA,RAB34 
leukotriene B4 4.65E-02 MPO 
calcipotriene 4.65E-02 BGLAP 
Cyclin E 4.65E-02 CD34 
NMDA Receptor 4.65E-02 PTGS2 
HCAR2 4.65E-02 PTGS2 
WWTR1 4.65E-02 BGLAP 
TEAD1 4.65E-02 PTGS2 
Endothelin 4.65E-02 PTGS2 
fontolizumab 4.65E-02 IL12RB2 
p85 (pik3r) 4.65E-02 PTGS2 
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CBX4 4.65E-02 HOXA7 
FKBP4 4.65E-02 HOXA10 
miR-4766-5p (and 
other miRNAs w/seed 
CUGAAAG) 4.65E-02 ATP6V0A2 
WNT7A 4.65E-02 HOXA10 
TACR1 4.65E-02 PTGS2 
S1PR1 4.65E-02 PTGS2 
PD 169316 4.65E-02 PTGS2 
ellagic acid 4.65E-02 PTGS2 
ethoxyquin 4.65E-02 GSTM5 
NO 1886 4.65E-02 PTGS2 
ethyl pyruvate 4.65E-02 PTGS2 
dipyridamole 4.65E-02 PTGS2 
isoliquiritigenin 4.65E-02 PTGS2 
magnolol 4.65E-02 PTGS2 
ammonium chloride 4.65E-02 SNCA 
vanadate 4.65E-02 BGLAP 
miR-335-5p (and 
other miRNAs w/seed 
CAAGAGC) 4.65E-02 NDFIP1,OSBPL3,SCRN1 
SMAD7 4.73E-02 HDAC9,LTBP3 
HGF 4.75E-02 EPCAM,GUCY1B3,PTGS2,SOCS2 
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miR-133a-3p (and 
other miRNAs w/seed 
UUGGUCC) 4.75E-02 CPNE3,HOXA9,NFIA,RAB34,SNCA 
Pdgf Ab 4.92E-02 EREG 
3M-002 4.92E-02 PTGS2 
artesunic acid 4.92E-02 PTGS2 
miR-4652-3p 
(miRNAs w/seed 
UUCUGUU) 4.92E-02 CPNE8 
HOXB9 4.92E-02 EREG 
CREB3L1 4.92E-02 BGLAP 




GDPKHPKSF 4.92E-02 PTGS2 
IL2 4.93E-02 IL12RB2,LTB,PTGS2,SOCS2 
TLR4 4.94E-02 EREG,PTGS2,SH3BP5 
miR-7a-5p (and other 
miRNAs w/seed 





Table 2.10. Association of LSC epigenetic signature with DMRs of genetic mutations 
Columns are chromosome, start, end, diffMethyl(difference of methylation percentage for LSC-Blast), diffexp( difference of 
expression log2 value for LSC-Blast), Gene, DMR name, DNMT3A,IDH1,IDH2,TET2,NPM1,ASXL1(Genetic mutations 
tested here to look at overlap of LSC epigenetic signature and DMR for mutations), Mechanism(which mechanism regulate 
each DMR). 
"1" represent overlap and "0" represents no overlap between the corresponding LSC epigenetic signature and DMRs for 
DNMT3A, IDH1, IDH2, TET2, NPM1 and ASXL1. 
 
Gene DMR name DNMT3A IDH1 IDH2 TET1 TET2 NPM1 ASXL1 Mechanism 
MPO MPO/DMR1 0 0 0 0 0 0 1 UpstremRegulator 
HOXA9 HOXA9/DMR1 0 0 0 0 0 0 0 PrimaryEpi 
HOXA9 HOXA9/DMR2 0 0 0 0 0 0 0 PrimaryEpi 
HOXA9 HOXA9/DMR3 0 0 0 0 0 1 0 UpstremRegulator 
HOXA9 HOXA9/DMR4 0 0 0 0 0 1 0 UpstremRegulator 
HOXA9 HOXA9/DMR5 0 0 0 0 0 0 0 PrimaryEpi 
SCRN1 SCRN1/DMR1 1 0 0 0 0 0 0 EpigeneticEnzyme 
CD34 CD34 0 0 0 0 0 0 1 UpstremRegulator 
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CPNE3 CPNE3 0 0 0 0 0 0 0 PrimaryEpi 
HOXA10 HOXA10 0 0 0 0 0 1 0 UpstremRegulator 
MANSC1 MANSC1 0 0 0 0 0 0 0 PrimaryEpi 
NDFIP1 NDFIP1 0 0 0 0 0 0 0 PrimaryEpi 
FAM24B FAM24B 0 0 0 1 0 0 0 EpigeneticEnzyme 
FAM169A FAM169A 1 0 0 0 0 0 0 EpigeneticEnzyme 
MPPED2 MPPED2 1 0 0 0 0 0 0 EpigeneticEnzyme 
PTGER4 PTGER4 0 0 0 0 0 0 0 PrimaryEpi 
HOXA7 HOXA7/DMR1 0 0 0 0 0 0 0 PrimaryEpi 
HOXA7 HOXA7/DMR2 1 0 0 0 0 1 0 CommonTarget 
RHBDF1 RHBDF1 1 0 0 0 0 0 0 EpigeneticEnzyme 
EREG EREG 0 0 0 0 0 0 0 PrimaryEpi 
CPNE8 CPNE8 0 0 0 0 0 1 0 UpstremRegulator 
RAB34 RAB34/DMR1 0 0 0 0 0 0 0 PrimaryEpi 
LTBP3 LTBP3 0 0 0 0 0 0 0 PrimaryEpi 
RAB34 RAB34/DMR2 0 0 0 0 0 0 0 PrimaryEpi 
ROBO3 ROBO3 0 0 0 0 0 0 1 UpstremRegulator 
GSTM5 GSTM5 0 0 0 0 0 0 1 UpstremRegulator 
DDIT4 DDIT4 0 0 0 0 0 0 1 UpstremRegulator 
REC8 REC8 1 0 0 0 1 0 1 CommonTarget 
ZFP3 ZFP3 0 0 0 0 0 0 0 PrimaryEpi 
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SLITRK5 SLITRK5 0 0 0 0 0 0 0 PrimaryEpi 
HOXA6 HOXA6 1 0 0 0 0 1 0 CommonTarget 
FAAH FAAH 0 0 0 0 0 0 1 UpstremRegulator 
DOCK1 DOCK1 0 1 0 0 1 1 0 CommonTarget 
ATP6V0A2 ATP6V0A2 1 0 0 0 0 0 0 EpigeneticEnzyme 
MAFF MAFF 0 0 0 0 0 0 0 PrimaryEpi 
EID3 EID3 1 0 0 0 0 0 0 EpigeneticEnzyme 
NAP1L3 NAP1L3 0 0 0 0 0 0 0 PrimaryEpi 
MPO MPO/DMR2 0 0 0 0 0 0 1 UpstremRegulator 
EPCAM EPCAM 0 0 1 1 0 0 0 EpigeneticEnzyme 
ALDH2 ALDH2/DMR1 0 0 0 0 0 0 0 PrimaryEpi 
ALDH2 ALDH2/DMR2 0 0 0 0 0 0 0 PrimaryEpi 
HOXA9 HOXA9/DMR6 0 0 0 0 0 0 0 PrimaryEpi 
SH3BP5 SH3BP5 1 0 0 0 0 0 0 EpigeneticEnzyme 
SCRN1 SCRN1/DMR2 0 0 0 0 1 0 0 EpigeneticEnzyme 
SCRN1 SCRN1/DMR3 1 0 0 0 0 0 0 EpigeneticEnzyme 
HOXA5 HOXA5 0 0 0 0 0 1 0 UpstremRegulator 
H1F0 H1F0 0 0 0 0 0 0 1 UpstremRegulator 
RBPMS RBPMS 0 0 0 0 0 0 0 PrimaryEpi 
TRIP6 TRIP6 0 0 0 0 0 0 0 PrimaryEpi 
HOXA7 HOXA7/DMR3 1 0 0 1 0 1 0 CommonTarget 
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OSBPL3 OSBPL3 0 0 0 0 0 0 0 PrimaryEpi 
HOXA7 HOXA7/DMR4 0 0 0 0 0 1 0 UpstremRegulator 
MOSC2 MOSC2 0 0 0 0 0 0 0 PrimaryEpi 
IL12RB2 IL12RB2 0 0 0 0 0 0 0 PrimaryEpi 
LAMB2 LAMB2 0 1 0 0 0 0 0 EpigeneticEnzyme 
CYorf15A CYorf15A 0 0 0 0 0 0 0 PrimaryEpi 
PTGS2 PTGS2 0 0 0 0 0 0 0 PrimaryEpi 
CRHBP CRHBP 0 1 0 0 0 0 1 CommonTarget 
LTB LTB 1 0 0 0 0 0 0 EpigeneticEnzyme 
SNCA SNCA 0 0 0 0 0 0 0 PrimaryEpi 
ERMP1 ERMP1 1 0 0 0 0 0 0 EpigeneticEnzyme 
CHRDL1 CHRDL1 0 0 0 0 0 0 0 PrimaryEpi 
GUCY1B3 GUCY1B3 0 0 0 0 0 0 0 PrimaryEpi 
HOOK1 HOOK1 0 0 0 0 0 0 0 PrimaryEpi 
LOC729046 /// RPL17 RPL17 0 0 0 0 0 0 0 PrimaryEpi 
MPP6 MPP6 1 0 0 0 0 0 0 EpigeneticEnzyme 
NFIA NFIA 0 0 0 0 0 0 0 PrimaryEpi 
SOCS2 SOCS2 0 0 0 0 0 0 1 UpstremRegulator 
MREG MREG 0 0 0 0 0 0 0 PrimaryEpi 
CBR1 CBR1 0 0 0 0 0 0 0 PrimaryEpi 
TMEM22 TMEM22 0 0 0 0 0 0 0 PrimaryEpi 
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C10orf10 C10orf10 0 0 0 0 0 0 0 PrimaryEpi 
BGLAP BGLAP 0 0 0 0 0 0 0 PrimaryEpi 
MS4A3 MS4A3 0 1 1 1 0 0 1 CommonTarget 
VNN1 VNN1 1 0 0 0 0 1 0 CommonTarget 
LST1 LST1 1 0 0 0 0 1 0 CommonTarget 
LPAR6 LPAR6 0 0 0 0 0 0 0 PrimaryEpi 
FAM30A FAM30A 0 0 0 0 0 0 1 UpstremRegulator 
CD52 CD52 1 0 0 0 0 0 0 EpigeneticEnzyme 
RXFP1 RXFP1 0 0 0 0 0 0 0 PrimaryEpi 
BLNK BLNK 0 0 0 0 0 1 0 UpstremRegulator 
TNS3 TNS3 1 0 0 0 0 1 0 CommonTarget 
CLIC2 CLIC2 0 0 0 0 1 1 0 CommonTarget 
HDAC9 HDAC9 0 0 0 0 0 0 0 PrimaryEpi 
    19 4 2 4 4 15 13   
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Table 2.11. Multivariate analysis of overall survival of TCGA patients using either DNA 











 DNA Methylation Gene Expression 
Variable HR(95% CI) p HR(95% CI) p 
Group 1.9(1.2-2.9) 0.003 1.7(1.0-2.7) 0.03 
Age 1.04(1.03-1.06) 8.5X 10-7 1.04(1.02-1.06) 1 X 10-6 
Cytogenetic risk     
Intermediate vs low 2.7(1.3-5.2) 0.005 2.2(1.0-4.5) 0.04 
High vs low 2.7(1.3-5.6) 0.006 2.2(1.0-4.7) 0.05 
NPM1 0.8(0.5-1.3) 0.39 1.0(0.6-1.7) 1.00 
FLT3 1.7(1.1-2.8) 0.03 1.5(0.9-2.5) 0.10 
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Table 2.12. Univariate overall survival analysis for LSC epigenetic signature regarding differential gene expression in various 
cohorts 
 TCGA Metzeler et al Wouters et al  Wilson et al 
Variable HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p 
LSC score 
(High vs. Low)* 2.4 (1.6-3.6) 1x10
-5 1.9 (1.3-2.8) 1 x 10-3 2.3 (1.7-3.1) 2x10-7 2.2 (1.6-3.1) 2x10-6 
Age 1.04 (1.03-1.06) 1x10-9 1.03 (1.01-1.04) 3 x 10
-4 1.01 (1.0-1.03) 3 x 10-2 1.03 (1.02-1.05) 4x10
-6 
Cytogenetics         
Intermediate  
vs. low 2.7 (1.4-5.2) 2 x 10
-3 - - 2.8 (1.7-4.7) 3x10-5 1.9 (0.9-4.1) 1.1 x 10-1 
High vs. low 3.9 (1.9-7.8) 2 x 10-4 - - 4.7 (2.7-8.4) 1x10-7 4.2 (1.9-9.6) 6x 10-4 
FLT3 1.1 (0.7-1.7) 7.1 x 10-1 2.2 (1.5-3.3) 8x10-5 1.8 (1.3-2.5) 5 x 10-4 1.1 (0.8-1.6) 5.2 x 10-1 
NPM1 1.4 (0.9-2.1) 1.8 x 10-1 0.8 (0.5-1.2) 2.4 x 10-1 0.9 (0.6-1.3) 5.1 x  10-1 0.8 (0.5-1.1) 2.0 x 10-1 
*LSC score is determined as described in method 
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Table 2.13. Multivariate overall survival analysis for LSC epigenetic signature regarding 
differential gene expression in various cohorts 
 Metzeler et al Wouters et al Wilson et al 
Variable HR (95% CI) p HR (95% CI) p HR (95% CI) p 
LSC score 
(High vs. Low)* 1.6 (1.0-2.4) 4 x 10
-2 1.8 (1.2-2.6) 3 x 10-3 1.8 (1.2-2.6) 5 x 10-3 
Age 1.03 (1.01-1.04) 4 x 10
-4 1.02 (1.0-1.03) 3 x 10-2 1.02 (1.01-1.04) 2 x 10
-3 
Cytogenetics       
Intermediate vs. low         -      - 2.4 (1.4-4.2) 2 x 10-3 1.4 (0.6-3.3) 3.9 x 10-1 
High vs. low - - 3.1 (1.6-5.9) 7 x 10-4 3.0 (1.2-7.1) 2 x 10-2 
FLT3 2.3 (1.5-3.6) 1 x 10-4 1.8 (1.3-2.6) 2 x 10-3 1.6 (1.0-2.5) 4 x 10-2 
NPM1 0.7 (0.5-1.1) 8 x 10-2 0.5 (0.3-0.7) 2 x 10-4 0.7 (0.5-1.1) 1.2 x 10-1 













Table 2.14. Univariate overall survival analysis for genetic mutations in epigenome 
modifying enzymes in TCGA 
Genetic mutation HR (95% CI) p 
DNMT3A 1.8 (1.2-2.7) 0.004 
IDH1 0.8 (0.4-1.5) 0.4 
IDH2 1.0 (0.6-1.9) 0.9 
TET2 0.8 (0.4-1.7) 0.6 















Table 2.15. Multivariate overall survival analysis including DNMT3A mutation for LSC 
epigenetic signature in TCGA 
 DNA Methylation Gene Expression 
Variable HR(95% CI) p HR(95% CI) p 
Group 1.9 (1.2-3.0) 0.005 1.7 (1.0-2.7) 0.04 
Age 1.0 (1.0-1.0) 9.3 x 10-7 1.0 (1.0-1.0) 1.2x10-6 
Cytogenetic risk     
Intermediate/Normal 2.7 (1.3-5.6) 0.007 2.2 (1.0-4.6) 0.04 
High 2.8 (1.3-5.9) 0.007 2.2 (1.0-4.8) 0.06 
NPM1 0.8 (0.5-1.4) 0.46 1.0 (0.6-1.7) 0.99 
FLT3 1.7 (1.0-2.8) 0.04 1.5 (0.9-2.5) 0.1 













Table 2.16. Multivariate overall survival analysis for LSC epigenetic signature within 
intermediate cytogenetic risk patients in TCGA 
 DNA Methylation Gene Expression 
Variable HR (95% CI) p HR (95% CI) p 
Group 1.8 (1.0-3.1) 0.05 1.9 (1.1-3.3) 0.03 
Age 1.0 (1.0-1.1) 3 x 10-4 1.0 (1.0-1.1) 2 x 10-4 
NPM1 0.7 (0.4-1.3) 0.2 0.9 (0.9-1.1) 0.7 
FLT3 2.5 (1.3-4.8) 4 x 10-3 2.3 (1.2-4.2) 0.01 































CD34 APC 340667 1:50 
CD38 PE-Cy7 335790 1:100 




To test chimerism/ 
engraftment of 
LSC frequency in 
NSG mice 
CD19 APC 555415 1:50 
CD33 PE 555450 1:50 
CD45 PB 560367 1:50 
CD45.1 
(mouse) PE-Cy7 eBioscience 
25-0453-82 1:100 
Ter119 




Table 2.18. Primers used for sequencing of TET2, IDH1, IDH2, and DNMT3A mutations of AML 
 
Primers Sequence 5' to 3' Size Tm Reference 
(1) TET2 exon 3 PCR1 F TGAACTTCCCACATTAGCTGGT 955 55 Gelsi-Boyer et al. British 
Journal of Haematology 
2009, 145(6): 788-800 (2) TET2 exon 3 PCR1 R GAAACTGTAGCACCATTAGGCATT   
(3) TET2 exon 3 PCR1 Seq GATAGAAATAAACACATTTT   
(4) TET2 exon 3 PCR2 F CAAAAGGCTAATGGAGAAAGACGTA 836 55 
(5) TET2 exon 3 PCR2 R GCAGAAAAGGAATCCTTAGTGAACA   
(6) TET2 exon 3 PCR3 F GCCAGTAAACTAGCTGCAATGCTAA 846 55 
(7) TET2 exon 3 PCR3 R TGCCTCATTACGTTTTAGATGGG   
(8) TET2 exon 3 PCR4 F GACCAATGTCAGAACACCTCAA 867 60 
(9) TET2 exon 3 PCR4 R TTGATTTTGAATACTGATTTTCACCA   
(10) TET2 exon 3 PCR5 F TTGCAACATAAGCCTCATAAACAG 788 60 
(11) TET2 exon 3 PCR5 R ATTGGCCTGTGCATCTGACTAT   
(12) TET2 exon 3 PCR6 F GCAACTTGCTCAGCAAAGGTACT 781 60 
(13) TET2 exon 3 PCR6 R TGCTGCCAGACTCAAGATTTAAAA   
(14) TET2 exon 4 F ATACTACATATAATACATTCTAATTCCCTCACTG 495 55 
(15) TET2 exon 4 R TGTTTACTGCTTTGTGTGTGAAGG   
(16) TET2 exon 5 F CATTTCTCAGGATGTGGTCATAGAAT 286 55 
(17) TET2 exon 5 R CCCAATTCTCAGGGTCAGATTTA   
(18) TET2 exon 6 F AGACTTATGTATCTTTCATCTAGCTCTGG 599 60 
(19) TET2 exon 6 R ACTCTCTTCCTTTCAACCAAAGATT   
(20) TET2 exon 7 F ATGCCACAGCTTAATACAGAGTTAGAT 362 55 
(21) TET2 exon 7 R TGTCATATTGTTCACTTCATCTAAGCTAAT   
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(22) TET2 exon 8 F GATGCTTTATTTAGTAATAAAGGCACCA 354 55 
(23) TET2 exon 8 R TTCAACAATTAAGAGGAAAAGTTAGAATAATATTT   
(24) TET2 exon 9 F TGTCATTCCATTTTGTTTCTGGATA 361 55 
(25) TET2 exon 9 R AAATTACCCAGTCTTGCATATGTCTT   
(26) TET2 exon 10 F CTGGATCAACTAGGCCACCAAC 774 55 
(27) TET2 exon 10 R CCAAAATTAACAATGTTCATTTTACAATAAGAG   
(28) TET2 exon 11 PCR1 F GCTCTTATCTTTGCTTAATGGGTGT 748 60 
(29) TET2 exon 11 PCR1 R TGTACATTTGGTCTAATGGTACAACTG   
(30) TET2 exon 11 PCR2 F AATGGAAACCTATCAGTGGACAAC 1107 60 
(31) TET2 exon 11 PCR2 R TATATATCTGTTGTAAGGCCCTGTGA   




(33) IDH1 exon 4 R TGCCACCAACGACCAAGTCA   
(34) IDH2 exon 4 F GGGGTTCAAATTCTGGTTGA 290 53 
(35) IDH2 exon 4 R CTAGGCGAGGAGCTCCAGT   
(36) DNMT3A exons 7-8 F ATGGTCCCCTTGAGTGTCAG 836 56 Fernandez-Mercado et al. 
PLoS One 2012, 7(8): 
e42334 (37) DNMT3A exons 7-8 R CATCACCCCAATTCCAGACT   
(38) DNMT3A exons 9-10 F CTGTATCTGGTCCCCTCCAG 747 56 
(39) DNMT3A exons 9-10 R CTCCCTAAGCATGGCTTTCC   
(40) DNMT3A exons 11-12 F GGGAACAAGTTGGAGACCAG 490 56 
(41) DNMT3A exons 11-12 R GGTCCCATGTCATTCAAACC   
(42) DNMT3A exon 13 F GTCACAGTGCCTCCCTTTTC 308 56 
(43) DNMT3A exon 13 R TGGACACAGTCAGCCAGAAG   
(44) DNMT3A exon 14 F CAGGGCTTAGGCTCTGTGAG 359 56 
(45) DNMT3A exon 14 R AGGTGTGCTACCTGGAATGG   
(46) DNMT3A exons 15-16 F CGGTCTTTCCATTCCAGGTA 614 56 
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(47) DNMT3A exons 15-16 R CATCATTTCGTTTTGCCAGA   
(48) DNMT3A exon 17 F GACTTGGGCCTACAGCTGAC 345 58 
(49) DNMT3A exon 17 R CAAAATGAAAGGAGGCAAGG   
(50) DNMT3A exons 18-19 F CTTCCTGTCTGCCTCTGTCC 552 56 
(51) DNMT3A exons 18-19 R ATGAAGCAGCAGTCCAAGGT   
(52) DNMT3A exons 19b-20 
F 
GCAGCACTGTGCAATATGGT 549 56 
(53) DNMT3A exons 19b-20 
R 
CTTCCCCACTATGGGTCATC   
(54) DNMT3A exons 21 F GCGGGGAGTTTGAAGAGAGT 342 56 
(55) DNMT3A exons 21 R CCACACTAGCTGGAGAAGCA   
(56) DNMT3A exons 22 F TTTGGTAGACGCATGACCAG 301 56 
(57) DNMT3A exons 22 R CAGGACGTTTGTGGAAAACA   
(58) DNMT3A exons 23 F TCCTGCTGTGTGGTTAGACG 654 56 
(59) DNMT3A exons 23 R CCTCTCTCCCACCTTTCCTC   
(60) DNMT3A exon 17 F CCTCGATGTCCTTACTATGGATACTCCA 402 63 Additional primers 
designed to cover the ones 
not working in previous 
rows, all the three new 
pairs worked on DNMT3A 
exon 17 
(61) DNMT3A exon 17 R CAAGGGCTGCCTCCAGGTGCTGAG  69 
(62) DNMT3A exon 17 F CTCACCTGCCGAGACCAG 276 59 
(63) DNMT3A exon 17 R CCTCCAGGTGCTGAGTGTG  60 
(48) DNMT3A exon 17 F GACTTGGGCCTACAGCTGAC 437 60 
(64) DNMT3A exon 17 R TTTGCCCTTTACCCTCTCAA  57 
Note: For IDH1 and IDH2, a single point mutation was tested in exon 4 (R132 and R140 respectively); for TET2 and DNMT3A mutations, multiple 
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This work is an ongoing project of the Feinberg Lab and Johns Hopkins. All publication 
rights are reserved for these institutions and the presentation of this work here does not 
preclude future publication elsewhere. 
 
Summary 
 DNA methylation plays an indispensable role during tissue development and 
cellular differentiation.  Hematopoiesis is one of best-understood and characterized 
developmental processes. We hypothesized that DNA methylation would be an essential 
mechanism during lineage differentiation in human hematopoiesis. Here, we provide a 
comprehensive methylome map of HSPCs, particularly in myeloid lineage, by 
performing a genome-wide DNA methylation analysis. We found that DNA methylation 
distinguished distinct lineages of hematopoiesis, suggesting a critical role of it during 
hematopoietic development. In concordance with previous studies for tissue development, 
we observed that most of DNA methylation changes during hematopoietic differentiation 
occurred at non-CpG island regions such as CpG island shores or open seas. We 
identified DMRs in potential novel regulators of hematopoiesis including HMHB1 and 
MIR539, as well as in previously known genes such as MPO and CDK6. The DMRs for 
normal hematopoiesis were enriched in a regulatory genomic element, super-enhancer. 
We found massive epigenetic variation between murine and human hematopoiesis, 





Comprehensive DNA Methylation Analysis Shows Tight Clustering of Human 
Hematopoietic Stem and Progenitor Cells 
Human hematopoiesis proceeds through a series of multipotent and oligopotent 
stem and progenitor cells that progressively lose self-renewal ability and become more 
restricted in their differentiation potential (Figure 3.1). These critical functional 
properties are mediated in part through epigenetic mechanisms, including DNA 
methylation. We obtained bone marrow from five normal donors and isolated HSPC by 
fluorescence-activated cell sorting (FACS) including: hematopoietic stem cells (HSC), 
multipotent progenitors (MPP), L-MPP, common myeloid progenitors (CMP), 
megakaryocyte/erythroid progenitors (MEP), and GMP (Figure 3.2, Tables 3.1 and 3.2). 
In order to further understand epigenetic variation during early human 
hematopoiesis, we generated genome-scale methylation profiles for normal 
hematopoietic stem and progenitor cell populations. Strikingly, multidimensional scaling 
analysis utilizing the top 1000 most variable CpG positions revealed tight clustering of 
human HSPC populations by lineage with no outliers (Figure 3.3). As the distance 
between clusters in multidimensional scaling is a measure of their similarity, this analysis 
indicates that DNA methylation reflects the function and hierarchy of the HSPC 
populations. For example, HSC and MPP clusters are close together reflecting their 
functional similarities. Similarly, L-MPP are located between HSC/MPP and GMP 
clusters, but farther away from MEP, supporting the hypothesis that L-MPP is an early 
lymphoid progenitor, which retains myeloid programs for GMP, but not MEP, 
differentiation (Doulatov et al., 2010; Goardon et al., 2011).  
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DMR Analysis Identified Previously Known and Novel Regulators in Human 
Hematopoietic Development 
The DMRs identified across HSPC not only permit clustering of these populations, 
but also have the potential to reveal novel regulators of hematopoietic lineage 
development. We first examined the DMRs for genes already known to play such a role. 
The DMR analysis identified myeloperoxidase (MPO), a well-established protein 
involved in neutrophil activity (Klebanoff, 2005), which showed progressive 
hypomethylation going from HSC to GMP, but exhibited hypermethylation in MEP 
(Figure 3.4). Similarly, CDK6, a cyclin-dependent protein kinase important in 
hematopoietic cell differentiation (Kozar and Sicinski, 2005; Malumbres et al., 2004), 
was progressively hypermethylated during differentiation from HSC to MEP and GMP 
(Figure 3.4). In both cases, these results were confirmed through direct pyrosequencing 
of these loci (Figure 3.4), validating the DNA methylation array approach. In addition to 
these two examples, a number of genes known to be involved in early hematopoiesis 
were found to be differentially methylated including: STAT3, KEL, IDH2, HLF, 
NOTCH1, GATA1, and HOX family genes (Table 3.3, see Appendix2).  
This analysis also identified novel sites of epigenetic variation during 
hematopoiesis. For example, HMHB1, encoding one of the minor histocompatibility 
antigens, was found to be hypomethylated in L-MPP and GMP, suggesting a possible 
role in GMP differentiation (Figure 3.5). Progressive hypomethylation was also identified 
in MIR539 going from HSC to MEP, suggesting that this microRNA may contribute to 
erythropoiesis (Figure 3.5). Interestingly, the MIR539 gene is located in DLK1-DIO3 
imprinting region that contains a miRNA cluster involved in leukemia pathogenesis 
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(Benetatos et al., 2013). Further validation of these novel candidate regulators will 
require functional experiments. 
We next sought to classify the DMRs among normal HSPCs according to their 
global genomic location in islands, shores, shelves, and open seas. Focusing on the 
comparison of HSC with GMP, we found that most DMRs were not in CpG islands, but 
were enriched outside of the islands, predominantly in shelves and open seas, compared 
to the distribution of random length matched DMRs (Figure 3.6a). The comparison of 
HSC with MEP also showed enrichment of DMRs at non-CpG island regions such as 
shores, shelves, and open seas (Figure 3.6b). Similarly, genes with an inverse correlation 
between DNA methylation and gene expression were located outside of the islands 
themselves, with the strongest correlation at shores and open seas for both comparisons 
(Figure 3.7). In addition to these comparisons, more than 50% of the DMRs among 
HSPCs were in open seas (Table 3.4). Thus, functional epigenetic differences during 
early human hematopoietic differentiation occur in CpG sparse regions, consistent with 
other recent studies of differentiation (Irizarry et al., 2009; Ji et al., 2010) and cancer 
(Hansen et al., 2011; Irizarry et al., 2009). 
DMRs for Normal Hematopoiesis are Enriched in Super-enhancers 
In order to further investigate a direct mechanistic link between DNA methylation 
change and regulation of hematopoietic development, we examined the overlap of DMRs 
that we identified for normal hematopoiesis in DNA regulatory elements, super-
enhancers. Super-enhancers are clusters of transcriptional enhancers bound by mater 
transcription factors, and associated with genes that define cell identity and tissue types 
(Hnisz et al., 2013; Whyte et al., 2013). From a published study that has identified super-
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enhancer in 86 different human cell and tissue samples, we selected three categories of 
tissue types; first, normal cell types related to hematopoietic development such as CD34+ 
(hematopoietic progenitor cells) and CD14+ (monocytes), second, cell lines related to 
hematological disorders including jurkat, K562 and MM1S, third, other normal tissues or 
cell lines including H1, adipose, angular gyrus, and spleen. First, we examined the 
enrichment of DMRs from normal hematopoiesis including HSC vs GMP and HSC vs 
MEP comparisons, in super-enhancers of the different tissues or cell types.  Remarkably, 
DMRs for GMP differentiation were significantly enriched in relevant cell types 
including monocytes and CD34+ cell population (Table 3.5). We identified master 
transcription factors showing differential methylation as HSC differentiates into GMP, 
such as ZNF217, known to be involved in cell proliferation (Figure 3.8a and Table 3.6, 
see Appendix3). Among the DMRs of HSC vs GMP comparison, contained within super-
enhancers of monocytes, 27.9% was located in monocyte (CD14+ cells) specific super-
enhancers (Table 3.6, see Appendix3). For example, a DMR of TREM1 that encodes a 
receptor expressed on monocytes was located in a monocyte specific super-enhancer and 
showed hypomethylation along with upregulation in GMP (Figure 3.8b and Table 3.6, 
see Appendix3). In addition to the relevant cell types, the DMRs of HSC vs GMP were 
overlapped with super-enhancers of jurkat and MM1S cells whereas, DMRs 
distinguishing MEP from HSC are enriched in K562 cells, implying involvement of 
epigenetic deregulation of the regulatory region in disease pathogenesis.  
Human Hematopoiesis Displays Distinct Epigenetic Regulation Compared to Murine 
Hematopoiesis 
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In addition to these genomic regional changes, there was an overall global change 
in the level of DNA methylation in human hematopoiesis (Figure 3.9 and Table 3.4). 
Global hypomethylation was observed upon MEP differentiation from CMP, but not in 
GMP differentiation, and most DMRs distinguishing MPP from CMP were less 
methylated in CMP in human hematopoiesis (Figure 3.9 and Table 3.4). We also found 
that all DMRs lost methylation when L-MPP differentiates into GMP (Figure 3.9 and 
Table 3.4). Previous epigenetic study of mouse hematopoiesis (Ji et al., 2010) allowed us 
to compare human and mouse hematopoietic differentiation for two pairs, MPP vs CMP 
and CMP vs GMP. We examined overlap of genes of DMR lists of the two comparisons. 
In both comparisons, most of the genes were different with only 4-5% of total genes in 
human overlapping with mouse: 7 out of 166 genes of MPP vs CMP, and 30 out of 728 
genes of CMP vs GMP (Table 3.7, see Appendix4). Among the 7 and 30 common genes 
for the two comparisons, 5 and 14 of them showed the opposite direction of methylation 
changes for the MPP vs CMP and CMP vs GMP pairs, respectively. For example, 
VKORC1L1 that encodes a subunit of the vitamin K epoxide reductase complex, was 
hypermethylated when CMP differentiate into GMP in human, but hypomethylated in the 
CMP to GMP transition in mouse (Table 3.7, see Appendix4). These results suggest that 




 The role of DNA methylation in hematopoietic development has been implicated 
in several studies that have shown an indispensable role of DNMT1, DNMT3A, and 
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DNMT3B in hematopoiesis (Broske et al., 2009; Challen et al., 2012; Tadokoro et al., 
2007; Trowbridge et al., 2009). In addition, dynamic DNA methylation changes during 
hematopoietic development in mouse and human have been demonstrated (Bartholdy et 
al., 2014; Bock et al., 2012; Ji et al., 2010). In order to provide a comprehensive 
methylome map of human hematopoiesis, particularly myeloid lineage, we analyzed 
genome-wide DNA methylation of a complete set of HSPCs in myeloid lineage. Our 
study suggested several significant findings for the epigenetic basis of human 
hematopoietic development. First, global hypomethylation is a core mechanism of 
hematopoietic differentiation, as MPP to CMP, CMP to MEP, and L-MPP to GMP 
differentiations were accompanied by loss of methylation (Figure 3.9). In addition to 
identifying previously known and novel candidate genes during hematopoietic 
differentiation, we found that DNA methylation were likely to occur at regulatory 
elements such as super-enhancer, suggesting a critical role of epigenetics in gene 
expression of lineage specific genes. Furthermore, we found distinct epigenetic plasticity 
between human and mouse hematopoiesis. We observed few overlaps of genes with 
DNA methylation changes between mouse and human hematopoiesis. Besides the 
distinct study design and experimental platform between the studies, intrinsically distinct 
mechanisms exist in hematopoietic development in mouse and human. For example, 
human blood contains 3 to 5-fold more neutrophils than mouse, while mouse blood has 2 
fold more lymphocytes, indicating differences in the generation of specific types of 
hematopoietic progenitor cells (Mestas and Hughes, 2004). Furthermore, mouse 
hematopoietic system is composed of a different set of HSPCs, and a different set of cell 
surface markers for HSPCs are used to isolate each population. For example, multiple 
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subpopulations constitute an MPP compartment, and Flk2 and Slamf1 are used to 
differentiate those subpopulations (Bock et al., 2012; Chao et al., 2008; Doulatov et al., 
2012; Ji et al., 2010).   
 We could compare our results to previous DNA methylation study of human 
hematopoiesis, and found few common observations, yet there were many distinct and 
novel findings in this study. We observed global hypomethylation when MPPs 
differentiated into CMPs, as Bartholdy et al. has reported. However, we identified global 
hypomethylation in CMP to MEP transition, while Bartholdy et al. has observed balanced 
hyper and hypomethylation in this differentiation (Bartholdy et al., 2014). In addition, we 
noticed that DMR lists from all pair-wise comparisons among HSPCs (p <0.01) of our 
study significantly differed from 561 loci distinguishing LT-HSC, ST-HSC, CMP, and 
MEP, identified in Bartholdy et al. 51 out of 3613 (1.4%) DMRs of our lists including 
DMRs in KLF1 and GATA1, overlapped with the 561 loci from Bartholdy et al. The 
discordance between our study and Bartholdy et al. may come from two major sources:  a 
different set of HSPCs and methods used in those studies. Our study includes two more 
progenitor populations, L-MPP and GMP, beside HSC, MPP (called as ST-HSC in 
Bartholdy et al.), CMP, and MEP. We have used 450K array which interrogate ~48000 
CpGs across the genome without a bias toward CpG islands and gene promoters, while 
HELP_Promoter array, used in Bartholdy et al., examines ~26000 loci, primarily 
targeting gene promoters.  
 In summary, we provide a comprehensive methylome map of a complete set of 
HSPCs in myeloid lineage, demonstrating the role of DNA methylation at regulatory 
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elements during lineage differentiation and dynamic epigenetic plasticity distinguishing 
human hematopoiesis from murine hematopoietic development.   
 
Materials and Methods 
Human Samples   
Fresh human bone marrow mononuclear cells (BMMC) from healthy donors (2 x 108 
cells per donor, Catalog#: ABM006) were purchased from ALLCELLS® (Emeryville, 
CA).  A CD34+ cell-enrichment step was performed with the human progenitor cells 
enrichment kit with CD61 depletion (Stem Cell Technologies, Canada, Catalog # 19356) 
on a RobSep machine from the same company. PBMC or BMMC were separated with 
Ficoll-Paque Plus (Amersham Biosciences, Piscataway, NJ, Catalog number: 17-1440-
03), and cryopreserved in 1 x freezing medium (90%FBS + 10%DMSO).   
Flow Cytometry Analysis and Cell Sorting 
A battery of antibodies (Abs) was used for staining, analysis and sorting of progenitor 
cells from either healthy BMMCs, as well as lineage analysis human 
chimerism/engraftment (Table 3.2).  Cells were either analyzed or sorted using a FACS 
Aria II cytometer (BD Biosciences, Franklin Lakes, NJ).  Analysis of flow cytometry raw 
data was done with FlowJo Software (Treestar, Ashland, OR). 
Illumina Infinium Human Methylation 450 Bead Array Assay  
Genomic DNA from each sample was purified using the MasterPure DNA purification 
kit (Epicentre) according to the manufacturer’s protocol. The genomic DNA (250-500ng) 
was treated with sodium bisulfate using the Zymo EZ DNA Methylation Kit (ZYMO 
Research) as recommended by the manufacturer, with the alternative incubation 
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conditions for the Illumina Infinium Methylation Assay. Converted DNA was eluted in 
11ul of elution buffer. DNA methylation level was measured using Illumina Infinium HD 
Methylation Assay (Illumina) according to the manufacturer’s specifications. 
Methylation array data are deposited at the Gene Expression Omnibus (GEO) with 
accession number GSE63409. 
Illumina Infinium Human Methylation 450 Bead Array Analysis 
Raw intensity files were obtained using minfi package (Aryee et al., 2014) to calculate 
methylation ratios (Beta values). The data was normalized using Illumina preprocessing 
method implemented in minfi. Several quality control measures were applied to remove 
arrays with low quality. Control probes were examined on the 450k array to assess 
several measures including bisulfite conversion, extension, hybridization, specificity and 
others. One of the MPP samples (BM2712) showed low quality for the measures, so they 
were removed for further analysis.  Next, median methylated and unmethylated signals 
were calculated for each arrays; no array was identified for signal values lower than 10.5. 
For multidimensional scaling analysis, probes containing an annotated SNP (dbSNP137) 
at the single-base extension or CpG sites were removed (17398 probes removed). Minfi 
1.8.9 was used. 
Bump hunting method previously described was applied to identify DMRs in 450k array 
(Aryee et al., 2014; Jaffe et al., 2012). Beta value of 0.1 (10% of methylation difference) 
was used as cutoff when finding DMRs. Statistical significance was assigned by 
permutations testing and the P-value cutoff used for downstream analysis was <0.01 that 
corresponded to Benjamini-Hochberg adjusted p-value <0.1 (data not shown) unless 
different cutoff was designated in result part. Bumphunter 1.2.0 was used.  
146	  
Bisulfite Pyrosequencing  
100ng of genomic DNA from each sample was treated with sodium bisulfate using an EZ 
DNA methylation Gold Kit (ZYMO research) following manufacturer’s protocol. The 
bisulfate treated DNA was PCR amplified using unbiased nested primers. Quantitative 
pyrosequencing was performed using a PSQ HS96 (Biotage) to validate DMR regions. 
The DNA methylation percentage at each CpG site was measured using the Q-CpG 
methylation software (Biotage). SssI treated human genomic DNA was used as 100% 
methylated controls and human genomic DNA amplified by Repli-G mini kit (Qiagen) 
was used as the non-methylated (0%) DNA control. Table 3.8 provides the primer 
sequence used for the pyrosequencing reactions with the chromosomal coordinates in the 
University of California at Santa Cruz February 2009 human genome assembly (hg19) 
for each CpG site investigated.  
Affymetrix Microarray Expression Analysis  
Total RNA was extracted from each FACS-sorted cell population using RNeasy® Plus 
Mini (QIAGEN, Valencia, CA, Catalog#: 74134) according to the manufacture’s 
protocol.  All RNA samples were quantified with 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA), subjected to reverse transcription, two consecutive 
rounds of linear amplification, and production and fragmentation of biotinylated cRNA.  
15µg of cRNA from each sample was hybridized to HG U133 Plus 2.0 microarrays.  
Hybridization and scanning were performed according to the manufacture’s instruction 
(Affymetrix).  This step was performed at the PAN center of Stanford University. Data 
were normalized by GC robust multi-array average method and analyzed on 
R/Bioconductor. BM2770 GMP, BM 2759 L-MPP, BM2761 CMP, BM2770 CMP were 
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removed from further analysis due to low quality (GEO GSE63270). University of 
California at Santa Cruz February 2009 human genome assembly (hg19) for each CpG 
site investigated.  
Affymetrix Microarray Expression Analysis  
Total RNA was extracted from each FACS-sorted cell population using RNeasy® Plus 
Mini (QIAGEN, Valencia, CA, Catalog#: 74134) according to the manufacture’s 
protocol.  All RNA samples were quantified with 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA), subjected to reverse transcription, two consecutive 
rounds of linear amplification, and production and fragmentation of biotinylated cRNA.  
15µg of cRNA from each sample was hybridized to HG U133 Plus 2.0 microarrays. 
Hybridization and scanning were performed according to the manufacture’s instruction 
(Affymetrix).  This step was performed at the PAN center of Stanford University. Data 
were normalized by GC robust multi-array average method and analyzed on 
R/Bioconductor. BM2770 GMP, BM 2759 L-MPP, BM2761 CMP, BM2770 CMP were 











	  Figure 3.1. Schematic of human hematopoiesis with the immunophenotype of 
individual HSPC populations as indicated.  Note the color scheme for each HSPC 




































Figure 3.2. Pre-sort and post-sort FACS analysis of HSPCs from human bone 
marrow. Top panel: FACS-sorting scheme of six populations of HSPCs from normal 
































Figure 3.3. Comprehensive DNA methylation analysis shows tight clustering of 
HSPCs by their lineages. Multidimensional scaling examining the top 1,000 most 
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Supplementary Figure 6. Comprehensive DNA methylation analysis shows tight 
clustering of human hematopoietic stem and progenitor cells (HSPCs) 
(a) Schematic of human hematopoiesis with the immunophenotype of individual HSPC 
populations as indicated. Note the color scheme for each HSPC population is used 
throughout. 
(b) Pre-sort and post-sort FACS analysis of HSPCs from human bone marrow. Top 
panel: FACS-sorting scheme of six populations of HSPCs from normal human BM.  
Other panels: The second round of post-sort analysis to check the purity of sorting. 
(c) Multidimensional scaling examining the top 1,000 most variable methylation positions 
among normal progenitors shows tight clustering of distinct lineages.  
(d) DMR plots indicating genomic loci for newly identified genes with previously unknown 
functions in hematopoiesis HMHB1 and MIR539. Top: level of CpG methylation (beta) of 
each sample for the region; Middle: CpG density (curve), CpG sites (black tick marks), 
CpG islands (red lines); Bottom: gene annotation; Lower panel: bisulfite pyrosequencing 




Figure 3.4. DMR plots indicating genomic loci for genes with previously known 
functions in hematopoiesis MPO and CDK6. Top: level of CpG methylation (beta) of 
each sample for the region; Middle: CpG density (curve), CpG sites (black tick marks), 
CpG islands (red lines); Bottom: gene annotation; Lower panel: bisulfite pyrosequencing 
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Figure 3.5. DMR plots indicating genomic loci for newly identified genes with 
previously unknown functions in hematopoiesis HMHB1 and MIR539. Top: level of 
CpG methylation (beta) of each sample for the region; Middle: CpG density (curve), CpG 
sites (black tick marks), CpG islands (red lines); Bottom: gene annotation; Lower panel: 
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Figure 3.6. Location of DMRs for normal hematopoiesis relative to CpG island. Left 
panel shows proportion of DMRs located in CpG island, overlapping region (50% 
overlap with island), shore, shelf, and open sea. Right panel shows distribution of length-
matched random regions relative to CpG island, overlap, shore, shelf, and open sea. (a) 
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Figure 3.7. Gene expression inversely correlates with DMRs at non-CpG island 
regions in normal hematopoiesis.  DMRs located within 2kb of gene TSSs (black dots) 
were classified into 4 groups according to the distance relative to CpG island: island, 
shore, shelf, and open sea. DMRs located further than 2kb of gene TSSs are denoted as 
black pluses in the middle. Log2 ratios of differential expression were plotted against 
differential methylation (all values are from group2-group1). Wilcoxon rank-sum test 
was performed to test the null hypothesis that the expression differences for the hypo- or 
hypermethylated DMRs within 2kb of gene TSSs (black dots) showed stronger inverse 
correlation than the expression differences of the random DMRs that are located further 
than 2kb of TSSs (black pluses). Random DMRs were shown in the middles of DNA 
methylation axis regardless of their methylation differences.  (a) For HSC vs GMP, shore 
showed statistically inverse correlation of DMR with gene expression. (b) For HSC vs 











Figure 3.8. Examples of DMRs located in master transcription factor or super-
enhancer.  (a) ZNF217, a master transcription factor in monocyte differentiation. (b) 


































































































































































































































































































Figure 3.9. Global methylation changes during hematopoietic development in 
human and mouse. The direction of global methylation change is shown for each 
comparison in red for human and blue for mouse hematopoiesis. The dotted lines 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.1. Normal bone marrow donor sample analysis 
 
Sample ID Age Gender Application 
BM2627 30 M 450K 
BM2710 29 F 450K 
BM2712 39 M 450K 
BM2748 24 M 450K 
BM2753 22 F 450K 
BM2759 38 M GEP 
BM2761 26 M GEP 
BM2768 25 M GEP 
BM2770 39 F GEP 
BM2793 18 F GEP 
BM2794 21 M GEP 
BM2806 35 M GEP 
BM3604 26 M P 
BM3668 24 M P 
BM3671 24 M P 
Abbreviations: 450K, Illumina Infinium Human Methylation 450K BeadChip array; F, female; GEP, gene 





Table 3.2. Antibodies for flow cytometry 
Cell Surface 











To sort normal 












CD34 APC 340667 1:50 
CD38 PE-Cy7 335790 1:100 
CD45RA PB 560362 1:25 
CD90 FITC 555595 1:25 
CD123 PE 554529 1:25 
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Table 3.3. DMR lists for pair-wise comparisons among HSPCs (See Appendix2)
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(Group1 versus Group2) 
Numbers of DMRs* Locations of DMRs relative to CpG islands (%) 
Group1>Group2 Group1<Group2 Islands Shores Shelves Open seas 
HSC vs MPP 14 2 33.3 0 0 66.7 
MPP vs CMP 158 8 3.6 22.3 10.2 63.9 
CMP vs GMP 366 362 2.5 17.0 15.4 65.1 
CMP vs MEP 319 13 3.6 25.6 16.0 54.8 
GMP vs MEP 1308 764 2.4 19.3 15.3 63 
MPP vs L-MPP 49 54 2.9 15.5 19.4 62.1 
HSC vs L-MPP 165 109 2.2 19.0 15.0 63.7 
L-MPP vs GMP 556 0 2.2 15.5 13.3 69.1 
HSC vs GMP 1168 162 2.0 17.8 13.5 66.7 
HSC vs MEP 1545 190 2.5 23.7 14.9 58.9 
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Table 3.5. Enrichment of DMRs for normal hematopoiesis in super-enhancers 
Tissues or Cell lines Cell type DMR lists* 
HSC vs GMP HSC vs MEP 
CD34+(adult) HSPC 0.009 2.5 x 10-9 
CD14 Monocyte 6.9 x 10-16 0.12 
Jurkat T cell leukemia 5.3 x 10-6 1 
K562 Erythroleukemia(CML) 1 9.6 x 10-9 
MM1S Multiple myeloma 0.04 0.08 
Adipose Adipose 1 1 
Angular gyrus Brain 0.15 0.66 
H1 Embryonic stem cell 0.90 0.78 
Spleen Spleen 1.1 x 10-5 0.003 














Table 3.6. DMRs of normal hematopoiesis located in super-enhancer of different tissues 
and cell types (See Appendix3)  
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Table 3.7. Common genes between mouse and human hematopoiesis (See Appendix4)  
Columns are chromosome, start, end, diffMethyl (difference of methylation percentage 
for group2-group1 for group1 vs group2 comparison), p.value, fwer, Gene, annotation, 
relation to gene, distance to gene. 
Yellow colored DMRs are showing opposite direction of methylation change compared 
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Table 3.8. Primers for bisulfite pyrosequencing 
Gene Primer type Sequence(5'→3') 
MIR539 Nested forward TATGATAAGTTTTGTAAAGGGATGTA 
 
Nested reverse /5Biosg/CAAATCCCTAATAACACCAAAAAAT 
 
Long forward GTGTTGTTGTTTTATATTTGAGGAGAA 
 
Long reverse CATATCCAAAAAATACCTCCAAAAA 
 
Sequencing 1 (F) TGATAAGTTTTGTAAAGGGATG 
 Sequencing 2 (F) GTTTTAATTTTAGAATTTTGGA 
CDK6 Nested forward TGTTTTTGAGATAGTAGTAGGGTATTTTG 
 
Nested reverse /5Biosg/TAACCAATCTAAACCCCATTTACTC 
 
Long forward GGGGTAGATAGTTTTATATAGGGTAGTTGT 
 
Long reverse TTCCACCCCAAAATTTATTATAACA 
 
Sequencing 1 (F) GATAGTAGTAGGGTATTTTGAT 
 
Sequencing 2 (F) ATTGTTTTTTTTTTGTTAAAGG 
 Sequencing 3 (F) TAAGTGGGAATTAAGTTTTGAG 
SLC39A4 Nested forward AGGGGAAGGTAGATTTTAGGGTAG 
 
Nested reverse /5Biosg/AACCCCAAAACACTAAACTCAATAC 
 
Long forward TTTTGAGTTTAGAGGTTTTATTTTTAT 
 
Long reverse ACAAACTCCCCTAAAAACCC 
 
Sequencing 1 (F) AGGGGGAGTTTAGATGTTATTT 
 Sequencing 2 (F) GTTTGAGGTTTAAGGATTTTGT 
ZDHHC14 Nested forward GGGAAAGAAGAGAATTATTTTTAGGTT 
 
Nested reverse /5Biosg/CAAACCCAATACCTCTATCAAAATC 
 
Long forward GTGTTAATGGTATTTTTTGATAGT 
 
Long reverse AAACTATCTTTACTTTTACTCAAAC 
 
Sequencing 1 (F) GAGGAAATGGGAGTTTTGTTTT 
 
Sequencing 2 (F) GAGTTTATTTATGTTTGTAGAT 
 
Sequencing 3 (F) AAATATATTTTTTTTTTTTATT 
 Sequencing 4 (F) GAAGTTTTTTTTGATTTTTGTTT 
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TRPM2 Nested forward GGGTTGTTTAGAAGGGTTATTGATT 
 
Nested reverse /5Biosg/CCCAATTCTATTCTCCCAAAAATATA 
 
Long forward TTTTTAGTTTTGAGGAAAGTTGGTT 
 
Long reverse AATAATCATACAACCCACAAAAAAC 
 
Sequencing 1 (F) GATTTGGGGATGGTTTTTAATT 
 
Sequencing 2 (F) GAGTTGGAGGTTATAGTGTTTT 
 
Sequencing 3 (F) TTGTTGGTTAGTTTGTAGTTGG 
 Sequencing 4 (F) TTGTTGGTTAGTTTGTAGTTGG 
MAEA Nested forward TTAGTTTAGGATGGTAGGAAGTTAT 
 
Nested reverse /5Biosg/TTATCTTTTACAATTAACCAAAAAA 
 
Long forward TTTTTAAGAAGTTTTTTAGGGGATT 
 
Long reverse ATATCATCATCATATTTTCACCAACAC 
 
Sequencing 1 (F) TAGTTTAGGATGGTAGGAAGTT 
 
Sequencing 2 (F) AATATGAGATTGGTTTTTTTAG 
 Sequencing 3 (F) TATTTTTGGTTTTGTGATGAGT 
STAT3 Nested forward GGTTTTTAATGTAGGTAATTTGTTGT 
 
Nested reverse /5Biosg/TATTTTAATTTCCAACCAAAACATC 
 
Long forward TTTTTTATTTTTTATTAGTTTTTTAGT 
 
Long reverse CTTACTTAATTTCTAAAAAATTCCTACTCT 
 
Sequencing 1 (F) TTTTAATGTAGGTAATTTGTT 
 Sequencing 2 (F) GTGAGAGTTTTTTG 
HMHB1 Nested forward TGGAGAAATTAGAATTGGAGGAGTA 
 
Nested reverse /5Biosg/CTAAATAATCCCAACAACAAAAACC 
 
Long forward ATGAGGAAATTATATTTTAGGAGGT 
 
Long reverse CAACCAAACAATAAACTATAAAACC 
 
Sequencing 1 (F) GAGAAGAAAAAAGAGGTGAGGG 
 Sequencing 2 (F) TATAATAGGTGAAAATAGGGAT 
MPO Nested forward TAGTTTTAGTTGGTTGGATATGTTG 
 
Nested reverse /5Biosg/AACCTCTCTCTATACCTCAAATCCC 
 
Long forward TAGGTTGTTAAAGGGTAGTAGGGTT 
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Long reverse TACCAAAAATCCTAAAAACAAAAAA 
 
Sequencing 1 (F) AGTTTTAGTTGGTTGGATATGT 
 
Sequencing 2 (F) GTAGGTTTTTGGTTAGGGGTTT 
 Sequencing 3 (F) GGATGGTGATGTTGTT 
/5Biosg/ = 5’ biotin added 
 F = forward 
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Chapter 4 
 The cell of origin of leukemia stem cell
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This work is an ongoing project of the Feinberg Lab and Johns Hopkins. All publication 
rights are reserved for these institutions and the presentation of this work here does not 
preclude future publication elsewhere. 
 
Summary 
 The question of the cell of origin of LSC has long been remained in the field, yet 
much of it still needs to be understood. We hypothesized that DNA methylation could be 
useful to infer the cell identity of LSCs compared to HSPCs, as it has been shown that 
transformed or reprogrammed cells retained an epigenetic memory of the cell of origin 
(Kim et al., 2010; Kim et al., 2011; Polak et al., 2015). We were able to provide a clue for 
the cell of origin of LSCs by comparing the DNA methylation profile of LSCs to normal 
HSPCs, obtained from previous chapter. Clustering analysis based on DNA methylation 
status showed LSCs clustered with either L-MPP or GMP. This result was replicated in 
TCGA data set, a larger cohort, and supported by molecular characteristics of each 
cluster such as FAB types, genetic mutations, and cytogenetic risk groups. These results 
suggested L-MPP and GMP would be major sources of LSCs. 
 
Results 
LSC Forms Two Clusters with L-MPP-like and GMP-like 
In order to relate normal hematopoiesis to LSC, we first identified the DMRs 
from all possible pairwise comparisons among the 6 HSPC after applying a more 
rigorous cutoff of FWER<0.1 (Table 4.1). The resulting 216 DMRs were applied in 
clustering analysis including all 6 normal HSPC populations with LSCs and Blasts 
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(Figure 4.1). Strikingly, this analysis revealed that AML samples formed 2 distinct 
clusters, L-MPP-like and GMP-like (Figure 4.1). Importantly, the GMP-like cluster 
included several CD34+CD38- subpopulations, indicating that these clusters could not 
have been identified by immunophenotype alone. Moreover, clustering analysis using an 
equal number of length-matched random regions showed that the clustering of AML 
populations with either L-MPP or GMP was unique to the selected DMRs (Figure 4.2).  
TCGA AML Samples Form Two Major Clusters, L-MPP-like and GMP-like  
Strikingly, using the same 216 DMRs, the TCGA samples also formed the same 
two major clusters, L-MPP-like and GMP-like (Figure 4.3). In addition to the two major 
clusters, we also identified a minor CMP-like cluster that was not observed in our smaller 
cohort. We calculated scores indicating the similarity of each TCGA sample to each of 
the six progenitors, and designated a counterpart HSPC population for each TCGA 
sample based on highest similarity. This approach showed that 76.6% of TCGA samples 
resembled GMP and 14.6% had a methylation profile most similar to L-MPP (Figure 4.4).   
We hypothesized that if the assignment of AML samples to L-MPP-like and 
GMP-like clusters was related to the cell of origin, then the degree of maturity and 
morphology might differ between the two groups. Consistent with this, we compared the 
distribution of the French-American-British (FAB) classification of the TCGA samples 
and found that the L-MPP-like cases mainly consisted of more immature M0, M1, and 
M2 types, while the more differentiated M4 and M5 types were enriched in GMP-like 
AML (p<1x10-4, chi-square test, Figure 4.5). It should be noted that the LSC epigenetic 
signature is not merely a recapitulation of FAB types, as our signature is prognostic in 
multivariate analysis while FAB types are not. In addition, it is not possible to know the 
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cell of origin simply by examining FAB types (Table 4.2). For example, in 38 cases of 
M1 AML, 29/38 are GMP-like and 9/29 are L-MPP-like (Table 4.2).  
Finally, we sought to investigate if the L-MPP-like and GMP-like clusters, and 
therefore the potential cell of origin, were associated with cytogenetic abnormalities or 
recurrent mutations of specific genes including DNMT3A, IDH1, IDH2, TET1, TET2, 
FLT3, and NPM1. The GMP-like cluster was enriched for patients in the low and 
intermediate cytogenetic risk groups, while the L-MPP-like cluster was enriched for 
patients in the high cytogenetic risk group (p=1x10-4, Fisher’s exact test; Figure 4.6a). 
We found that IDH1 and IDH2 mutations were enriched in the L-MPP like group (p<0.01 
for both, Fisher’s exact test), and FLT3 and NPM1 mutations were enriched in the GMP-
like group (p<0.01 for both, Fisher’s exact test). DNMT3A and TET1 mutations were 
more enriched in the L-MPP group, but this was not statistically significant (Figure 4.6b). 
Together, these results demonstrate that DNA methylation signatures permit a novel 
clustering of AML into L-MPP-like and GMP-like groups that may reflect the cell of 
origin for each case and demonstrate an association with key disease features. 
 
Discussion 
As DNA methylation is a potential marker of cell identity, here we compared 
DNA methylomes of normal HSPC to LSC as a marker for the cell of origin in AML. 
Using this approach, we observed two subtypes in our cohort: L-MPP-like and GMP-like. 
These two subtypes were also identified in the TCGA cohort, suggesting that leukemic 
transformation predominantly occurs at either the L-MPP or GMP stage of hematopoietic 
development. We found that other features of AML were associated with these two 
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subtypes including FAB type, several mutations, and cytogenetic abnormalities, 
suggesting that the cell of origin may drive key clinical features in AML. 
We newly identified a small subset of AML cells clustering with CMP and few 
samples clustering with HSC, MPP, and MEP that could not be identified in smaller 
datasets including our own data and a previous study (Goardon et al., 2011). The result 
from TCGA indicates that the cell of origin of AML could be variable among HSPCs. 
The result for the cell of origin should be considered carefully, as it is hard to provide 
definite proof of the question due to experimental limitations. Despite this caveat that 
affects all of human primary cancer biology, we do provide the first epigenetic evidence 
for cell of origin in human leukemia and believe that our approach using epigenomic 
profiles suggests an efficient way to study cell of origin in cancer biology using large 
data sets. 
 
Materials and Methods 
Illumina Infinium Human Methylation 450 Bead Array Assay  
Genomic DNA from each sample was purified using the MasterPure DNA purification 
kit (Epicentre) according to the manufacturer’s protocol. The genomic DNA (250-500ng) 
was treated with sodium bisulfate using the Zymo EZ DNA Methylation Kit (ZYMO 
Research) as recommended by the manufacturer, with the alternative incubation 
conditions for the Illumina Infinium Methylation Assay. Converted DNA was eluted in 
11ul of elution buffer. DNA methylation level was measured using Illumina Infinium HD 
Methylation Assay (Illumina) according to the manufacturer’s specifications. 
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Methylation array data are deposited at the Gene Expression Omnibus (GEO) with 
accession number GSE63409. 
Illumina Infinium Human Methylation 450 Bead Array Analysis 
Raw intensity files were obtained using minfi package (Aryee et al., 2014) to calculate 
methylation ratios (Beta values). The data was normalized using Illumina preprocessing 
method implemented in minfi. Several quality control measures were applied to remove 
arrays with low quality. Control probes were examined on the 450k array to assess 
several measures including bisulfite conversion, extension, hybridization, specificity and 
others. One of the MPP samples (BM2712) and two samples of TCGA (Patient ID: 2934 
and 2827) showed low quality for the measures, so they were removed for further 
analysis.  Next, median methylated and unmethylated signals were calculated for each 
arrays; no array was identified for signal values lower than 10.5. For multidimensional 
scaling analysis, probes containing an annotated SNP (dbSNP137) at the single-base 
extension or CpG sites were removed (17398 probes removed). Minfi 1.8.9 was used. 
Bump hunting method previously described was applied to identify DMRs in 450k array 
(Aryee et al., 2014; Jaffe et al., 2012). Beta value of 0.1 (10% of methylation difference) 
was used as cutoff when finding DMRs. Bumphunter 1.2.0 was used.  
Statistical Analysis 
To assign cell identity of normal HSPCs to TCGA samples, mean methylation value of 
each 216 DMRs for normal hematopoiesis (methylation profile) was retrieved and 
standard deviation of the mean value for each signature was calculated. Then scores 
(probability density values as log value) for each TCGA sample regarding normal HSPCs’ 
profile was calculated using dnorm function with the mean and standard deviation 
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calculated in previous step. Maximum value of scores among the ones regarding normal 
HSPC methylation profile was chosen, and then cell identity assigned.  
For clustering analysis, hclust function with ward method in R was used to generate all 








































Figure 4.1. Epigenetic signatures define subgroups of AML LSC reflecting the cell 
of origin.  A total of 216 DMRs identified from all possible pairwise comparisons among 
6 HSPCs were used to cluster all normal HSPC with all AML subpopulations. The 
primary AML subpopulations form two major clusters: L-MPP-like and GMP-like. LSC 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































Cell type TCGA % 
HSC 1 0.5 
MPP 3 1.6
L-MPP 28 14.6 
CMP 12 6.3 
GMP 147 76.6
MEP 1 0.5 

























GMP-like cluster L-MPP-like cluster
176	  
Figure 4.2. Clustering analysis of AML populations with normal HSPCs using 
length matched random 216 regions. Clustering analysis using random length matched 
regions shows no clustering between AML populations or normal HSPCs. Normal 































































































































































































































































































































































































































































































































Supplementary Figure 8. Clustering analysis of AML populations with normal 
HSPCs using length matched random 216 regions. Clustering analysis using random 
length matched regions shows no clustering between AML populations or normal HSPCs. 




Figure 4.3. Epigenetic signatures define subgroups of AML samples in TCGA 
reflecting the cell of origin. Clustering analysis of TCGA AML samples with normal 
human HSPC using the 216 DMRs shows that the L-MPP-like and GMP-like clusters are 























































































































































































































































































































































































































































































































































































































































































































































































































































































































Cell type TCGA % 
HSC 1 0.5 
MPP 3 1.6
L-MPP 28 14.6 
CMP 12 6.3 
GMP 147 76.6
MEP 1 0.5 
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Figure 4.4. Cell identity of TCGA AML samples. TCGA samples were classified into 
one of HSPC populations according to their DNA methylation profile by generating 
methylation profiles of all the normal HSPC, and then calculating scores of each sample 
based on the closest population. The normal progenitor cell identity for each TCGA 























































































































































































































































































































































































































































































































































































































































































































































































































































































































Cell type TCGA % 
HSC 1 0.5 
MPP 3 1.6
L-MPP 28 14.6 
CMP 12 6.3 
GMP 147 76.6
MEP 1 0.5 
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Figure 4.5. Distribution of FAB types for L-MPP-like and GMP-like TCGA AML 
samples. The L-MPP-like and GMP-like TCGA samples were grouped according to their 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































Cell type TCGA % 
HSC 1 0.5 
MPP 3 1.6
L-MPP 28 14.6 
CMP 12 6.3 
GMP 147 76.6
MEP 1 0.5 
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Figure 4.6. Correlation of disease features with cell identity. (a) Number of TCGA 
samples that belong to each cytogenetic risk group is shown for GMP-like and L-MPP-
like AML samples. Information on cytogenetic risk group was retrieved from clinical 
annotation of TCGA patients. (b) Percentage of AML samples with specific mutations 
including DNMT3A, IDH1, IDH2, TET1, TET2, NPM1, and FLT3 are shown for L-MPP-
like and GMP-like AML samples. Mutations that showed statistical significance of 
association with specific cell types are colored in red. Information on mutations was 














Cell identity  Favorable Intermediate/Normal  Poor 
GMP-like  33 90 22 
L-MPP-like  0 13 15 
  L-MPP (%) GMP (%) 
DNMT3A 33.3 25.0
IDH1  33.3 6.3 
IDH2  29.6 5.6 
TET1 3.7 0.7 
TET2 7.4  7.6 
NPM1 3.7 34.7 




Supplementary Figure 9. Correlation of disease features with cell identity. (a) 
Number of TCGA samples that belong to each cytogenetic risk group is shown for GMP-
like and L-MPP-like AML samples. Information on cytogenetic risk group was retrieved 
from clinical annotation of TCGA patients. (b) Percentage of AML samples with specific 
mutations including DNMT3A, IDH1, IDH2, TET1, TET2, NPM1, and FLT3 are shown for 
L-MPP-like and GMP-like AML samples. Mutations that showed statistical significance of 
association with specific cell types are colored in red. Information on mutations was 
retrieved from TCGA Mutation Annotation Format (MAF) file. 
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Table 4.1. DMRs for normal hematopoiesis 
chr start end gene name 
chr1 2164542 2164602 SKI 
chr1 12538341 12538541 VPS13D 
chr1 19652788 19652788 PQLC2 
chr1 25598878 25599066 RHD 
chr1 25747376 25747437 RHCE 
chr1 39513326 39513326 NDUFS5 
chr1 43290834 43291209 ERMAP 
chr1 44114346 44114355 KDM4A 
chr1 45103896 45103967 RNF220 
chr1 51986130 51986254 EPS15 
chr1 53103294 53103294 FAM159A 
chr1 116193783 116193783 VANGL1 
chr1 145828001 145828006 GPR89A 
chr1 159866558 159866558 CCDC19 
chr1 179016233 179016233 FAM20B 
chr1 182760143 182761262 NPL 
chr1 185253495 185253495 SWT1 
chr1 199827580 199827580 NR5A2 
chr1 226012913 226013010 EPHX1 
chr1 226036279 226036279 TMEM63A 
chr10 11631072 11631072 USP6NL 
chr10 32621403 32621403 EPC1 
chr10 70805603 70805603 KIAA1279 
chr10 97036527 97036527 PDLIM1 
chr10 100220809 100220809 HPSE2 
chr10 135059097 135059289 MIR202 
182	  
chr11 1297066 1297087 TOLLIP 
chr11 1325718 1325852 TOLLIP 
chr11 5276490 5276490 HBG2 
chr11 8385712 8385767 STK33 
chr11 12136405 12136405 MICAL2 
chr11 33759043 33759043 CD59 
chr11 47885166 47885166 NUP160 
chr11 59823993 59824161 MS4A3 
chr11 67251677 67251939 AIP 
chr11 69061454 69061473 MYEOV 
chr11 73681281 73681281 DNAJB13 
chr11 108422791 108423124 EXPH5 
chr11 117695591 117696015 FXYD2 
chr12 1922058 1922067 CACNA2D4 
chr12 14996508 14996587 ART4 
chr12 25103173 25103643 BCAT1 
chr12 32530696 32530696 BICD1 
chr12 53602179 53602179 ITGB7 
chr12 89938002 89938002 POC1B-GALNT4 
chr12 96390059 96390143 HAL 
chr12 114232702 114232905 RBM19 
chr12 117480333 117480333 TESC 
chr12 123632825 123633306 PITPNM2 
chr13 41631052 41631052 WBP4 
chr13 49147573 49147573 RCBTB2 
chr13 113305704 113305901 C13orf35 
chr13 114828264 114828455 RASA3 
chr13 114918702 114918702 RASA3 
chr14 21359295 21359943 RNASE3 
183	  
chr14 81425912 81426015 TSHR 
chr14 101513572 101514051 MIR539 
chr14 103565867 103566172 EXOC3L4 
chr14 104190678 104190829 ZFYVE21 
chr14 104197160 104197160 ZFYVE21 
chr14 104625249 104625669 KIF26A 
chr15 60907749 60907749 RORA 
chr15 65066231 65066710 RBPMS2 
chr15 80938098 80938098 ARNT2 
chr15 90643766 90643766 IDH2 
chr15 90727560 90727570 SEMA4B 
chr15 101720914 101720914 CHSY1 
chr15 101777761 101777800 CHSY1 
chr16 23880664 23880664 PRKCB 
chr16 56892460 56892460 MIR138-2 
chr16 67567158 67567158 FAM65A 
chr16 85551478 85551748 KIAA0182 
chr16 85622205 85622276 KIAA0182 
chr16 85708039 85708039 KIAA0182 
chr16 86011615 86012085 IRF8 
chr16 88558065 88558237 ZFPM1 
chr16 88563934 88564934 ZFPM1 
chr17 998432 998504 ABR 
chr17 5138259 5138696 LOC100130950 
chr17 14222235 14222235 HS3ST3B1 
chr17 26517057 26517057 NLK 
chr17 38717206 38717275 CCR7 
chr17 40489569 40489785 STAT3 
chr17 45286354 45286609 MYL4 
184	  
chr17 46648525 46648582 HOXB3 
chr17 47372126 47372126 ZNF652 
chr17 74844962 74845007 MGAT5B 
chr17 76142333 76142461 C17orf99 
chr17 76850256 76850277 TIMP2 
chr17 79623603 79623661 PDE6G 
chr17 80273242 80273322 CD7 
chr17 80581701 80581925 WDR45L 
chr18 55250568 55250568 FECH 
chr18 60646614 60646671 PHLPP1 
chr19 827715 827843 AZU1 
chr19 2865997 2865997 ZNF556 
chr19 12895288 12895529 JUNB 
chr19 12997997 12998927 KLF1 
chr19 15391832 15391946 BRD4 
chr19 39048014 39048014 RYR1 
chr19 47839132 47839187 GPR77 
chr19 50848024 50848461 NR1H2 
chr19 51858208 51858276 ETFB 
chr19 52076691 52076691 ZNF175 
chr19 55417390 55417647 NCR1 
chr2 24233923 24234017 MFSD2B 
chr2 37642493 37642493 QPCT 
chr2 39355435 39355435 SOS1 
chr2 55642894 55642894 CCDC88A 
chr2 61407270 61407414 AHSA2 
chr2 65593761 65594021 SPRED2 
chr2 68348796 68348796 WDR92 
chr2 74753691 74753759 AUP1 
185	  
chr2 75089669 75089669 HK2 
chr2 109789810 109789810 SH3RF3 
chr2 113885116 113885277 IL1RN 
chr2 128052778 128052889 ERCC3 
chr2 144992352 144992352 GTDC1 
chr2 149259371 149259371 MBD5 
chr2 149639612 149639914 KIF5C 
chr2 170779769 170779769 UBR3 
chr2 172377981 172378036 CYBRD1 
chr2 179149472 179149605 OSBPL6 
chr2 220436894 220436948 INHA 
chr2 239330171 239330202 ASB1 
chr2 240225062 240225142 HDAC4 
chr20 45319350 45319455 TP53RK 
chr20 52199594 52199778 ZNF217 
chr21 43823749 43824262 UBASH3A 
chr21 45773189 45774294 TRPM2 
chr22 24108000 24108140 CHCHD10 
chr22 39106452 39106452 GTPBP1 
chr3 3123308 3123308 IL5RA 
chr3 12994821 12994919 IQSEC1 
chr3 46394550 46395356 CCR2 
chr3 49127364 49127364 QRICH1 
chr3 58200471 58200569 DNASE1L3 
chr3 71295684 71295684 FOXP1 
chr3 127473936 127473936 MGLL 
chr3 128998952 128998952 C3orf37 
chr3 148581801 148581837 CPA3 
chr3 156537970 156537970 LOC730091 
186	  
chr3 176919597 176919597 TBL1XR1 
chr3 184297380 184297522 EPHB3 
chr3 193405999 193405999 OPA1 
chr3 195603697 195603697 TNK2 
chr3 196351986 196352142 LRRC33 
chr4 1195845 1196179 SPON2 
chr4 1294783 1295078 MAEA 
chr4 2431872 2432313 LOC402160 
chr4 3374767 3374909 RGS12 
chr4 24590014 24590014 DHX15 
chr4 38859706 38859770 TLR6 
chr4 87938832 87938832 AFF1 
chr4 144266241 144266241 GAB1 
chr4 157897045 157897045 PDGFC 
chr5 1089722 1089800 SLC12A7 
chr5 1555791 1555887 SDHAP3 
chr5 32297979 32297979 MTMR12 
chr5 55148493 55148534 IL31RA 
chr5 67586170 67586258 PIK3R1 
chr5 125694354 125694418 GRAMD3 
chr5 137224213 137224284 MYOT 
chr5 143191565 143192067 HMHB1 
chr5 153753045 153753045 GALNT10 
chr5 169617918 169617918 C5orf58 
chr5 177913434 177913485 COL23A1 
chr6 6588693 6589075 LY86 
chr6 16933816 16933816 FLJ23152 
chr6 26030329 26030329 HIST1H3B 
chr6 28885444 28885568 TRIM27 
187	  
chr6 30956397 30956440 MUC21 
chr6 31088343 31088434 PSORS1C1 
chr6 31629088 31629199 GPANK1 
chr6 31654389 31654533 ABHD16A 
chr6 32099450 32099564 FKBPL 
chr6 32121055 32121393 PPT2 
chr6 32135715 32136052 EGFL8 
chr6 32810742 32810833 PSMB8 
chr6 32825040 32825897 PSMB9 
chr6 32905085 32905320 HLA-DMB 
chr6 41010111 41010316 UNC5CL 
chr6 41254433 41254471 TREM1 
chr6 109812795 109812795 AKD1 
chr6 135517041 135517046 MYB 
chr6 140168822 140168822 LOC100132735 
chr6 142721804 142721804 GPR126 
chr6 157876915 157877120 ZDHHC14 
chr7 1545385 1545819 INTS1 
chr7 2653651 2654120 IQCE 
chr7 30108301 30108301 PLEKHA8 
chr7 33765409 33765409 BBS9 
chr7 65419185 65419288 VKORC1L1 
chr7 73645723 73645783 RFC2 
chr7 80267619 80267943 CD36 
chr7 101361395 101361745 MYL10 
chr7 138347826 138348384 SVOPL 
chr7 138816336 138816336 TTC26 
chr7 142659349 142659425 KEL 
chr8 1708438 1708526 CLN8 
188	  
chr8 1870722 1870798 ARHGEF10 
chr8 12608579 12608579 LONRF1 
chr8 13105155 13105155 DLC1 
chr8 33421410 33421410 RNF122 
chr8 41654331 41655078 ANK1 
chr8 42125496 42125496 IKBKB 
chr8 42623730 42623946 CHRNA6 
chr8 68022262 68022262 CSPP1 
chr8 99105576 99105576 C8orf47 
chr8 128972450 128972829 PVT1 
chr8 131368433 131368433 ASAP1 
chr8 141312892 141312979 TRAPPC9 
chr8 145643083 145643626 SLC39A4 
chr9 132145105 132145105 C9orf106 
chr9 136726359 136726575 VAV2 











Table 4.2. FAB type distribution for L-MPP-like and GMP-like AML samples 
 M0 M1 M2 M3 M4 M5 M6 M7 NA 
L-MPP 11 9 7 0 0 0 1 0 0 
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